

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 12, 2004, 15:21:09 ; Search time 41.6471 Seconds  
(without alignments)  
400.276 Million cell updates/sec

Title: US-09-620-955B-10  
Perfect score: 287  
Sequence: 1 LVPRGSMATLEKLMKAFESL.....QQQQQQQQQLQPGSTRAAAS 59

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_29Jan04:\*  
1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000s:\*  
4: geneseqp2001s:\*  
5: geneseqp2002s:\*  
6: geneseqp2003as:\*  
7: geneseqp2003bs:\*  
8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

RESULTS							
Result No.	%		Query		DB	ID	Description
	Score	Match	Length				
1	287	100.0	59	4	AAB69605	Aab69605	Huntingti
2	231	80.5	66	4	AAB69613	Aab69613	Huntingti
3	218	76.0	145	4	AAB69614	Aab69614	Huntingti
4	208	72.5	63	5	AAE26651	Aae26651	Human hun
5	208	72.5	64	4	AAB69607	Aab69607	Huntingti
6	208	72.5	86	2	AAW95073	Aaw95073	GST-HD fu
7	208	72.5	86	2	AAW95078	Aaw95078	GST-HD fu
8	208	72.5	89	4	AAB69608	Aab69608	Huntingti
9	208	72.5	94	2	AAW95075	Aaw95075	GST-HD fu

10	208	72.5	94	2	AAW95080	Aaw95080	GST-HD fu
11	208	72.5	98	4	AAB69610	Aab69610	Huntingti
12	208	72.5	108	2	AAW95071	Aaw95071	Amino aci
13	208	72.5	108	2	AAW95076	Aaw95076	Amino aci
14	208	72.5	121	4	AAB69609	Aab69609	Huntingti
15	208	72.5	123	4	AAB69611	Aab69611	Huntingti
16	208	72.5	155	4	AAB69612	Aab69612	Huntingti
17	208	72.5	171	5	AAE26650	Aae26650	Human hun
18	197	68.6	3223	4	ABB11407	Abb11407	Human Hun
19	197	68.6	3223	4	ABB11470	Abb11470	Human Hun
20	196	68.3	79	4	AAB69616	Aab69616	Huntingto
21	196	68.3	171	2	AAW99022	Aaw99022	Human hun
22	196	68.3	513	2	AAAY33500	Aay33500	Human hun
23	196	68.3	530	2	AAAY33501	Aay33501	Human apo
24	196	68.3	552	2	AAAY33502	Aay33502	Human apo
25	196	68.3	589	2	AAAY33503	Aay33503	Human apo
26	196	68.3	3144	2	AAR58777	Aar58777	Protein e
27	196	68.3	3144	2	AAW36887	Aaw36887	Previousl
28	196	68.3	3144	2	AAW09871	Aaw09871	Human hun
29	196	68.3	3144	2	AAW44742	Aaw44742	Human hun
30	196	68.3	3144	2	AAAY33493	Aay33493	Human hun
31	181	63.1	87	5	ABG30880	Abg30880	Human pro
32	181	63.1	87	6	ABP72612	Abp72612	Huntingto
33	181	63.1	1542	5	ABB78013	Abb78013	Amino aci
34	180	62.7	55	2	AAW95072	Aaw95072	GST-HD fu
35	180	62.7	55	2	AAW95077	Aaw95077	GST-HD fu
36	180	62.7	63	2	AAW95074	Aaw95074	GST-HD fu
37	180	62.7	63	2	AAW95079	Aaw95079	GST-HD fu
38	172.5	60.1	3139	2	AAAY08898	Aay08898	Human Hun
39	152	53.0	69	4	AAB69604	Aab69604	Huntingti
40	147	51.2	1081	6	ABR53539	Abr53539	Protein s
41	147	51.2	1109	7	ADC59312	Adc59312	Human pol
42	147	51.2	1340	6	AAE37017	Aae37017	Human nuc
43	147	51.2	1761	4	ABB59512	Abb59512	Drosophil
44	145	50.5	80	4	AAB69622	Aab69622	TATA bind
45	145	50.5	338	5	AAU77921	Aau77921	Human Tat

# ALIGNMENTS

## RESULT 1

AAB69605

ID AAB69605 standard; protein; 59 AA.

XX

AC AAB69605;

XX

DT 30-APR-2001 (first entry)

XX

DE Huntingtin accumulation inhibitor peptide GST-HD-Q25.

XX

KW Neurological disorder; Huntington's disease; Alzheimer's disease;

KW Parkinson's disease; prion disease; frontotemporal dementia;

KW amyotrophic lateral sclerosis; spinal and bulbar muscular atrophy;

KW dentatorubal-pallidoluysian atrophy; spinocerebellar ataxia type 1; SCA2;

KW SCA3; SCA4; SCA5; SCA6; SCA7; protein accumulation; intrabody.

XX

OS Synthetic.  
 XX  
 PN WO200106989-A2.  
 XX  
 PD 01-FEB-2001.  
 XX  
 PF 24-JUL-2000; 2000WO-US020131.  
 XX  
 PR 27-JUL-1999; 99US-0146047P.  
 PR 21-JUL-2000; 2000US-00620955.  
 XX  
 PA (HUST/) HUSTON J S.  
 PA (MESS/) MESSER A.  
 PA (LECE/) LECERF J.  
 XX  
 PI Huston JS, Messer A, Lecerf J;  
 XX  
 DR WPI; 2001-182700/18.  
 XX  
 PT Inhibiting intracellular polypeptide accumulation, useful for treating  
 PT neurological disorders, e.g. Alzheimer's disease, comprises contacting  
 PT the polypeptide with a specific intrabody.  
 XX  
 PS Disclosure; Page 96; 108pp; English.  
 XX  
 CC The present invention describes a method for inhibiting the formation of  
 CC aggregates of certain proteins, involving contacting the protein with a  
 CC binding molecule known as an intrabody. Proteins to be bound include  
 CC those associated with neurological disorders, and so the method can be  
 CC used in the prevention of diseases such as Alzheimer's, Parkinson's and  
 CC Huntington's diseases, prion disease, frontotemporal dementia,  
 CC amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy,  
 CC dentatorubal-pallidoluyisian atrophy, spinocerebellar ataxia type 1  
 CC (SCA1), SCA2, SCA3, SCA4, SCA5, SCA6 and SCA7  
 XX  
 SQ Sequence 59 AA;

Query Match 100.0%; Score 287; DB 4; Length 59;  
 Best Local Similarity 100.0%; Pred. No. 4.6e-26;  
 Matches 59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LVPRGSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLPGSTRAAAS 59  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Db 1 LVPRGSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLPGSTRAAAS 59

# RESULT 2

AAB69613

ID AAB69613 standard; protein; 66 AA.

XX

AC AAB69613;

XX

DT 30-APR-2001 (first entry)

XX

DE Huntingtin accumulation inhibitor peptide GFP-HD-Q25.

XX

KW Neurological disorder; Huntington's disease; Alzheimer's disease;

KW Parkinson's disease; prion disease; frontotemporal dementia;  
 KW amyotrophic lateral sclerosis; spinal and bulbar muscular atrophy;  
 KW dentatorubal-pallidoluysian atrophy; spinocerebellar ataxia type 1; SCA2;  
 KW SCA3; SCA4; SCA5; SCA6; SCA7; protein accumulation; intrabody.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200106989-A2.  
 XX  
 PD 01-FEB-2001.  
 XX  
 PF 24-JUL-2000; 2000WO-US020131.  
 XX  
 PR 27-JUL-1999; 99US-0146047P.  
 PR 21-JUL-2000; 2000US-00620955.  
 XX  
 PA (HUST/) HUSTON J S.  
 PA (MESS/) MESSER A.  
 PA (LECE/) LECERF J.  
 XX  
 PI Huston JS, Messer A, Lecerf J;  
 XX  
 DR WPI; 2001-182700/18.  
 XX  
 PT Inhibiting intracellular polypeptide accumulation, useful for treating  
 PT neurological disorders, e.g. Alzheimer's disease, comprises contacting  
 PT the polypeptide with a specific intrabody.  
 XX  
 PS Disclosure; Page 99; 108pp; English.  
 XX  
 CC The present invention describes a method for inhibiting the formation of  
 CC aggregates of certain proteins, involving contacting the protein with a  
 CC binding molecule known as an intrabody. Proteins to be bound include  
 CC those associated with neurological disorders, and so the method can be  
 CC used in the prevention of diseases such as Alzheimer's, Parkinson's and  
 CC Huntington's diseases, prion disease, frontotemporal dementia,  
 CC amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy,  
 CC dentatorubal-pallidoluysian atrophy, spinocerebellar ataxia type 1  
 CC (SCA1), SCA2, SCA3, SCA4, SCA5, SCA6 and SCA7  
 XX  
 SQ Sequence 66 AA;

Query Match 80.5%; Score 231; DB 4; Length 66;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-19;  
 Matches 47; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 GSMATLEKLMKAFESLKSFOOOOOOOOOOOOOOOOOOOOOOOOQLQP 51  
 ||||||||||||||||||||||||||||||||||||||||||||  
 Db 15 GSMATLEKLMKAFESLKSFOOOOOOOOOOOOOOOOOOOOOOOOQLQP 61

RESULT 3  
 AAB69614  
 ID AAB69614 standard; protein; 145 AA.  
 XX  
 AC AAB69614;  
 XX



DT 30-APR-2001 (first entry)  
 XX  
 DE Huntingtin accumulation inhibitor peptide GFP-HD-Q104.  
 XX  
 KW Neurological disorder; Huntington's disease; Alzheimer's disease;  
 KW Parkinson's disease; prion disease; frontotemporal dementia;  
 KW amyotrophic lateral sclerosis; spinal and bulbar muscular atrophy;  
 KW dentatorubal-pallidoluysian atrophy; spinocerebellar ataxia type 1; SCA2;  
 KW SCA3; SCA4; SCA5; SCA6; SCA7; protein accumulation; intrabody.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200106989-A2.  
 XX  
 PD 01-FEB-2001.  
 XX  
 PF 24-JUL-2000; 2000WO-US020131.  
 XX  
 PR 27-JUL-1999; 99US-0146047P.  
 PR 21-JUL-2000; 2000US-00620955.  
 XX  
 PA (HUST/) HUSTON J S.  
 PA (MESS/) MESSER A.  
 PA (LECE/) LECERF J.  
 XX  
 PI Huston JS, Messer A, Lecerf J;  
 XX  
 DR WPI; 2001-182700/18.  
 XX  
 PT Inhibiting intracellular polypeptide accumulation, useful for treating  
 PT neurological disorders, e.g. Alzheimer's disease, comprises contacting  
 PT the polypeptide with a specific intrabody.  
 XX  
 PS Disclosure; Page 100; 108pp; English.  
 XX  
 CC The present invention describes a method for inhibiting the formation of  
 CC aggregates of certain proteins, involving contacting the protein with a  
 CC binding molecule known as an intrabody. Proteins to be bound include  
 CC those associated with neurological disorders, and so the method can be  
 CC used in the prevention of diseases such as Alzheimer's, Parkinson's and  
 CC Huntington's diseases, prion disease, frontotemporal dementia,  
 CC amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy,  
 CC dentatorubal-pallidoluysian atrophy, spinocerebellar ataxia type 1  
 CC (SCA1), SCA2, SCA3, SCA4, SCA5, SCA6 and SCA7  
 XX  
 SQ Sequence 145 AA;

Query Match 76.0%; Score 218; DB 4; Length 145;  
 Best Local Similarity 97.8%; Pred. No. 1.2e-17;  
 Matches 45; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 GSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 |||||  
 Db 15 GSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 60

RESULT 4

AAE26651

ID AAE26651 standard; protein; 63 AA.

XX

AC AAE26651;

XX

DT 13-DEC-2002 (first entry)

XX

DE Human huntington (htQ25) protein.

XX

KW Human; protein misfolding; Alzheimer's disease; AD; Parkinson's disease;  
KW PD; Familial amyloid polyneuropathy; tauopathy; frontotemporal dementia;  
KW Pick disease; lobar atrophy; trinucleotide disease; fragile-X syndrome;  
KW Huntington's disease; spinocerebellar ataxia; SCA; myotonic dystrophy;  
KW dentatorubral pallidoluysian atrophy; DRPLA; Creutzfeldt-Jacob disease;  
KW CJD; prion disease; Gerstmann-Straussler-Scheinker disease; GSS; FFI;  
KW fatal familia insomnia; mad cow disease; scrapie; kuru; anticonvulsant;  
KW nootropic; neuroprotective; cerebroprotective; htQ25 protein.

XX

OS Homo sapiens.

XX

PN WO200265136-A2.

XX

PD 22-AUG-2002.

XX

PF 15-FEB-2002; 2002WO-US004632.

XX

PR 15-FEB-2001; 2001US-0269157P.

XX

PA (UYCH-) UNIV CHICAGO.

XX

PI Lindquist S, Krobitsch S, Outeiro T;

XX

DR WPI; 2002-667026/71.

DR N-PSDB; AAD44411.

XX

PT Screening for therapeutic agents for protein misfolding disease, by  
PT contacting a yeast cell with compound, that expresses misfolded disease  
PT protein, and with a toxicity inducing agent, and evaluating cell for  
PT viability.

XX

PS Disclosure; Page 90; 93pp; English.

XX

CC The present invention relates to novel screening methods for identifying  
CC therapeutic agents for diseases associated with protein misfolding. The  
CC method involves contacting a yeast cell with a candidate compound, where  
CC the yeast cell expresses a polypeptide comprising a misfolded disease  
CC protein, contacting the yeast cell with a toxicity inducing agent and  
CC evaluating the yeast cell for viability, where the viability indicates  
CC the candidate compound is a candidate therapeutic agent. The method is  
CC useful to screen for therapeutic agents for diseases associated with  
CC protein misfolding such as Alzheimer's disease (AD), Parkinson's disease  
CC (PD), Familial amyloid polyneuropathy, tauopathies (e.g. Pick disease,  
CC lobar atrophy, frontotemporal dementia) or trinucleotide diseases (e.g.  
CC Huntington's disease, spinocerebellar ataxia (SCA), fragile-X syndrome,  
CC myotonic dystrophy, dentatorubral pallidoluysian atrophy (DRPLA) and  
CC prion diseases (e.g. Creutzfeldt-Jacob disease (CJD), fatal familia  
CC insomnia (FFI), Gerstmann-Straussler-Scheinker disease (GSS), mad cow





DR WPI; 1999-153955/13.  
 XX  
 PT Detecting amyloid-like fibrils or protein aggregates insoluble in  
 PT detergent or urea - from their retention on a filter, used for diagnosis,  
 PT particularly of diseases associated with polyglutamine expansion.  
 XX  
 PS Disclosure; Fig 8; 56pp; English.  
 XX  
 CC The invention relates to the detection of amyloid-like fibrils or protein  
 CC aggregates, insoluble in detergents or urea. The method comprises: (a)  
 CC applying material suspected of containing protein aggregates to a filter;  
 CC and (b) detecting retention of protein aggregates on the filter. This  
 CC method also helps to identify inhibitors of protein aggregates formation.  
 CC The method is particularly used to detect protein aggregates that are  
 CC indicative of disease, for assessing onset or progression of the  
 CC diseases. The inhibitors identified are potential therapeutic agents for  
 CC treating the diseases. Other applications include detection of inclusion  
 CC bodies in bacteria and to study kinetics of aggregate formation. Diseases  
 CC associated with polyglutamine expansion are particularly diagnosed, e.g.  
 CC Huntington's, Alzheimer's or Parkinson's diseases; spinal and bulbar  
 CC muscular atrophy; spinocerebellar ataxia; systemic amyloidosis; type II  
 CC diabetes; bovine spongiform encephalopathy; kuru; familial insomnia;  
 CC scrapie. The protein aggregates can now be detected simply, routinely and  
 CC rapidly, without requiring sophisticated equipment. The method can be  
 CC made quantitative, by analysing a series of dilutions, and can be  
 CC automated to allow many samples to be analysed on the same filter.  
 CC Sequences AAW95072-75 represent GST-HD fusion proteins  
 XX  
 SQ Sequence 86 AA;

Query Match 72.5%; Score 208; DB 2; Length 86;  
 Best Local Similarity 97.7%; Pred. No. 1e-16;  
 Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 ||||||||||||||||||||||||||||||||||||||||  
 Db 8 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 51

# RESULT 7

AAW95078

ID AAW95078 standard; protein; 86 AA.

XX

AC AAW95078;

XX

DT 20-MAY-1999 (first entry)

XX

DE GST-HD fusion protein GST-HD51DELP.

XX

KW Fusion protein; amyloidogenic polypeptide; amyloid-like fibril; scrapie;  
 KW protein aggregate; Alzheimer's disease; CAG-repeat expansion; spinal;  
 KW Huntington's disease; bulbar muscular atrophy; spinocerebellar ataxia;  
 KW dentatorubral pallidoluysian atrophy; Creutzfeld-Jakob disease; enzyme;  
 KW GST-HD; HD.

XX

OS Synthetic.

OS Homo sapiens.

XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1  
 FT /note= "this residue is connected to a GST protein which  
 FT is not indicated in the sequence"  
 XX  
 PN WO9906545-A2.  
 XX  
 PD 11-FEB-1999.  
 XX  
 PF 31-JUL-1998; 98WO-EP004811.  
 XX  
 PR 01-AUG-1997; 97EP-00113306.  
 XX  
 PA (PLAC ) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.  
 XX  
 PI Wanker E, Lehrach H, Scherzinger E, Bates G;  
 XX  
 DR WPI; 1999-153775/13.  
 XX  
 PT Composition containing fusion protein that includes amyloidogenic peptide  
 PT - able to self-assemble into fibrils or aggregates, used to detect and  
 PT monitor neuronal diseases, and also to screen for therapeutic inhibitors.  
 XX  
 PS Disclosure; Fig 8; 62pp; English.  
 XX  
 CC The invention relates to a composition comprising a fusion protein of (i)  
 CC (poly)peptide that increases solubility and/or prevents aggregation of  
 CC fusion protein, and (ii) amyloidogenic (poly)peptide that can self-  
 CC assemble into amyloid-like fibrils or protein aggregates. Host cells  
 CC transformed with a vector containing the nucleic acid encoding the fusion  
 CC protein are used for the recombinant expression of the fusion protein.  
 CC The composition is used to detect onset and progression of diseases  
 CC associated with fibrils/protein aggregates. It is potentially useful for  
 CC treatment of such diseases (e.g. Alzheimer's disease, scrapie or CAG-  
 CC repeat expansion conditions such as Huntington's disease (HD), spinal and  
 CC bulbar muscular atrophy, dentatorubral pallidoluysian atrophy,  
 CC spinocerebellar ataxia, Creutzfeldt-Jakob disease). Assay methods based on  
 CC release of the amyloidogenic polypeptide from fusion protein have a  
 CC precise starting time for aggregate formation, allowing kinetic  
 CC measurements, and use of an enzyme for cleavage allows testing under  
 CC physiological conditions. Sequences AAW95077-80 represent GST-HD fusion  
 CC proteins  
 XX  
 SQ Sequence 86 AA;

Query Match 72.5%; Score 208; DB 2; Length 86;  
 Best Local Similarity 97.7%; Pred. No. 1e-16;  
 Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 ||||||||||||||||||||||||||||||||||||||||  
 Db 8 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 51

RESULT 8  
 AAB69608



AAW95075

XX

XX

XX

XX

XX

OS Homo sapiens.

XX

FT Misc-difference 1

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

The invention relates to the detection of amyloid-like fibrils or protein aggregates, insoluble in detergents or urea. The method comprises: (a) applying material suspected of containing protein aggregates to a filter; and (b) detecting retention of protein aggregates on the filter. This method also helps to identify inhibitors of protein aggregates formation. The method is particularly used to detect protein aggregates that are indicative of disease, for assessing onset or progression of the diseases. The inhibitors identified are potential therapeutic agents for treating the diseases. Other applications include detection of inclusion bodies in bacteria and to study kinetics of aggregate formation. Diseases



CC associated with polyglutamine expansion are particularly diagnosed, e.g.  
 CC Huntington's, Alzheimer's or Parkinson's diseases; spinal and bulbar  
 CC muscular atrophy; spinocerebellar ataxia; systemic amyloidosis; type II  
 CC diabetes; bovine spongiform encephalopathy; kuru; familial insomnia;  
 CC scrapie. The protein aggregates can now be detected simply, routinely and  
 CC rapidly, without requiring sophisticated equipment. The method can be  
 CC made quantitative, by analysing a series of dilutions, and can be  
 CC automated to allow many samples to be analysed on the same filter.  
 CC Sequences AAW95072-75 represent GST-HD fusion proteins  
 XX  
 SQ Sequence 94 AA;

Query Match 72.5%; Score 208; DB 2; Length 94;  
 Best Local Similarity 97.7%; Pred. No. 1.1e-16;  
 Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 |||||  
 Db 8 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 51

# RESULT 10

AAW95080

ID AAW95080 standard; protein; 94 AA.

XX

AC AAW95080;

XX

DT 20-MAY-1999 (first entry)

XX

DE GST-HD fusion protein GST-HD51DELPBio.

XX

KW Fusion protein; amyloidogenic polypeptide; amyloid-like fibril; scrapie;  
 KW protein aggregate; Alzheimer's disease; CAG-repeat expansion; spinal;  
 KW Huntington's disease; bulbar muscular atrophy; spinocerebellar ataxia;  
 KW dentatorubral pallidoluysian atrophy; Creutzfeld-Jakob disease; enzyme;  
 KW GST-HD; HD.

XX

OS Synthetic.

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Misc-difference 1

FT /note= "this residue is connected to a GST protein which  
 FT is not indicated in the sequence"

XX

PN WO9906545-A2.

XX

PD 11-FEB-1999.

XX

PF 31-JUL-1998; 98WO-EP004811.

XX

PR 01-AUG-1997; 97EP-00113306.

XX

PA (PLAC ) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.

XX

PI Wanker E, Lehrach H, Scherzinger E, Bates G;

XX

DR WPI; 1999-153775/13.  
 XX  
 PT Composition containing fusion protein that includes amyloidogenic peptide  
 PT - able to self-assemble into fibrils or aggregates, used to detect and  
 PT monitor neuronal diseases, and also to screen for therapeutic inhibitors.  
 XX  
 PS Disclosure; Fig 8; 62pp; English.  
 XX  
 CC The invention relates to a composition comprising a fusion protein of (i)  
 CC (poly)peptide that increases solubility and/or prevents aggregation of  
 CC fusion protein, and (ii) amyloidogenic (poly)peptide that can self-  
 CC assemble into amyloid-like fibrils or protein aggregates. Host cells  
 CC transformed with a vector containing the nucleic acid encoding the fusion  
 CC protein are used for the recombinant expression of the fusion protein.  
 CC The composition is used to detect onset and progression of diseases  
 CC associated with fibrils/protein aggregates. It is potentially useful for  
 CC treatment of such diseases (e.g. Alzheimer's disease, scrapie or CAG-  
 CC repeat expansion conditions such as Huntington's disease (HD), spinal and  
 CC bulbar muscular atrophy, dentatorubral pallidoluysian atrophy,  
 CC spinocerebellar ataxia, Creutzfeld-Jakob disease). Assay methods based on  
 CC release of the amyloidogenic polypeptide from fusion protein have a  
 CC precise starting time for aggregate formation, allowing kinetic  
 CC measurements, and use of an enzyme for cleavage allows testing under  
 CC physiological conditions. Sequences AAW95077-80 represent GST-HD fusion  
 CC proteins  
 XX  
 SQ Sequence 94 AA;

Query Match 72.5%; Score 208; DB 2; Length 94;  
 Best Local Similarity 97.7%; Pred. No. 1.1e-16;  
 Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 ||||||||||||||||||||||||||||||||||||||||  
 Db 8 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 51

# RESULT 11

AAB69610

ID AAB69610 standard; protein; 98 AA.

XX

AC AAB69610;

XX

DT 30-APR-2001 (first entry)

XX

DE Huntingtin accumulation inhibitor peptide HD-Q47-Myc-HIS6.

XX

KW Neurological disorder; Huntington's disease; Alzheimer's disease;  
 KW Parkinson's disease; prion disease; frontotemporal dementia;  
 KW amyotrophic lateral sclerosis; spinal and bulbar muscular atrophy;  
 KW dentatorubal-pallidoluysian atrophy; spinocerebellar ataxia type 1; SCA2;  
 KW SCA3; SCA4; SCA5; SCA6; SCA7; protein accumulation; intrabody.

XX

OS Synthetic.

XX

PN WO200106989-A2.

XX

PD 01-FEB-2001.  
 XX  
 PF 24-JUL-2000; 2000WO-US020131.  
 XX  
 PR 27-JUL-1999; 99US-0146047P.  
 PR 21-JUL-2000; 2000US-00620955.  
 XX  
 PA (HUST/) HUSTON J S.  
 PA (MESS/) MESSER A.  
 PA (LECE/) LECERF J.  
 XX  
 PI Huston JS, Messer A, Lecerf J;  
 XX  
 DR WPI; 2001-182700/18.  
 XX  
 PT Inhibiting intracellular polypeptide accumulation, useful for treating  
 PT neurological disorders, e.g. Alzheimer's disease, comprises contacting  
 PT the polypeptide with a specific intrabody.  
 XX  
 PS Disclosure; Page 98; 108pp; English.  
 XX  
 CC The present invention describes a method for inhibiting the formation of  
 CC aggregates of certain proteins, involving contacting the protein with a  
 CC binding molecule known as an intrabody. Proteins to be bound include  
 CC those associated with neurological disorders, and so the method can be  
 CC used in the prevention of diseases such as Alzheimer's, Parkinson's and  
 CC Huntington's diseases, prion disease, frontotemporal dementia,  
 CC amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy,  
 CC dentatorubal-pallidoluysian atrophy, spinocerebellar ataxia type 1  
 CC (SCA1), SCA2, SCA3, SCA4, SCA5, SCA6 and SCA7  
 XX  
 SQ Sequence 98 AA;

Query Match 72.5%; Score 208; DB 4; Length 98;  
 Best Local Similarity 97.7%; Pred. No. 1.2e-16;  
 Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 ||||||||||||||||||||||||||||||||||||||||  
 Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 44

# RESULT 12

AAW95071

ID AAW95071 standard; protein; 108 AA.

XX

AC AAW95071;

XX

DT 20-MAY-1999 (first entry)

XX

DE Amino acid sequence of Huntington's gene exon 1 in GST-HD fusion protein.

XX

KW Amyloid-like fibril; protein aggregate; inhibitor; inclusion body;

KW polyglutamine expansion; Huntington's disease; Alzheimer's disease;

KW Parkinson's disease; spinal; bulbar muscular atrophy; type II diabetes;

KW systemic amyloidosis; spinocerebellar ataxia; kuru; familial insomnia;

KW bovine spongiform encephalopathy; kuru; scrapie; GST-HD.

XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT Misc-difference 1  
 FT /note= "GST protein connected to the N-terminal"  
 FT Misc-difference 25  
 FT /note= "polyglutamine expansion that can comprise upto 51  
 FT glutamines"  
 XX  
 PN WO9906838-A2.  
 XX  
 PD 11-FEB-1999.  
 XX  
 PF 31-JUL-1998; 98WO-EP004810.  
 XX  
 PR 01-AUG-1997; 97EP-00113320.  
 XX  
 PA (PLAC ) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.  
 XX  
 PI Wanker E, Lehrach H, Scherzinger E, Bates G;  
 XX  
 DR WPI; 1999-153955/13.  
 XX  
 PT Detecting amyloid-like fibrils or protein aggregates insoluble in  
 PT detergent or urea - from their retention on a filter, used for diagnosis,  
 PT particularly of diseases associated with polyglutamine expansion.  
 XX  
 PS Example 1; Fig 2; 56pp; English.  
 XX  
 CC The invention relates to the detection of amyloid-like fibrils or protein  
 CC aggregates, insoluble in detergents or urea. The method comprises: (a)  
 CC applying material suspected of containing protein aggregates to a filter;  
 CC and (b) detecting retention of protein aggregates on the filter. This  
 CC method also helps to identify inhibitors of protein aggregates formation.  
 CC The method is particularly used to detect protein aggregates that are  
 CC indicative of disease, for assessing onset or progression of the  
 CC diseases. The inhibitors identified are potential therapeutic agents for  
 CC treating the diseases. Other applications include detection of inclusion  
 CC bodies in bacteria and to study kinetics of aggregate formation. Diseases  
 CC associated with polyglutamine expansion are particularly diagnosed, e.g.  
 CC Huntington's, Alzheimer's or Parkinson's diseases; spinal and bulbar  
 CC muscular atrophy; spinocerebellar ataxia; systemic amyloidosis; type II  
 CC diabetes; bovine spongiform encephalopathy; kuru; familial insomnia;  
 CC scrapie. The protein aggregates can now be detected simply, routinely and  
 CC rapidly, without requiring sophisticated equipment. The method can be  
 CC made quantitative, by analysing a series of dilutions, and can be  
 CC automated to allow many samples to be analysed on the same filter. The  
 CC present sequence represents the Huntington's gene exon 1 translation  
 CC product which is connected to a GST protein to form a fusion protein. The  
 CC sequence of the GST protein is not indicated  
 XX  
 SQ Sequence 108 AA;

Query Match 72.5%; Score 208; DB 2; Length 108;  
 Best Local Similarity 97.7%; Pred. No. 1.3e-16;

Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

### RESULT 13

AAW95076

ID AAW95076 standard; protein; 108 AA.

XX

AC AAW95076;

XX

DT 20-MAY-1999 (first entry)

XX

DE Amino acid sequence of Huntington's gene exon 1 in GST-HD fusion protein.

XX

KW Fusion protein; amyloidogenic polypeptide; amyloid-like fibril; scrapie;  
KW protein aggregate; Alzheimer's disease; CAG-repeat expansion; spinal;  
KW Huntington's disease; bulbar muscular atrophy; spinocerebellar ataxia;  
KW dentatorubral pallidoluysian atrophy; Creutzfeld-Jakob disease; enzyme;  
KW GST-HD; HD.

XX

OS Synthetic.

OS Homo sapiens.

XX

FH	Key	Location/Qualifiers
----	-----	---------------------

FT Misc-difference 1

```
FT          /note= "GST protein connected to the N-terminal"
```

FT Misc-difference 25

FT                    /note= "polyglutamine expansion that can comprise upto 51  
FT                    glutamines"

XX

PN WO9906545-A2.

XX

PD 11-FEB-1999.

XX

PF 31-JUL-1998; 98WO-EP004811.

XX

PR 01-AUG-1997; 97EP-00113306.

XX

PA (PLAC ) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.

XX

PI Wanker E, Lehrach H, Scherzinger E, Bates G;

XX

DR WPI; 1999-153775/13.

XX

PT Composition containing fusion protein that includes amyloidogenic peptide  
PT - able to self-assemble into fibrils or aggregates, used to detect and  
PT monitor neuronal diseases, and also to screen for therapeutic inhibitors.  
...

XX

PS Example 1; Fig 2; 62pp; English.

XX

CC The invention relates to a composition comprising a fusion protein of (i)  
CC (poly)peptide that increases solubility and/or prevents aggregation of  
CC fusion protein, and (ii) amyloidogenic (poly)peptide that can self-  
CC assemble into amyloid-like fibrils or protein aggregates. Host cells

CC transformed with a vector containing the nucleic acid encoding the fusion  
 CC protein are used for the recombinant expression of the fusion protein.  
 CC The composition is used to detect onset and progression of diseases  
 CC associated with fibrils/protein aggregates. It is potentially useful for  
 CC treatment of such diseases (e.g. Alzheimer's disease, scrapie or CAG-  
 CC repeat expansion conditions such as Huntington's disease (HD), spinal and  
 CC bulbar muscular atrophy, dentatorubral pallidoluysian atrophy,  
 CC spinocerebellar ataxia, Creutzfeld-Jakob disease). Assay methods based on  
 CC release of the amyloidogenic polypeptide from fusion protein have a  
 CC precise starting time for aggregate formation, allowing kinetic  
 CC measurements, and use of an enzyme for cleavage allows testing under  
 CC physiological conditions. The present sequence represents the  
 CC Huntington's gene exon 1 translation product which is connected to a GST  
 CC protein to form a fusion protein. The sequence of the GST protein is not  
 CC indicated

XX

SQ Sequence 108 AA;

Query Match 72.5%; Score 208; DB 2; Length 108;  
 Best Local Similarity 97.7%; Pred. No. 1.3e-16;  
 Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 ||||||||||||||||||||||||||||||||||||||||  
 Db 8 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 51

#### RESULT 14

AAB69609

ID AAB69609 standard; protein; 121 AA.

XX

AC AAB69609;

XX

DT 30-APR-2001 (first entry)

XX

DE Huntingtin accumulation inhibitor peptide HD-Q104-GFP.

XX

KW Neurological disorder; Huntington's disease; Alzheimer's disease;  
 KW Parkinson's disease; prion disease; frontotemporal dementia;  
 KW amyotrophic lateral sclerosis; spinal and bulbar muscular atrophy;  
 KW dentatorubal-pallidoluysian atrophy; spinocerebellar ataxia type 1; SCA2;  
 KW SCA3; SCA4; SCA5; SCA6; SCA7; protein accumulation; intrabody.

XX

OS Synthetic.

XX

PN WO200106989-A2.

XX

PD 01-FEB-2001.

XX

PF 24-JUL-2000; 2000WO-US020131.

XX

PR 27-JUL-1999; 99US-0146047P.

PR 21-JUL-2000; 2000US-00620955.

XX

PA (HUST/) HUSTON J S.

PA (MESS/) MESSER A.

PA (LECE/) LECERF J.

XX  
 PI Huston JS, Messer A, Lecerf J;  
 XX  
 DR WPI; 2001-182700/18.  
 XX  
 PT Inhibiting intracellular polypeptide accumulation, useful for treating  
 PT neurological disorders, e.g. Alzheimer's disease, comprises contacting  
 PT the polypeptide with a specific intrabody.  
 XX  
 PS Disclosure; Page 98; 108pp; English.  
 XX  
 CC The present invention describes a method for inhibiting the formation of  
 CC aggregates of certain proteins, involving contacting the protein with a  
 CC binding molecule known as an intrabody. Proteins to be bound include  
 CC those associated with neurological disorders, and so the method can be  
 CC used in the prevention of diseases such as Alzheimer's, Parkinson's and  
 CC Huntington's diseases, prion disease, frontotemporal dementia,  
 CC amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy,  
 CC dentatorubal-pallidoluysian atrophy, spinocerebellar ataxia type 1  
 CC (SCA1), SCA2, SCA3, SCA4, SCA5, SCA6 and SCA7  
 XX  
 SQ Sequence 121 AA;

Query Match 72.5%; Score 208; DB 4; Length 121;  
 Best Local Similarity 97.7%; Pred. No. 1.5e-16;  
 Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 |||||  
 Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 44

# RESULT 15

AAB69611

ID AAB69611 standard; protein; 123 AA.  
 XX  
 AC AAB69611;  
 XX  
 DT 30-APR-2001 (first entry)  
 XX  
 DE Huntingtin accumulation inhibitor peptide HD-Q72-Myc-HIS6.  
 XX  
 KW Neurological disorder; Huntington's disease; Alzheimer's disease;  
 KW Parkinson's disease; prion disease; frontotemporal dementia;  
 KW amyotrophic lateral sclerosis; spinal and bulbar muscular atrophy;  
 KW dentatorubal-pallidoluysian atrophy; spinocerebellar ataxia type 1; SCA2;  
 KW SCA3; SCA4; SCA5; SCA6; SCA7; protein accumulation; intrabody.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200106989-A2.  
 XX  
 PD 01-FEB-2001.  
 XX  
 PF 24-JUL-2000; 2000WO-US020131.  
 XX  
 PR 27-JUL-1999; 99US-0146047P.

PR 21-JUL-2000; 2000US-00620955.

XX

PA (HUST/) HUSTON J S.

PA (MESS/) MESSER A.

PA (LECE/) LECERF J.

XX

PI Huston JS, Messer A, Lecerf J;

XX

DR WPI; 2001-182700/18.

XX

PT Inhibiting intracellular polypeptide accumulation, useful for treating  
PT neurological disorders, e.g. Alzheimer's disease, comprises contacting  
PT the polypeptide with a specific intrabody.

XX

PS Disclosure; Page 98-99; 108pp; English.

XX

CC The present invention describes a method for inhibiting the formation of  
CC aggregates of certain proteins, involving contacting the protein with a  
CC binding molecule known as an intrabody. Proteins to be bound include  
CC those associated with neurological disorders, and so the method can be  
CC used in the prevention of diseases such as Alzheimer's, Parkinson's and  
CC Huntington's diseases, prion disease, frontotemporal dementia,  
CC amyotrophic lateral sclerosis, spinal and bulbar muscular atrophy,  
CC dentatorubal-pallidoluyian atrophy, spinocerebellar ataxia type 1  
CC (SCA1), SCA2, SCA3, SCA4, SCA5, SCA6 and SCA7

XX

SQ Sequence 123 AA;

Query Match 72.5%; Score 208; DB 4; Length 123;

Best. Local Similarity 97.7%; Pred. No. 1.5e-16;

Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 50

|||||||||||||||||||||||||||||||||||||||||

Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 44

Search completed: March 12, 2004, 15:38:30

Job time : 42.6471 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 12, 2004, 15:38:34 ; Search time 12.1471 Seconds  
(without alignments)  
250.755 Million cell updates/sec

Title: US-09-620-955B-10  
Perfect score: 287  
Sequence: 1 LVPRGSMATLEKLMKAFESL.....QQQQQQQQQLQPGSTRAAAS 59

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued\_Patents\_AA:\*  
1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pep:\*  
2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pep:\*  
3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pep:\*  
4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pep:\*  
5: /cgn2\_6/ptodata/2/iaa/PCTUS\_COMB.pep:\*  
6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query		DB	ID	Description
	Score	Match Length			
1	196	68.3 513	3	US-09-041-886-28	Sequence 28, Appl
2	196	68.3 530	3	US-09-041-886-29	Sequence 29, Appl
3	196	68.3 552	3	US-09-041-886-30	Sequence 30, Appl
4	196	68.3 589	3	US-09-041-886-31	Sequence 31, Appl
5	196	68.3 3144	1	US-08-246-982A-6	Sequence 6, Appli
6	196	68.3 3144	1	US-08-453-265-6	Sequence 6, Appli
7	196	68.3 3144	2	US-08-457-273B-42	Sequence 42, Appl
8	196	68.3 3144	3	US-08-556-419-21	Sequence 21, Appl
9	196	68.3 3144	3	US-09-041-886-15	Sequence 15, Appl
10	143	49.8 1402	4	US-09-125-635-12	Sequence 12, Appl

11	142.5	49.7	528	4	US-09-086-663A-82	Sequence 82, Appl
12	142.5	49.7	548	4	US-09-086-663A-71	Sequence 71, Appl
13	142.5	49.7	596	4	US-09-086-663A-2	Sequence 2, Appli
14	142.5	49.7	596	4	US-09-086-663A-80	Sequence 80, Appl
15	140.5	49.0	513	3	US-09-100-193-3	Sequence 3, Appli
16	137	47.7	360	2	US-08-531-927B-2	Sequence 2, Appli
17	137	47.7	360	3	US-09-041-886-13	Sequence 13, Appl
18	136	47.4	2074	4	US-09-491-356C-9	Sequence 9, Appli
19	135	47.0	910	4	US-08-997-685A-2	Sequence 2, Appli
20	131	45.6	2023	4	US-09-491-356C-8	Sequence 8, Appli
21	130	45.3	1420	4	US-09-125-635-4	Sequence 4, Appli
22	129	44.9	521	4	US-09-086-663A-79	Sequence 79, Appl
23	129	44.9	521	4	US-09-086-663A-81	Sequence 81, Appl
24	129	44.9	1282	4	US-09-543-681A-5419	Sequence 5419, Ap
25	129	44.9	2703	1	US-08-185-432-19	Sequence 19, Appl
26	129	44.9	2703	4	US-08-899-232-4	Sequence 4, Appli
27	125	43.6	25	3	US-09-041-886-9	Sequence 9, Appli
28	123	42.9	816	2	US-08-267-803B-9	Sequence 9, Appli
29	123	42.9	816	3	US-09-041-886-17	Sequence 17, Appl
30	121.5	42.3	154	3	US-09-041-886-32	Sequence 32, Appl
31	121.5	42.3	918	3	US-09-041-886-11	Sequence 11, Appl
32	120	41.8	1088	4	US-09-233-857-13	Sequence 13, Appl
33	120	41.8	1099	4	US-09-442-100-2	Sequence 2, Appli
34	120	41.8	1099	4	US-08-939-106-2	Sequence 2, Appli
35	120	41.8	1099	4	US-09-442-102-2	Sequence 2, Appli
36	118	41.1	71	4	US-09-146-054-9	Sequence 9, Appli
37	118	41.1	71	4	US-09-664-977A-9	Sequence 9, Appli
38	118	41.1	795	1	US-07-716-827C-5	Sequence 5, Appli
39	118	41.1	1070	4	US-09-091-042A-2	Sequence 2, Appli
40	118	41.1	3119	1	US-08-246-982A-16	Sequence 16, Appl
41	118	41.1	3119	1	US-08-453-265-16	Sequence 16, Appl
42	117	40.8	428	1	US-08-190-802A-29	Sequence 29, Appl
43	117	40.8	428	3	US-08-477-346-29	Sequence 29, Appl
44	117	40.8	428	4	US-08-473-089-29	Sequence 29, Appl
45	117	40.8	428	4	US-08-487-072A-29	Sequence 29, Appl

#### ALIGNMENTS

##### RESULT 1

US-09-041-886-28

; Sequence 28, Application US/09041886

; Patent No. 6235872

##### ; GENERAL INFORMATION:

; APPLICANT: Bredesen, Dale E.

; APPLICANT: Rabizadeh, Sharroz

; TITLE OF INVENTION: Proapoptotic Peptides, Dependence

; TITLE OF INVENTION: Polypeptides and Methods of Use

; NUMBER OF SEQUENCES: 72

##### ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Campbell & Flores LLP

; STREET: 4370 La Jolla Village Drive, Suite 700

; CITY: San Diego

; STATE: California

; COUNTRY: United States

; ZIP: 92122

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/041,886
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-LJ 2626
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 513 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-041-886-28

```

```

Query Match          68.3%; Score 196; DB 3; Length 513;
Best Local Similarity 91.1%; Pred. No. 6.2e-16;
Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

Qy      7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51
        |||
Db      1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQPPPPP 45

```

# RESULT 2

US-09-041-886-29

```

; Sequence 29, Application US/09041886
; Patent No. 6235872
; GENERAL INFORMATION:
; APPLICANT: Bredesen, Dale E.
; APPLICANT: Rabizadeh, Sharroz
; TITLE OF INVENTION: Proapoptotic Peptides, Dependence
; TITLE OF INVENTION: Polypeptides and Methods of Use
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/041,886

```

```

; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-LJ 2626
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 530 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-09-041-886-29

```

```

Query Match          68.3%; Score 196; DB 3; Length 530;
Best Local Similarity 91.1%; Pred. No. 6.5e-16;
Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

Qy      7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51
        |||||||||||||||||||||||||||||||||||||
Db      1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQPPPPP 45

```

RESULT 3

US-09-041-886-30

```

; Sequence 30, Application US/09041886
; Patent No. 6235872
; GENERAL INFORMATION:
; APPLICANT: Bredesen, Dale E.
; APPLICANT: Rabizadeh, Sharroz
; TITLE OF INVENTION: Proapoptotic Peptides, Dependence
; TITLE OF INVENTION: Polypeptides and Methods of Use
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/041,886
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-LJ 2626
; TELECOMMUNICATION INFORMATION:

```



; MOLECULE TYPE: peptide  
US-09-041-886-31

Query Match 68.3%; Score 196; DB 3; Length 589;  
Best Local Similarity 91.1%; Pred. No. 7.3e-16;  
Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
|||||  
Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQPPPPP 45

RESULT 5

US-08-246-982A-6

; Sequence 6, Application US/08246982A

; Patent No. 5686288

; GENERAL INFORMATION:

; APPLICANT: MacDonald, Marcy E.

; APPLICANT: Ambrose, Christine M.

; APPLICANT: Duyao, Mabel P.

; APPLICANT: Gusella, James F.

; TITLE OF INVENTION: Huntingtin DNA, Protein And Uses Thereof

; NUMBER OF SEQUENCES: 25

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Sterne, Kessler, Goldstein & Fox

; STREET: 1100 New York Avenue

; CITY: Washington

; STATE: D.C.

; COUNTRY: U.S.A.

; ZIP: 20005

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/246,982A

; FILING DATE: May 20, 1994

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Goldstein, Jorge, A.

; REGISTRATION NUMBER: 29,021

; REFERENCE/DOCKET NUMBER: 0609.3880002

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 371-2600

; TELEFAX: (202) 371-2540

; INFORMATION FOR SEQ ID NO: 6:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 3144 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-246-982A-6

Query Match 68.3%; Score 196; DB 1; Length 3144;  
Best Local Similarity 91.1%; Pred. No. 4.6e-15;  
Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
 |||||  
 Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQPPPPP 45

RESULT 6

US-08-453-265-6

; Sequence 6, Application US/08453265

; Patent No. 5693757

; GENERAL INFORMATION:

; APPLICANT: MacDonald, Marcy E.

; APPLICANT: Ambrose, Christine M.

; APPLICANT: Duyao, Mabel P.

; APPLICANT: Gusella, James F.

; TITLE OF INVENTION: Huntingtin DNA, Protein And Uses Thereof

; NUMBER OF SEQUENCES: 25

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Sterne, Kessler, Goldstein & Fox

; STREET: 1100 New York Avenue

; CITY: Washington

; STATE: D.C.

; COUNTRY: U.S.A.

; ZIP: 20005

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/453,265

; FILING DATE: 30-MAY-1995

; CLASSIFICATION: 514

; ATTORNEY/AGENT INFORMATION:

; NAME: Ludwig, Steven R.

; REGISTRATION NUMBER: 36,203

; REFERENCE/DOCKET NUMBER: 0609.3880003

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 371-2600

; TELEFAX: (202) 371-2540

; INFORMATION FOR SEQ ID NO: 6:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 3144 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-453-265-6

Query Match 68.3%; Score 196; DB 1; Length 3144;

Best Local Similarity 91.1%; Pred. No. 4.6e-15;

Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
 |||||  
 Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQPPPPP 45

## RESULT 7

```

US-08-457-273B-42
; Sequence 42, Application US/08457273B
; Patent No. 5849995
; GENERAL INFORMATION:
;   APPLICANT:  Hayden, Michael
;   APPLICANT:  Lin, Biaoyang
;   APPLICANT:  Nasir, Jamal
;   TITLE OF INVENTION:  Mouse Model for Huntington's Disease and
;   TITLE OF INVENTION:  Related DNA Sequences
;   NUMBER OF SEQUENCES:  42
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Virginia Bennett
;     STREET:    PO Box 37428
;     CITY:      Raleigh
;     STATE:     No. 5849995th Carolina
;     COUNTRY:   US
;     ZIP:       27627
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:     IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:     PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/457,273B
;     FILING DATE:
;     CLASSIFICATION:    800
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Bennett, Virginia C.
;     REGISTRATION NUMBER:  37,092
;     REFERENCE/DOCKET NUMBER:  3477-85A
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  919-854-1400
;     TELEFAX:    919-854-1401
;   INFORMATION FOR SEQ ID NO:  42:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  3144 amino acids
;       TYPE:    amino acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  peptide
US-08-457-273B-42

```

Query Match 68.3%; Score 196; DB 2; Length 3144;  
Best Local Similarity 91.1%; Pred. No. 4.6e-15;  
Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

QY      7 MATLEKLMKAFESLKSFOOOOOOOOOOOOOOOOOOOOOOOOOLQP 51
        |||||||||||||||||||||||||||||||||||||
Db      1 MATLEKLMKAFESLKSFOOOOOOOOOOOOOOOOOOOOOOOPPPPP 45

```

## RESULT 8

US-08-556-419-21  
; Sequence 21, Application US/08556419C  
; Patent No. 6093549  
; GENERAL INFORMATION:



; APPLICANT: Ross, Christopher  
 ; APPLICANT: Li, Xiao-Jiang  
 ; APPLICANT: Li, Shi-Hua  
 ; APPLICANT: Sharp, Alan  
 ; APPLICANT: Lanahan, Anthony  
 ; APPLICANT: Worley, Paul  
 ; APPLICANT: Snyder, Solomon  
 ; TITLE OF INVENTION: Huntingtin-associated protein  
 ; FILE REFERENCE: 01107.52271  
 ; CURRENT APPLICATION NUMBER: US/08/556,419C  
 ; CURRENT FILING DATE: 1995-11-09  
 ; NUMBER OF SEQ ID NOS: 25  
 ; SOFTWARE: FastSEQ for Windows Version 3.0  
 ; SEQ ID NO 21  
 ; LENGTH: 3144  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-08-556-419-21

Query Match 68.3%; Score 196; DB 3; Length 3144;  
 Best Local Similarity 91.1%; Pred. No. 4.6e-15;  
 Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
 |||||  
 Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQPPPPP 45

RESULT 9

US-09-041-886-15

; Sequence 15, Application US/09041886  
 ; Patent No. 6235872  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Bredesen, Dale E.  
 ; APPLICANT: Rabizadeh, Sharroz  
 ; TITLE OF INVENTION: Proapoptotic Peptides, Dependence  
 ; TITLE OF INVENTION: Polypeptides and Methods of Use  
 ; NUMBER OF SEQUENCES: 72  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Campbell & Flores LLP  
 ; STREET: 4370 La Jolla Village Drive, Suite 700  
 ; CITY: San Diego  
 ; STATE: California  
 ; COUNTRY: United States  
 ; ZIP: 92122  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/041,886  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Campbell, Cathryn A.  
 ; REGISTRATION NUMBER: 31,815

```
; REFERENCE/DOCKET NUMBER: P-LJ 2626
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3144 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-041-886-15
```

```
Query Match          68.3%; Score 196; DB 3; Length 3144;
Best Local Similarity 91.1%; Pred. No. 4.6e-15;
Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
Qy      7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51
          |||
Db      1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQPPPPP 45
```

# RESULT 10

US-09-125-635-12

```
; Sequence 12, Application US/09125635
; Patent No. 6562589
; GENERAL INFORMATION:
; APPLICANT: THE UNITED STATES OF AMERICA represented by THE SE
; TITLE OF INVENTION: AIB1, A novel steroid receptor co-activator
; FILE REFERENCE: 49944
; CURRENT APPLICATION NUMBER: US/09/125,635
; CURRENT FILING DATE: 1998-08-21
; PRIOR APPLICATION NUMBER: 60/049,728
; PRIOR FILING DATE: 1997-06-17
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 12
; LENGTH: 1402
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-125-635-12
```

```
Query Match          49.8%; Score 143; DB 4; Length 1402;
Best Local Similarity 62.5%; Pred. No. 4.7e-09;
Matches 35; Conservative 5; Mismatches 8; Indels 8; Gaps 2;
```

```
Qy      2 VPR----GSMATL----EKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQL 49
          :||  ||: ||  :| | ||: |||||
Db      937 LPRPAMGGSVPTLPLRSNRLPGARPSLQQQQQQQQQQQQQQQQQQQQQQQQQQQM 992
```

# RESULT 11

US-09-086-663A-82

```
; Sequence 82, Application US/09086663A
; Patent No. 6518063
; GENERAL INFORMATION:
; APPLICANT: DUCY, PATRICIA
; APPLICANT: KARSENTY, GERARD
```



RESULT 13

US-09-086-663A-2

; Sequence 2, Application US/09086663A  
 ; Patent No. 6518063  
 ; GENERAL INFORMATION:  
 ; APPLICANT: DUCY, PATRICIA  
 ; APPLICANT: KARSENTY, GERARD  
 ; TITLE OF INVENTION: OSF2/CBFA1 COMPOSITIONS AND METHODS OF USE  
 ; FILE REFERENCE: UTSC:525  
 ; CURRENT APPLICATION NUMBER: US/09/086,663A  
 ; CURRENT FILING DATE: 1998-05-29  
 ; PRIOR APPLICATION NUMBER: 60/080,189  
 ; PRIOR FILING DATE: 1998-03-24  
 ; PRIOR APPLICATION NUMBER: 60/048,430  
 ; PRIOR FILING DATE: 1997-05-29  
 ; NUMBER OF SEQ ID NOS: 83  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 2  
 ; LENGTH: 596  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
 ; OTHER INFORMATION: Peptide

US-09-086-663A-2

Query Match 49.7%; Score 142.5; DB 4; Length 596;  
 Best Local Similarity 58.2%; Pred. No. 2.1e-09;  
 Matches 32; Conservative 7; Mismatches 11; Indels 5; Gaps 1;

Qy 5 GSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ LQPGSTRAAAS 59  
 | |: : :: | : | | | | | | | | | | | | | | | | | : | | |:  
 Db 105 GKMSDVSPVVAQQ-----QQQQQQQQQQQQQQQQQQQQQQQQQQQQQEAAAAAAAA 154

RESULT 14

US-09-086-663A-80

; Sequence 80, Application US/09086663A  
 ; Patent No. 6518063  
 ; GENERAL INFORMATION:  
 ; APPLICANT: DUCY, PATRICIA  
 ; APPLICANT: KARSENTY, GERARD  
 ; TITLE OF INVENTION: OSF2/CBFA1 COMPOSITIONS AND METHODS OF USE  
 ; FILE REFERENCE: UTSC:525  
 ; CURRENT APPLICATION NUMBER: US/09/086,663A  
 ; CURRENT FILING DATE: 1998-05-29  
 ; PRIOR APPLICATION NUMBER: 60/080,189  
 ; PRIOR FILING DATE: 1998-03-24  
 ; PRIOR APPLICATION NUMBER: 60/048,430  
 ; PRIOR FILING DATE: 1997-05-29  
 ; NUMBER OF SEQ ID NOS: 83  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 80  
 ; LENGTH: 596  
 ; TYPE: PRT

; ORGANISM: Artificial Sequence  
;  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: Peptide  
US-09-086-663A-80

Query Match 49.7%; Score 142.5; DB 4; Length 596;  
Best Local Similarity 58.2%; Pred. No. 2.1e-09;  
Matches 32; Conservative 7; Mismatches 11; Indels 5; Gaps 1;

Qy 5 GSMATLEKLMKAFESLKSFOOOOOOOOOOOOOOOOOOOOOOOOQPGSTRAAAS 59  
| |: : :: | : ||||| : |||:  
Db 105 GKMSDVSPVVAQQ-----OOOOOOOOOOOOOOOOOOOOOOOEAAAAAAAAA 154

RESULT 15

US-09-100-193-3  
; Sequence 3, Application US/09100193  
; Patent No. 6153729  
; GENERAL INFORMATION:  
; APPLICANT: Gary S. Stein et al.  
; TITLE OF INVENTION: NUCLEAR MATRIX TARGETING PEPTIDES AND USES THEREFORE  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: LAHIVE & COCKFIELD  
; STREET: 28 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/100,193  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/050,104  
; FILING DATE: 20-JUNE-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Jane E. Remillard  
; REGISTRATION NUMBER: 38,872  
; REFERENCE/DOCKET NUMBER: UMM-024  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617)227-7400  
; TELEFAX: (617)742-4214  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 513 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: internal  
US-09-100-193-3



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 12, 2004, 15:36:59 ; Search time 9.83333 Seconds  
(without alignments)  
577.149 Million cell updates/sec

Title: US-09-620-955B-10  
Perfect score: 287  
Sequence: 1 LVPRGSMATLEKLMKAFESL.....QQQQQQQQQLQPGSTRAAAS 59

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR\_78:\*  
1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query		Length	DB	ID	Description
		Match					
1	196	68.3		3144	2	A46068	Huntington disease
2	147	51.2		1081	2	S66736	transcription acti
3	147	51.2		1761	2	T13675	hypothetical prote
4	145	50.5		339	1	TWHU2D	transcription init
5	145	50.5		1457	2	T14577	protein kinase Yak
6	141	49.1		966	2	S25365	CYC8 protein - yea
7	140.5	49.0		330	2	A35915	homeotic protein A
8	140.5	49.0		513	2	A48233	polyomavirus enhan
9	140	48.8		1572	2	S45251	SNF2alpha protein
10	139	48.4		2649	2	T51023	hypothetical prote
11	137	47.7		360	2	S50830	Machado-Joseph dis
12	136	47.4		139	2	A26892	Mopa box protein -
13	135	47.0		646	2	D82493	conserved hypothet

14	135	47.0	1154	2	S69206	regulator protein
15	134	46.7	1015	2	T13062	CLOCK protein - fr
16	134	46.7	1023	2	T13068	CLOCK protein - fr
17	134	46.7	1027	2	T13071	CLOCK protein - fr
18	133.5	46.5	445	1	S31224	transcription fact
19	133.5	46.5	445	1	A49447	transcription fact
20	133	46.3	796	2	JC7555	C14orf4 protein -
21	133	46.3	905	1	RGBYS5	regulatory protein
22	132.5	46.2	1586	2	S39580	HBRM protein - hum
23	132	46.0	356	2	S31574	hypothetical prote
24	131.5	45.8	1125	2	T14892	transcription fact
25	131	45.6	1969	2	T08875	histidine kinase h
26	130	45.3	623	2	A49840	segment polarity p
27	130	45.3	1424	2	T03851	thyroid hormone re
28	130	45.3	4957	2	T03455	ALR protein - huma
29	130	45.3	5262	2	T03454	ALR protein - huma
30	129	44.9	1090	2	A41696	regulatory protein
31	129	44.9	1905	2	T18267	multidrug resistan
32	129	44.9	2150	2	S71629	sensory transducti
33	129	44.9	2703	1	A24420	notch protein - fr
34	128	44.6	443	1	S29334	transcription fact
35	128	44.6	758	2	S54522	hypothetical prote
36	128	44.6	853	2	T46347	hypothetical prote
37	127	44.3	644	2	S39356	transcription fact
38	127	44.3	700	2	S09699	bib protein - frui
39	127	44.3	910	2	A34721	androgen receptor
40	127	44.3	911	2	B34721	androgen receptor
41	126.5	44.1	919	2	A39248	androgen receptor
42	126.5	44.1	1012	2	I53172	RAE-28 - mouse
43	126	43.9	1726	2	A39401	merozoite surface
44	126	43.9	3848	2	T17414	TipC protein - sli
45	125.5	43.7	539	2	S57972	hypothetical prote

#### ALIGNMENTS

##### RESULT 1

A46068

Huntington disease-associated protein - human

C;Species: Homo sapiens (man)

C;Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 08-Oct-1999

C;Accession: A46068; I54337

R;MacDonald, M.E.; Ambrose, C.M.; Duyao, M.P.; Myers, R.H.; Lin, C.; Srinidhi, L.; Barnes, G.; Taylor, S.A.; James, M.; Groot, N.; MacFarlane, H.; Jenkins, B.; Anderson, M.A.; Wexler, N.S.; Gusella, J.F.; Bates, G.P.; Baxendale, S.; Hummerich, H.; Kirby, S.; North, M.; Youngman, S.; Mott, R.; Zehetner, G.; Sedlacek, Z.; Poustka, A.; Frischauf, A.M.; Buckler, A.J.; Church, D.; Doucette-Stamm, L.; O'Donovan, M.C.; Riba-Ramirez, L.; Shah, M.; Stanton, V.P.; Strobel, S.A.; Draths, K.M.

Cell 72, 971-983, 1993

A;Authors: Wales, J.L.; Dervan, P.; Housman, D.E.; Altherr, M.; Shiang, R.; Thompson, L.; Fielder, T.; Wasmuth, J.J.; Tagle, D.; Valdes, J.; Elmer, L.; Allard, M.; Castilla, L.; Swaroop, M.; Blanchard, K.; Collins, F.S.; Snell, R.; Holloway, T.; Gillespie, K.; Datson, N.; Shaw, D.; Harper, P.S.

A;Title: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.



A;Reference number: A46068; MUID:93208892; PMID:8458085  
 A;Accession: A46068  
 A;Status: preliminary  
 A;Molecule type: mRNA  
 A;Residues: 1-3144 <MAC>  
 A;Cross-references: GB:L12392  
 R;Lin, B.; Rommens, J.M.; Graham, R.K.; Kalchman, M.; MacDonald, H.; Nasir, J.;  
 Delaney, A.; Goldberg, Y.P.; Hayden, M.R.  
 Hum. Mol. Genet. 2, 1541-1545, 1993  
 A;Title: Differential 3' polyadenylation of the Huntington disease gene results  
 in two mRNA species with variable tissue expression.  
 A;Reference number: I54337; MUID:94093536; PMID:7903579  
 A;Accession: I54337  
 A;Status: preliminary; translated from GB/EMBL/DDBJ  
 A;Molecule type: mRNA  
 A;Residues: 2563-3144 <RES>  
 A;Cross-references: GB:L20431; NID:g398028; PIDN:AAA52702.1; PID:g398029  
 C;Genetics:  
 A;Gene: GDB:HD  
 A;Cross-references: GDB:119307; OMIM:143100  
 A;Map position: 4p16.3-4p16.3

Query Match 68.3%; Score 196; DB 2; Length 3144;  
 Best Local Similarity 91.1%; Pred. No. 5.8e-11;  
 Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
 |||  
 Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQPPPPPP 45

## RESULT 2

S66736

transcription activator GAL11 - yeast (*Saccharomyces cerevisiae*)

N;Alternate names: protein O1280; protein YOL051w

C;Species: *Saccharomyces cerevisiae*

C;Date: 12-Jul-1996 #sequence revision 12-Jul-1996 #text change 23-Mar-2001

C;Accession: S66736; S66743; S59300; S61730; S45695; A31565

R;Ansorge, W.; Benes, V.; Rechmann, S.; Schwager, C.; Teodoru, C.; Voss, H.;  
 Wiemann, S.

submitted to the Protein Sequence Database, July 1996

A;Reference number: S66723

A;Accession: S66736

A;Molecule type: DNA

A;Residues: 1-1081 <ANS>

A;Cross-references: EMBL:Z74793; NID:g1419855; PID:e252273; PID:g1419856;

MIPS:YOL051w

A;Experimental source: strain S288C

R;Feldmann, H.; Mannhaupt, G.; Vetter, I.

submitted to the Protein Sequence Database, July 1996

A;Reference number: S66743

A;Accession: S66743

A;Molecule type: DNA

A;Residues: 1-351 <FEL>

A;Cross-references: EMBL:Z74793; MIPS:YOL051w

A;Experimental source: strain S288C

R;Mannhaupt, G.; Vetter, I.; Schwarzlose, C.; Mitzel, S.; Feldmann, H.

submitted to the EMBL Data Library, August 1995  
A;Description: Analysis of a 26kb region on the left arm of yeast chromosome XV.  
A;Reference number: S59285  
A;Accession: S59300  
A;Molecule type: DNA  
A;Residues: 1-351 <FEW>  
A;Cross-references: EMBL:X91067; NID:g984177; PID:g984193  
R;Mannhaupt, G.; Vetter, I.; Schwarzlose, C.; Mitzel, S.; Feldmann, H.  
Yeast 12, 67-76, 1996  
A;Title: Analysis of a 26 kb region on the left arm of yeast chromosome XV.  
A;Reference number: S61715; MUID:96381248; PMID:8789261  
A;Accession: S61730  
A;Status: nucleic acid sequence not shown; translation not shown  
A;Molecule type: DNA  
A;Residues: 1-351 <MAN>  
A;Cross-references: EMBL:X91067; NID:g984177; PIDN:CAA62537.1; PID:g984193  
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1995  
R;Suzuki, Y.; Nogi, Y.; Abe, A.; Fukasawa, T.  
Mol. Cell. Biol. 12, 4806, 1992  
A;Reference number: S45695; MUID:93024425; PMID:1406662  
A;Contents: erratum  
A;Accession: S45695  
A;Status: nucleic acid sequence not shown; translation not shown  
A;Molecule type: DNA  
A;Residues: 1-170,'T',172-301,'Q',303-498,'T',500-750,'Q',752-1081 <SUZ1>  
A;Cross-references: EMBL:M22481; NID:gl71549; PID:gl71550  
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1992  
A;Note: this is a revision to the sequence from reference A31565  
R;Suzuki, Y.; Nogi, Y.; Abe, A.; Fukasawa, T.  
Mol. Cell. Biol. 8, 4991-4999, 1988  
A;Title: GAL11 protein, an auxiliary transcription activator for genes encoding galactose-metabolizing enzymes in Saccharomyces cerevisiae.  
A;Reference number: A31565; MUID:89096873; PMID:3062377  
A;Accession: A31565  
A;Molecule type: DNA  
A;Residues: 118-1081 <SUZ2>  
A;Cross-references: EMBL:M22481  
A;Note: this sequence has been revised in reference S45695  
C;Genetics:  
A;Gene: SGD:GAL11  
A;Cross-references: SGD:S0005411; MIPS:YOL051w  
A;Map position: 15L  
C;Keywords: transcription regulation

Query Match 51.2%; Score 147; DB 2; Length 1081;  
Best Local Similarity 51.7%; Pred. No. 1.1e-06;  
Matches 30; Conservative 11; Mismatches 13; Indels 4; Gaps 1;

Qy 6 SMATLEKLMKAFESLKSFQ----QQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAAAS 59  
::|| : : : : : : | | | | | | | | | | | | | | : | | | | :  
Db 651 NIATQONMQQSLOQMQLHQLKMQQQQQQQQQQQQQQQQQQQQQQQQHIYPSSTPGVAN 708

RESULT 3  
T13675





[illegible]

RESULT 6

S25365

CYC8 protein - yeast (*Saccharomyces cerevisiae*)

N;Alternate names: glucose repression mediator; protein YBR0908; protein YBR112c; SSN6 protein

C;Species: *Saccharomyces cerevisiae*

C;Date: 17-Apr-1993 #sequence revision 17-Apr-1993 #text change 11-Jan-2000

C;Accession: S25365; S48277; S45980; S25404; S25405; A30906; S44692

R;Mannhaupt, G.; Stucka, R.; Ehnle, S.; Vetter, I.; Feldmann, H.

Yeast 8, 397-408, 1992

A;Title: Molecular analysis of yeast chromosome II between CMD1 and LYS2: the excision repair gene RAD16 located in this region belongs to a novel group of double-finger proteins.

A;Reference number: S25364; MUID:92327848; PMID:1626431

A;Accession: S25365

A;Molecule type: DNA

A;Residues: 1-966 <MAN>

A;Cross-references: EMBL:X66247; NID:g3548; PIDN:CAA46973.1; PID:g3550

R; Mannhaupt, G.; Stucka, R.; Ehnle, S.; Vetter, I.; Feldmann, H.

Yeast 10, 1363-1381, 1994

A;Title: Analysis of a 70 kb region on the right arm of yeast chromosome II.

A;Reference number: S48255; MUID:95208357; PMID:7900426

A;Accession: S48277

A;Status: nucleic acid sequence not shown; translation not shown

A;Molecule type: DNA

A;Residues: 1-966 <MAW>

A;Cross-references: EMBL:X78993; NID:g476045; PIDN:CAA55615.1; PID:g476068

A;Note: the nucleotide sequence was submitted to the EMBL Data Library, April 1994

R; Feldmann, H.; Mannhaupt, G.; Schwarzlose, C.; Vetter, I.

submitted to the Protein Sequence Database, August 1994

A;Reference number: S45927

A;Accession: S45980

A;Molecule type: DNA

A;Residues: 1-966 <FE2>

A;Cross-references: EMBL:Z35981; NID:g536449; PIDN:CAA85069.1; PID:g536450; MIPS:YBR112c

R;Schultz, J.; Carlson, M.

Mol. Cell. Biol. 7, 3637-3645, 1987

A;Title: Molecular analysis of SSN6, a gene functionally related to the SNF1 protein kinase of *Saccharomyces cerevisiae*.

A;Reference number: S25404; MUID:88065502; PMID:3316983

A;Accession: S25404

A;Molecule type: DNA

A;Residues: 1-546, 'K', 548-966 <SCH>

A;Cross-references: EMBL:M17826; NID:q172725; PIDN:AAA35103.1; PID:q172726

R;Trumbly, R.J.

Gene 73, 97-111, 1988

A;Title: Cloning and characterization of the CYC8 gene mediating glucose repression in yeast.

A;Reference number: S25405; MUID:89211964; PMID:2854095

A;Accession: S25405

A;Molecule type: DNA



## RESULT 8

A48233

polyomavirus enhancer-binding protein 2 alpha chain type 1 - mouse

Alternate names: PEA2 alpha chain type 1; PEA2 alpha chain type 2; PEBP2 alpha chain type 1; PEBP2 alpha chain type 2

C;Species: Mus musculus (house mouse)

C;Date: 26-May-1994 #sequence revision 26-May-1994 #text change 01-Dec-2000

C;Accession: A48233; B48233

R;Ogawa, E.; Maruyama, M.; Kagoshima, H.; Inuzuka, M.; Lu, J.; Satake, M.; Shigesada, K.; Ito, Y.

Proc. Natl. Acad. Sci. U.S.A. 90, 6859-6863, 1993

A;Title: PEBP2/PEA2 represents a family of transcription factors homologous to the products of the *Drosophila* runt gene and the human AML1 gene.

A;Reference number: A48233; MUID:93342088; PMID:8341710

A;Accession: A48233

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-513 &lt;OGA&gt;

A;Cross-references: GB:D14636; NID:q391766; PIDN:BAA03485.1; PID:d1003996;

PID: q391767

A;Accession: B48233

A;Status: preliminary

A;Molecule type: mRNA

```
A;Residues: 1-304,'L',306 <OG2>
```

A;Cross-references: GB:D14637; NID:q391768; PIDN:BAA03486.1; PID:q391769

C; Genetics:

A; Gene: PEBP2alphaA

C;Superfamily: transcription factor CBF alpha 2

C;Keywords: alternative splicing; DNA binding; T-cell; transcription factor; transcription regulation

Query Match 49.0%; Score 140.5; DB 2; Length 513;

Best Local Similarity 58.2%; Pred. No. 2.3e-06;

Matches 32; Conservative 6; Mismatches 10; Indels 7; Gaps 1;

Qy 5 GSMATLEKLMKAFESLKSFOOOOOOOOOOOOOOOOOOOOOOOOOOOOOLOPGSTRAAAS 59

[illegible]

## RESULT 9

S45251

SNF2alpha protein - human

C;Species: Homo sapiens (man)

C;Date: 10-Dec-1994 #sequence revision 10-Nov-1995 #text change 02-Aug-2002

C;Accession: S45251

R;Chiba, H.; Muramatsu, M.; Nomoto, A.; Kato, H.

Nucleic Acids Res. 22, 1815-1820, 1994

A;Title: Two human homologues of *Saccharomyces cerevisiae* SWI2/SNF2 and *Drosophila* brachy are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor.

A;Reference number: S45251; MUID:94268902; PMID:8208605

A;Accession: 545251

A;Status: preliminary

A;Molecule type: mRNA  
A;Residues: 1-1572 <CHI>  
A;Cross-references: GB:D26155; NID:g505086; PIDN:BAA05142.1; PID:d1005684;  
PID:g987661  
C;Superfamily: human SNF2alpha protein; bromodomain homology  
F;1409-1464/Domain: bromodomain homology <BRO>

Query Match 48.8%; Score 140; DB 2; Length 1572;  
Best Local Similarity 67.4%; Pred. No. 7e-06;  
Matches 29; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

Qy 9 TLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
||: :: :| |||||  
Db 201 TLQLAVQGKRTLPGQLQQQQQQQQQQQQQQQQQQQQQQQQPQQQP 243

#### RESULT 10

T51023

hypothetical protein B7F21.40 [imported] - Neurospora crassa

C;Species: Neurospora crassa

C;Date: 21-Jul-2000 #sequence\_revision 21-Jul-2000 #text\_change 21-Jul-2000

C;Accession: T51023

R;Schulte, U.; Aign, V.; Hoheisel, J.; Brandt, P.; Fartmann, B.; Holland, R.;  
Nyakatura, G.; Mewes, H.W.; Mannhaupt, G.

submitted to the Protein Sequence Database, July 2000

A;Reference number: Z25286

A;Accession: T51023

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-2649 <SCH>

A;Cross-references: EMBL:AL389901; GSPDB:GN00116; NCSP:B7F21.40

A;Experimental source: BAC clone B7F21; strain OR74A

C;Genetics:

A;Gene: NCSP:B7F21.40

A;Map position: 6

A;Introns: 1619/3; 2584/1

Query Match 48.4%; Score 139; DB 2; Length 2649;  
Best Local Similarity 61.2%; Pred. No. 1.4e-05;  
Matches 30; Conservative 5; Mismatches 14; Indels 0; Gaps 0;

Qy 4 RGSMTLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPG 52  
| :: :: | |: |||||  
Db 2207 REEWSSTQQGQAAVSGLQQRQQQQQQQQQQQQQQQQQQQQQQQQQQG 2255

#### RESULT 11

S50830

Machado-Joseph disease MJD1a protein - human

C;Species: Homo sapiens (man)

C;Date: 14-Jul-1995 #sequence\_revision 21-Jul-1995 #text\_change 28-May-1999

C;Accession: S50830

R;Kawaguchi, Y.; Okamoto, T.; Taniwaki, M.; Aizawa, M.; Inoue, M.; Katayama, S.;  
Kawakami, H.; Nakamura, S.; Nishimura, M.; Akiguchi, I.; Kimura, J.; Narumiya,  
S.; Kakizuka, A.

Nature Genet. 8, 221-228, 1994



A;Title: CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.  
A;Reference number: S50830; MUID:95179166; PMID:7874163  
A;Accession: S50830  
A;Status: preliminary  
A;Molecule type: mRNA  
A;Residues: 1-360 <KAW>  
A;Cross-references: GB:S75313; NID:g833927; PIDN:AAB33571.1; PID:g833928

Query Match 47.7%; Score 137; DB 2; Length 360;  
Best Local Similarity 68.2%; Pred. No. 3.6e-06;  
Matches 30; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

Qy 5 GSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 48  
|: | |:| | |: |||:|||||||  
Db 273 GTNLTSEELRKRREAYFEKQQQKQQQQQQQQQQQQQQQQQQQQQQ 316

#### RESULT 12

A26892

Mopa box protein - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 31-Mar-1989 #sequence\_revision 31-Mar-1989 #text\_change 05-Nov-1999

C;Accession: A26892

R;Duboule, D.; Haenlin, M.; Galliot, B.; Mohier, E.

Mol. Cell. Biol. 7, 2003-2006, 1987

A;Title: DNA sequences homologous to the Drosophila opa repeat are present in murine mRNAs that are differentially expressed in fetuses and adult tissues.

A;Reference number: A26892; MUID:87257908; PMID:2885744

A;Accession: A26892

A;Molecule type: mRNA

A;Residues: 1-139 <DUB>

A;Cross-references: GB:M16362; NID:g200142; PIDN:AAA39860.1; PID:g387503

Query Match 47.4%; Score 136; DB 2; Length 139;  
Best Local Similarity 77.8%; Pred. No. 1.9e-06;  
Matches 28; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

Qy 24 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAAAS 59  
|||||||  
Db 52 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQPHQQQQQAA 87

#### RESULT 13

D82493

conserved hypothetical protein VCA0171 [imported] - Vibrio cholerae (strain N16961 serogroup O1)

C;Species: Vibrio cholerae

C;Date: 18-Aug-2000 #sequence\_revision 20-Aug-2000 #text\_change 02-Feb-2001

C;Accession: D82493

R;Heidelberg, J.F.; Eisen, J.A.; Nelson, W.C.; Clayton, R.A.; Gwinn, M.L.;

Dodson, R.J.; Haft, D.H.; Hickey, E.K.; Peterson, J.D.; Umayam, L.A.; Gill,

S.R.; Nelson, K.E.; Read, T.D.; Tettelin, H.; Richardson, D.; Ermolaeva, M.D.;

Vamathevan, J.; Bass, S.; Qin, H.; Dragoi, I.; Sellers, P.; McDonald, L.;

Utterback, T.; Fleishmann, R.D.; Nierman, W.C.; White, O.; Salzberg, S.L.;

Smith, H.O.; Colwell, R.R.; Mekalanos, J.J.; Venter, J.C.; Fraser, C.M.

Nature 406, 477-483, 2000



CLOCK protein - fruit fly (*Drosophila melanogaster*)  
 N;Alternate names: circadian rhythm protein  
 C;Species: *Drosophila melanogaster*  
 C;Date: 13-Aug-1999 #sequence\_revision 13-Aug-1999 #text\_change 17-Nov-2000  
 C;Accession: T13062  
 R;Allada, R.; White, N.E.; So, W.V.; Hall, J.C.; Rosbash, M.  
 Cell 93, 791-804, 1998  
 A;Title: A mutant *Drosophila* homolog of mammalian CLOCK disrupts circadian rhythms and transcription of period and timeless.  
 A;Reference number: Z17596; MUID:98292177; PMID:9630223  
 A;Accession: T13062  
 A;Status: preliminary; translated from GB/EMBL/DDBJ  
 A;Molecule type: mRNA  
 A;Residues: 1-1015 <ALL>  
 A;Cross-references: EMBL:AF065133; NID:g3213257; PID:g3213258; PIDN:AAC39101.1  
 C;Genetics:  
 A;Gene: Clk  
 A;Cross-references: FlyBase:FBgn0023076  
 A;Map position: 3

Query Match 46.7%; Score 134; DB 2; Length 1015;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-05;  
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 24 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 |||||  
 Db 798 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 824

Search completed: March 12, 2004, 15:41:46  
 Job time : 10.8333 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 12, 2004, 15:39:10 ; Search time 23.4265 Seconds  
(without alignments)  
531.793 Million cell updates/sec

Title: US-09-620-955B-10  
Perfect score: 287  
Sequence: 1 LVPRGSMATLEKLMKAFESL.....QQQQQQQQQLQPGSTRAAAS 59

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 809742 seqs, 211153259 residues

Total number of hits satisfying chosen parameters: 809742

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications\_AA:\*

- 1: /cgn2\_6/ptodata/2/pubpaa/US07\_PUBCOMB.pep:\*
- 2: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB.pep:\*
- 3: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB.pep:\*
- 4: /cgn2\_6/ptodata/2/pubpaa/US06\_PUBCOMB.pep:\*
- 5: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB.pep:\*
- 6: /cgn2\_6/ptodata/2/pubpaa/PCTUS\_PUBCOMB.pep:\*
- 7: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB.pep:\*
- 8: /cgn2\_6/ptodata/2/pubpaa/US08\_PUBCOMB.pep:\*
- 9: /cgn2\_6/ptodata/2/pubpaa/US09A\_PUBCOMB.pep:\*
- 10: /cgn2\_6/ptodata/2/pubpaa/US09B\_PUBCOMB.pep:\*
- 11: /cgn2\_6/ptodata/2/pubpaa/US09C\_PUBCOMB.pep:\*
- 12: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB.pep:\*
- 13: /cgn2\_6/ptodata/2/pubpaa/US10A\_PUBCOMB.pep:\*
- 14: /cgn2\_6/ptodata/2/pubpaa/US10B\_PUBCOMB.pep:\*
- 15: /cgn2\_6/ptodata/2/pubpaa/US10C\_PUBCOMB.pep:\*
- 16: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB.pep:\*
- 17: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pep:\*
- 18: /cgn2\_6/ptodata/2/pubpaa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%  
Result Query  
No. Score Match Length DB ID Description

1	208	72.5	63	14	US-10-077-584-6	Sequence 6, Appli
2	208	72.5	171	14	US-10-077-584-4	Sequence 4, Appli
3	196	68.3	91	15	US-10-354-246-1	Sequence 1, Appli
4	181	63.1	87	14	US-10-215-432-27	Sequence 27, Appl
5	181	63.1	1543	9	US-09-904-987-7	Sequence 7, Appli
6	145	50.5	338	9	US-09-933-638A-12	Sequence 12, Appl
7	145	50.5	339	15	US-10-116-275-184	Sequence 184, App
8	145	50.5	371	9	US-09-849-243-16	Sequence 16, Appl
9	144	50.2	780	9	US-09-770-689A-5	Sequence 5, Appli
10	143	49.8	1402	14	US-10-379-616-12	Sequence 12, Appl
11	142.5	49.7	548	15	US-10-437-171-4	Sequence 4, Appli
12	142.5	49.7	596	15	US-10-437-171-2	Sequence 2, Appli
13	141	49.1	966	9	US-09-801-368-372	Sequence 372, App
14	140	48.8	1572	15	US-10-116-275-179	Sequence 179, App
15	139	48.4	1138	14	US-10-074-475-194	Sequence 194, App
16	138	48.1	97	9	US-09-864-761-35499	Sequence 35499, A
17	138	48.1	1070	9	US-09-735-367B-6	Sequence 6, Appli
18	138	48.1	2005	9	US-09-735-367B-3	Sequence 3, Appli
19	138	48.1	2063	9	US-09-735-367B-2	Sequence 2, Appli
20	137	47.7	406	15	US-10-369-493-3147	Sequence 3147, Ap
21	135.5	47.2	314	14	US-10-317-832-13	Sequence 13, Appl
22	135	47.0	80	14	US-10-177-725-14	Sequence 14, Appl
23	135	47.0	910	10	US-09-086-436-31	Sequence 31, Appl
24	133	46.3	796	13	US-10-044-205A-31	Sequence 31, Appl
25	130	45.3	623	15	US-10-464-939-12	Sequence 12, Appl
26	130	45.3	1420	14	US-10-379-616-4	Sequence 4, Appli
27	130	45.3	4952	15	US-10-051-874-56	Sequence 56, Appl
28	130	45.3	5008	15	US-10-051-874-166	Sequence 166, App
29	130	45.3	5159	15	US-10-085-198-112	Sequence 112, App
30	130	45.3	5262	15	US-10-051-874-165	Sequence 165, App
31	130	45.3	5262	15	US-10-051-874-167	Sequence 167, App
32	129	44.9	907	13	US-10-008-739A-2	Sequence 2, Appli
33	129	44.9	2150	13	US-10-135-322-17	Sequence 17, Appl
34	128.5	44.8	376	15	US-10-108-260A-3233	Sequence 3233, Ap
35	128	44.6	758	9	US-09-801-368-224	Sequence 224, App
36	126.5	44.1	919	14	US-10-205-823-36	Sequence 36, Appl
37	125	43.6	467	9	US-09-416-384A-7	Sequence 7, Appli
38	123	42.9	326	14	US-10-029-386-32987	Sequence 32987, A
39	123	42.9	723	13	US-10-044-205A-32	Sequence 32, Appl
40	123	42.9	816	14	US-10-207-706-3	Sequence 3, Appli
41	121.5	42.3	398	15	US-10-374-780A-2358	Sequence 2358, Ap
42	121.5	42.3	918	15	US-10-375-592A-3	Sequence 3, Appli
43	120	41.8	59	14	US-10-177-725-8	Sequence 8, Appli
44	119	41.5	386	15	US-10-374-780A-2526	Sequence 2526, Ap
45	118	41.1	71	14	US-10-007-557-9	Sequence 9, Appli

#### ALIGNMENTS

RESULT 1  
 US-10-077-584-6  
 ; Sequence 6, Application US/10077584  
 ; Publication No. US20030073610A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: LINDQUIST, SUSAN

```

; APPLICANT: KROBITSCH, SYLVIA
; APPLICANT: OUTEIRO, TIAGO F.
; TITLE OF INVENTION: YEAST SCREENS FOR THE TREATMENT OF HUMAN DISEASE
; FILE REFERENCE: ARCD:367US
; CURRENT APPLICATION NUMBER: US/10/077,584
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 60/269,157
; PRIOR FILING DATE: 2001-02-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-077-584-6

```

```

Query Match          72.5%; Score 208; DB 14; Length 63;
Best Local Similarity 95.6%; Pred. No. 4.3e-16;
Matches 43; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy      7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51
        |||||||||||||||||||||||||||||||||||||||||
Db      1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQPPP 45

```

# RESULT 2

```

US-10-077-584-4
; Sequence 4, Application US/10077584
; Publication No. US20030073610A1
; GENERAL INFORMATION:
; APPLICANT: LINDQUIST, SUSAN
; APPLICANT: KROBITSCH, SYLVIA
; APPLICANT: OUTEIRO, TIAGO F.
; TITLE OF INVENTION: YEAST SCREENS FOR THE TREATMENT OF HUMAN DISEASE
; FILE REFERENCE: ARCD:367US
; CURRENT APPLICATION NUMBER: US/10/077,584
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 60/269,157
; PRIOR FILING DATE: 2001-02-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 171
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-077-584-4

```

```

Query Match          72.5%; Score 208; DB 14; Length 171;
Best Local Similarity 97.7%; Pred. No. 1.3e-15;
Matches 43; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy      7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50
        |||||||||||||||||||||||||||||||||||||||||
Db      1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 44

```

# RESULT 3



US-09-904-987-7

Query Match 63.1%; Score 181; DB 9; Length 1543;  
Best Local Similarity 69.5%; Pred. No. 1.3e-11;  
Matches 41; Conservative 0; Mismatches 4; Indels 14; Gaps 1;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQ-----QQQQQLQP 51  
 |||  
 Db 1 MATLEKLMKAFESLKSFOQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPPOLPOPPPOAOP 59

US-09-933-638A-12

```
; Sequence 12, Application US/09933638A
; Patent No. US20020160952A1
; GENERAL INFORMATION:
; APPLICANT: Kazantsev, Aleksey G.
; APPLICANT: Thompson, Leslie M.
; APPLICANT: Housman, David E.
; TITLE OF INVENTION: INHIBITION OF PROTEIN-PROTEIN INTERACTION
; FILE REFERENCE: 01997-289001
; CURRENT APPLICATION NUMBER: US/09/933,638A
; CURRENT FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: US 60/226,502
; PRIOR FILING DATE: 2000-08-18
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 338
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-933-638A-12
```









; CURRENT FILING DATE: 2003-05-13  
; PRIOR APPLICATION NUMBER: 60/380,554  
; PRIOR FILING DATE: 2002-05-13  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 4  
; LENGTH: 548  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Peptide  
US-10-437-171-4

Query Match 49.7%; Score 142.5; DB 15; Length 548;  
Best Local Similarity 58.2%; Pred. No. 7.9e-08;  
Matches 32; Conservative 7; Mismatches 11; Indels 5; Gaps 1;

Qy 5 GSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAAAS 59  
| |: : :: | : ||||| : |||:  
Db 37 GKMSDVSPVVAQQ-----QQQQQQQQQQQQQQQQQQQQQQQQQQQEAAAAAAAAA 86

RESULT 12

US-10-437-171-2

; Sequence 2, Application US/10437171  
; Publication No. US20030235564A1  
; GENERAL INFORMATION:  
; APPLICANT: Doll, Bruce  
; APPLICANT: Fu, Huihua  
; APPLICANT: Hollinger, Jeffrey O.  
; APPLICANT: Sfier, Charles  
; TITLE OF INVENTION: Compositions and Devices Comprising or Encoding the Run  
X2

; TITLE OF INVENTION: Protein and Method of Use  
; FILE REFERENCE: 1915/14014US02  
; CURRENT APPLICATION NUMBER: US/10/437,171  
; CURRENT FILING DATE: 2003-05-13  
; PRIOR APPLICATION NUMBER: 60/380,554  
; PRIOR FILING DATE: 2002-05-13  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 2  
; LENGTH: 596  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Peptide  
US-10-437-171-2

Query Match 49.7%; Score 142.5; DB 15; Length 596;  
Best Local Similarity 58.2%; Pred. No. 8.6e-08;  
Matches 32; Conservative 7; Mismatches 11; Indels 5; Gaps 1;

Qy 5 GSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAAAS 59  
| |: : :: | : ||||| : |||:  
Db 105 GKMSDVSPVVAQQ-----QQQQQQQQQQQQQQQQQQQQQQQQQQQEAAAAAAAAA 154

RESULT 13

US-09-801-368-372

; Sequence 372, Application US/09801368

; Patent No. US20020128250A1

; GENERAL INFORMATION:

; APPLICANT: Busby, Robert

; APPLICANT: Cali, Brian

; APPLICANT: Hecht, Peter

; APPLICANT: Holtzman, Doug

; APPLICANT: Madden, Kevin

; APPLICANT: Maxon, Mary

; APPLICANT: Milne, Todd

; APPLICANT: No. US20020128250A1man, Thea

; APPLICANT: Royer, John

; APPLICANT: Salama, Sofie

; APPLICANT: Sherman, Amir

; APPLICANT: Silva, Jeff

; APPLICANT: Summers, Eric

; TITLE OF INVENTION: Methods for Improving Secondary Metabolite Production in Fungi

; FILE REFERENCE: 109272.147

; CURRENT APPLICATION NUMBER: US/09/801,368

; CURRENT FILING DATE: 2001-03-07

; PRIOR APPLICATION NUMBER: US 09/487,558

; PRIOR FILING DATE: 2000-01-19

; PRIOR APPLICATION NUMBER: US 60/160,587

; PRIOR FILING DATE: 1999-10-20

; NUMBER OF SEQ ID NOS: 440

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 372

; LENGTH: 966

; TYPE: PRT

; ORGANISM: Saccharomyces cerevisiae

US-09-801-368-372

Query Match 49.1%; Score 141; DB 9; Length 966;

Best Local Similarity 100.0%; Pred. No. 2.1e-07;

Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 24 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51

|||||

Db 563 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 590

RESULT 14

US-10-116-275-179

; Sequence 179, Application US/10116275

; Publication No. US20030211476A1

; GENERAL INFORMATION:

; APPLICANT: Elan Pharmaceutical Technology

; APPLICANT: O'Mahony, Daniel J.

; APPLICANT: Brayden, David

; APPLICANT: Byrne, Daragh

; APPLICANT: Lambkin, Imelda

; APPLICANT: Higgins, Lisa

; TITLE OF INVENTION: Genetic Analysis of Peyer's Patches and M Cells and Methods and  
 ; TITLE OF INVENTION: Compositions Targeting Peyer's Patches and M Cell Receptors  
 ; FILE REFERENCE: E1067/20087  
 ; CURRENT APPLICATION NUMBER: US/10/116,275  
 ; CURRENT FILING DATE: 2002-10-04  
 ; NUMBER OF SEQ ID NOS: 349  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 179  
 ; LENGTH: 1572  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-10-116-275-179

Query Match 48.8%; Score 140; DB 15; Length 1572;  
 Best Local Similarity 67.4%; Pred. No. 4.6e-07;  
 Matches 29; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

Qy 9 TLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
 ||: :: :| ||||| | | | | | | | | | | | | | | | | | |  
 Db 201 TLQLAVQGKRTLPGLOQQQQQQQQQQQQQQQQQQQQQQQQQQQPQQQP 243

RESULT 15

US-10-074-475-194  
 ; Sequence 194, Application US/10074475  
 ; Publication No. US20030092898A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Salceda, Susana  
 ; APPLICANT: Macina, Roberto  
 ; APPLICANT: Hu, Ping  
 ; APPLICANT: Recipon, Herve  
 ; APPLICANT: Karra, Kalpana  
 ; APPLICANT: Cafferkey, Robert  
 ; APPLICANT: Sun, Yongming  
 ; APPLICANT: Liu, Chenghua  
 ; TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific  
 ; TITLE OF INVENTION: Genes and Proteins  
 ; FILE REFERENCE: DEX-0313  
 ; CURRENT APPLICATION NUMBER: US/10/074,475  
 ; CURRENT FILING DATE: 2002-02-13  
 ; PRIOR APPLICATION NUMBER: 60/268,292  
 ; PRIOR FILING DATE: 2001-02-13  
 ; NUMBER OF SEQ ID NOS: 295  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 194  
 ; LENGTH: 1138  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapien  
 US-10-074-475-194

Query Match 48.4%; Score 139; DB 14; Length 1138;  
 Best Local Similarity 53.3%; Pred. No. 4.2e-07;  
 Matches 32; Conservative 7; Mismatches 17; Indels 4; Gaps 1;

Qy 2 VPRGSMATLEKLMKAF----ESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAA 57

Db           ||   |:  |:| :       :  |  ||:|||||||||||||||||||||  |  | : :  
457 VPSSDMSPAQLKQMAAQQQQRAKLMQQKQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQHNSQTS 516

Search completed: March 12, 2004, 15:44:13  
Job time : 23.4265 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 12, 2004, 15:34:19 ; Search time 28.9216 Seconds  
(without alignments)  
643.657 Million cell updates/sec

Title: US-09-620-955B-10  
Perfect score: 287  
Sequence: 1 LVPRGSMATLEKLMKAFESL.....QQQQQQQQQLQPGSTRAAAS 59

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : SPTREMBL\_25:\*  
1: sp\_archaea:\*  
2: sp\_bacteria:\*  
3: sp\_fungi:\*  
4: sp\_human:\*  
5: sp\_invertebrate:\*  
6: sp\_mammal:\*  
7: sp\_mhc:\*  
8: sp\_organelle:\*  
9: sp\_phage:\*  
10: sp\_plant:\*  
11: sp\_rodent:\*  
12: sp\_virus:\*  
13: sp Vertebrate:\*  
14: sp\_unclassified:\*  
15: sp\_rvirus:\*  
16: sp\_bacteriap:\*  
17: sp\_archeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	%	Query				
No.	Score	Match	Length	DB	ID	Description
-----						



1	196	68.3	3144	4	Q9UQB7	Q9uqb7 homo sapien
2	172.5	60.1	3139	6	Q9GM99	Q9gm99 sus scrofa
3	149.5	52.1	1356	5	Q8WRE2	Q8wre2 anopheles g
4	147	51.2	556	4	O15411	O15411 homo sapien
5	147	51.2	1157	4	Q96JK7	Q96jk7 homo sapien
6	147	51.2	1761	5	O77283	O77283 drosophila
7	147	51.2	1860	5	Q8IRT3	Q8irt3 drosophila
8	147	51.2	3124	4	Q96L91	Q96l91 homo sapien
9	146	50.9	2048	5	Q86JW3	Q86jw3 dictyosteli
10	145	50.5	151	4	Q7Z6S4	Q7z6s4 homo sapien
11	145	50.5	208	4	Q7Z6S5	Q7z6s5 homo sapien
12	145	50.5	653	3	Q9P788	Q9p788 schizosacch
13	145	50.5	1457	5	O44011	O44011 dictyosteli
14	144	50.2	752	11	Q8R506	Q8r506 rattus norv
15	144	50.2	780	11	Q9EQV7	Q9eqv7 rattus norv
16	144	50.2	830	11	Q99N38	Q99n38 rattus norv
17	144	50.2	858	11	Q99N37	Q99n37 rattus norv
18	143	49.8	1002	5	Q86AA4	Q86aa4 dictyosteli
19	143	49.8	1024	4	Q8IUL3	Q8iul3 homo sapien
20	143	49.8	1153	4	Q8IZL2	Q8izl2 homo sapien
21	143	49.8	1173	4	Q96JK6	Q96jk6 homo sapien
22	143	49.8	1297	5	Q8SSS5	Q8sss5 dictyosteli
23	142	49.5	1407	5	Q86H61	Q86h61 dictyosteli
24	141.5	49.3	536	3	Q9P466	Q9p466 neurospora
25	140	48.8	618	16	Q87G62	Q87g62 vibrio para
26	139.5	48.6	809	13	Q7ZVN7	Q7zvn7 brachydanio
27	139	48.4	739	11	Q7TPU6	Q7tpu6 mus musculu
28	139	48.4	1015	5	Q86AG0	Q86ag0 dictyosteli
29	139	48.4	1379	5	Q8I7P4	Q8i7p4 dictyosteli
30	139	48.4	2592	3	Q9P3J0	Q9p3j0 neurospora
31	138	48.1	398	3	Q8NJR3	Q8njr3 kluyveromyc
32	138	48.1	722	5	Q86H71	Q86h71 dictyosteli
33	138	48.1	1080	5	Q86KL1	Q86kl1 dictyosteli
34	137.5	47.9	570	11	Q9CTU8	Q9ctu8 mus musculu
35	137.5	47.9	1163	5	Q869M3	Q869m3 dictyosteli
36	137	47.7	544	4	Q9BZG7	Q9bzg7 homo sapien
37	137	47.7	1156	5	Q86HG5	Q86hg5 dictyosteli
38	137	47.7	1543	5	Q9GV71	Q9gv71 dictyosteli
39	137	47.7	1693	5	Q86JI7	Q86ji7 dictyosteli
40	137	47.7	4001	5	Q8WRQ7	Q8wrq7 drosophila
41	137	47.7	4001	5	Q9VCA8	Q9vca8 drosophila
42	136.5	47.6	149	4	Q8NFT3	Q8nft3 homo sapien
43	136.5	47.6	602	5	Q86GH6	Q86gh6 drosophila
44	136.5	47.6	1330	5	Q86GH2	Q86gh2 drosophila
45	136.5	47.6	1531	5	Q86GH1	Q86gh1 drosophila

# ALIGNMENTS

## RESULT 1

Q9UQB7

ID Q9UQB7 PRELIMINARY; PRT; 3144 AA.

AC Q9UQB7;

DT 01-MAY-2000 (TrEMBLrel. 13, Created)

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)

DE Huntingtin.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE=20469406; PubMed=11013077;  
 RA Matsuyama N., Hadano S., Onoe K., Osuga H., Shouguchi-Miyata J.,  
 RA Gondo Y., Ikeda J.-E.;  
 RT "Identification and characterization of the miniature pig Huntington's  
 RT disease gene homolog: evidence for conservation and polymorphism in  
 RT the CAG triplet repeat.";  
 RL Genomics 69:72-85(2000).  
 DR EMBL; AB016794; BAA36753.1; -.  
 DR GO; GO:0005737; C:cytoplasm; IEA.  
 DR InterPro; IPR000091; Huntingtin.  
 DR Pfam; PF03541; Huntingtin; 1.  
 DR PRINTS; PR00375; HUNTINGTIN.  
 SQ SEQUENCE 3144 AA; 347839 MW; 3F2BFFEFEE8E5D8E CRC64;

Query Match 68.3%; Score 196; DB 4; Length 3144;  
 Best Local Similarity 91.1%; Pred. No. 6.6e-13;  
 Matches 41; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 7 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
 |||||||||||||||||||||||||||||||||||||  
 Db 1 MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQPPPPP 45

## RESULT 2

Q9GM99

ID Q9GM99 PRELIMINARY; PRT; 3139 AA.  
 AC Q9GM99;  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE Huntingtin.  
 OS Sus scrofa (Pig).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.  
 OX NCBI\_TaxID=9823;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CSK goettingen; TISSUE=Testis;  
 RX MEDLINE=20469406; PubMed=11013077;  
 RA Matsuyama N., Hadano S., Onoe K., Osuga H., Shouguchi-Miyata J.,  
 RA Gondo Y., Ikeda J.-E.;  
 RT "Identification and characterization of the miniature pig Huntington's  
 RT disease gene homolog: evidence for conservation and polymorphism in  
 RT the CAG triplet repeat.";  
 RL Genomics 69:72-85(2000).  
 DR EMBL; AB016793; BAA36752.1; -.  
 DR GO; GO:0005737; C:cytoplasm; IEA.  
 DR InterPro; IPR008938; ARM.  
 DR InterPro; IPR001092; HLH\_basic.



Best Local Similarity 55.1%; Pred. No. 3.9e-08;  
Matches 38; Conservative 5; Mismatches 11; Indels 15; Gaps 2;

```
Qy      3 PRGSM-----ATLEKL-----MKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQ 47
      |||      || : |      | : : :| |||||
Db      1265 PRGPQGRSTDYHATQQPLPLPGLASEMQPQQLHRSQQQQQQQQQQQQQQQQQQQQQQ 1324

Qy      48 QLQPGSTRA 56
      | || ||:|
Db      1325 QHQPSTQA 1333
```

#### RESULT 4

O15411

ID O15411 PRELIMINARY; PRT; 556 AA.  
AC O15411;  
DT 01-JAN-1998 (TrEMBLrel. 05, Created)  
DT 01-JAN-1998 (TrEMBLrel. 05, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE CAGH32 (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Brain;  
RX MEDLINE=97369492; PubMed=9225980;  
RA Margolis R.L., Abraham M.R., Gatchell S.B., Li S.H., Kidwai A.S.,  
RA Breschel T.S., Stine O.C., Callahan C., McInnis M.G., Ross C.A.;  
RT "cDNAs with long CAG trinucleotide repeats from human brain";  
RL Hum. Genet. 100:114-122(1997).  
DR EMBL; U80743; AAB91441.1; -.  
FT NON\_TER 1 1  
SQ SEQUENCE 556 AA; 57588 MW; AAAF9DFEF777EE9E CRC64;

Query Match 51.2%; Score 147; DB 4; Length 556;  
Best Local Similarity 60.0%; Pred. No. 3.2e-08;  
Matches 36; Conservative 5; Mismatches 13; Indels 6; Gaps 1;

```
Qy      1 LVPRGSMATLEKL-----MKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQLQPGST 54
      |||: | || :|      | : | :| |||||
Db      267 LVPQVSQATGVQLPGKTITPAHFQLLRQQQQQQQQQQQQQQQQQQQQQQQQQQTTT 326
```

#### RESULT 5

Q96JK7

ID Q96JK7 PRELIMINARY; PRT; 1157 AA.  
AC Q96JK7;  
DT 01-DEC-2001 (TrEMBLrel. 19, Created)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE Hypothetical protein KIAA1818 (Fragment).  
GN KIAA1818.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE=21245130; PubMed=11347906;  
 RA Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;  
 RT "Prediction of the coding sequences of unidentified human genes. XX.  
 RT The complete sequences of 100 new cDNA clones from brain which code  
 RT for large Proteins in vitro.";  
 RL DNA Res. 8:85-95(2001).  
 DR EMBL; AB058721; BAB47447.1; -.  
 DR GO; GO:0005634; C:nucleus; IEA.  
 DR GO; GO:0003677; F:DNA binding; IEA.  
 DR InterPro; IPR001005; Myb\_DNA\_binding.  
 DR SMART; SM00717; SANT; 1.  
 DR PROSITE; PS50090; MYB\_3; 1.  
 KW Hypothetical protein.  
 FT NON\_TER 1 1  
 SQ SEQUENCE 1157 AA; 125525 MW; B08A6AE50B1A9E01 CRC64;

Query Match 51.2%; Score 147; DB 4; Length 1157;  
 Best Local Similarity 60.0%; Pred. No. 6.4e-08;  
 Matches 36; Conservative 5; Mismatches 13; Indels 6; Gaps 1;

Qy 1 LVPRGSMATLEKL-----MKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGST 54  
 |||: ||| :| | :| | | | | | | | | | | | | | | | | :|  
 Db 726 LVPQVSQATGVQLPGKTITPAHFQQLLRQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQT 785

RESULT 6  
 O77283

ID O77283 PRELIMINARY; PRT; 1761 AA.  
 AC O77283;  
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE EG:EG0002.3 protein.  
 GN EG:EG0002.3 OR CG2904.  
 OS Drosophila melanogaster (Fruit fly).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
 OC Ephydroidea; Drosophilidae; Drosophila.  
 OX NCBI\_TaxID=7227;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Berkeley;  
 RX MEDLINE=20196006; PubMed=10731132;  
 RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
 RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,  
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
 RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,  
 RA Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,  
 RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,  
 RA Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,  
 RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
 RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
 RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,

RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,  
RA Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,  
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,  
RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,  
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,  
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,  
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,  
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
RA Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,  
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,  
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;

RT "The genome sequence of *Drosophila melanogaster*.";

RL Science 287:2185-2195(2000).

RN [2]

RP SEQUENCE FROM N.A.

RA Bolshakov V., Borkova D., Minana B., Kafatos F.;

RT "Sequencing the distal X chromosome of *Drosophila melanogaster*.";

RL Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.

RN [3]

RP SEQUENCE FROM N.A.

RA Benos P.;

RL Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.

DR EMBL; AE003429; AAF45898.1; -.

DR EMBL; AL031130; CAA20016.1; -.

DR PIR; T13675; T13675.

DR FlyBase; FBgn0025376; EG:EG0002.3.

DR GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA.

DR GO; GO:0004221; F:ubiquitin thiolesterase activity; IEA.

DR GO; GO:0006511; P:ubiquitin-dependent protein catabolism; IEA.

DR InterPro; IPR001394; Peptidase\_C19.

DR Pfam; PF00443; UCH; 1.

SQ SEQUENCE 1761 AA; 192843 MW; BB300CC95D38EB77 CRC64;

Query Match 51.2%; Score 147; DB 5; Length 1761;

Best Local Similarity 60.4%; Pred. No. 9.5e-08;

Matches 29; Conservative 8; Mismatches 11; Indels 0; Gaps 0;

Qy 3 PRGSMATLEKLMKAFESLKSFOOOOOOOOOOOOOOOOOOOOOOOOOO 50

| | : | : : : : : | | | | | | | | | | | | | | | | | | |

Db 1474 PAGATADMQRVYVQRMQOOOOOOOOOOOOOOOOOOOOOOOOOOO 1521

## RESULT 7

Q8IRT3

ID Q8IRT3 PRELIMINARY; PRT; 1860 AA.  
AC Q8IRT3;  
DT 01-MAR-2003 (TrEMBLrel. 23, Created)  
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE CG2904-PB.  
GN EG:EG0002.3 OR CG2904.  
OS *Drosophila melanogaster* (Fruit fly).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
OC Ephydroidea; Drosophilidae; *Drosophila*.  
OX NCBI\_TaxID=7227;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=20196006; PubMed=10731132;  
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,  
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,  
RA Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,  
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,  
RA Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,  
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,  
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,  
RA Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,  
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,  
RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.,  
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,  
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,  
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,  
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
RA Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,  
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,  
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
RT "The genome sequence of *Drosophila melanogaster*.";  
RL Science 287:2185-2195(2000).  
RN [2]  
RP SEQUENCE FROM N.A.

RA Celniker S.E., Adams M.D., Kronmiller B., Wan K.H., Holt R.A.,  
 RA Evans C.A., Gocayne J.D., Amanatides P.G., Brandon R.C., Rogers Y.,  
 RA Banzon J., An H., Baldwin D., Banzon J., Beeson K.Y., Busam D.A.,  
 RA Carlson J.W., Center A., Champe M., Davenport L.B., Dietz S.M.,  
 RA Dodson K., Dorsett V., Doup L.E., Doyle C., Dresnek D., Farfan D.,  
 RA Ferriera S., Frise E., Galle R.F., Garg N.S., George R.A.,  
 RA Gonzalez M., Houck J., Hoskins R.A., Hostin D., Howland T.J.,  
 RA Ibegwam C., Jalali M., Kruse D., Li P., Mattei B., Moshrefi A.,  
 RA McIntosh T.C., Moy M., Murphy B., Nelson C., Nelson K.A., Nunoo J.,  
 RA Pacleb J., Paragas V., Park S., Patel S., Pfeiffer B.,  
 RA Phouanenvong S., Pittman G.S., Puri V., Richards S., Scheeler F.,  
 RA Stapleton M., Strong R., Svirskas R., Tector C., Tyler D.,  
 RA Williams S.M., Zaveri J.S., Smith H.O., Venter J.C., Rubin G.M.;  
 RT "Sequencing of Drosophila melanogaster genome.";  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RA Misra S., Crosby M.A., Matthews B.B., Bayraktaroglu L., Campbell K.,  
 RA Hradecky P., Huang Y., Kaminker J.S., Prochnik S.E., Smith C.D.,  
 RA Tupy J.L., Bergman C., Berman B., Carlson J.W., Celniker S.E.,  
 RA Clamp M., Drysdale R., Emmert D., Frise E., de Grey A., Harris N.,  
 RA Kronmiller B., Marshall B., Millburn G., Richter J., Russo S.,  
 RA Searle S.M.J., Smith E., Shu S., Smutniak F., Whitfield E.,  
 RA Ashburner M., Gelbart W.M., Rubin G.M., Mungall C.J., Lewis S.E.;  
 RT "Annotation of Drosophila melanogaster genome.";  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RA Adams M.D., Celniker S.E., Gibbs R.A., Rubin G.M., Venter C.J.;  
 RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.  
 RN [5]  
 RP SEQUENCE FROM N.A.  
 RA FlyBase;  
 RL Submitted (SEP-2002) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AE003429; AAN09109.1; -.  
 DR FlyBase; FBgn0025376; EG:EG0002.3.  
 DR GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA.  
 DR GO; GO:0004221; F:ubiquitin thiolesterase activity; IEA.  
 DR GO; GO:0006511; P:ubiquitin-dependent protein catabolism; IEA.  
 DR InterPro; IPR001394; Peptidase\_C19.  
 DR Pfam; PF00443; UCH; 1.  
 SQ SEQUENCE 1860 AA; 203948 MW; 84ABE9216C6AC6E5 CRC64;

Query Match 51.2%; Score 147; DB 5; Length 1860;  
 Best Local Similarity 60.4%; Pred. No. 1e-07;  
 Matches 29; Conservative 8; Mismatches 11; Indels 0; Gaps 0;

Qy 3 PRGSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 50  
 | | : | :: : : : : | | | | | | | | | | | | | | | | | | | | | |  
 Db 1573 PAGATADMQRVYVRMQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 1620

RESULT 8  
 Q96L91  
 ID Q96L91 PRELIMINARY; PRT; 3124 AA.  
 AC Q96L91;  
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)



DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE P400 SWI2/SNF2-related protein.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21400441; PubMed=11509179;  
 RA Fuchs M., Gerber J., Drapkin R., Sif S., Ikura T., Ogryzko V.,  
 RA Lane W.S., Nakatani Y., Livingston D.M.;  
 RT "The p400 complex is an essential E1A transformation target.";  
 RL Cell 106:297-307(2001).  
 DR EMBL; AY044869; AAK97789.1; -.  
 DR Genew; HGNC:11958; EP400.  
 DR GO; GO:0005634; C:nucleus; IEA.  
 DR GO; GO:0005524; F:ATP binding; IEA.  
 DR GO; GO:0008026; F:ATP dependent helicase activity; IEA.  
 DR GO; GO:0003677; F:DNA binding; IEA.  
 DR GO; GO:0016787; F:hydrolase activity; IEA.  
 DR InterPro; IPR001410; DEAD.  
 DR InterPro; IPR001650; Helicase\_C.  
 DR InterPro; IPR006562; HSA.  
 DR InterPro; IPR001005; Myb\_DNA\_binding.  
 DR InterPro; IPR000330; SNF2\_N.  
 DR Pfam; PF00271; helicase\_C; 1.  
 DR Pfam; PF00176; SNF2\_N; 2.  
 DR SMART; SM00487; DEXDc; 1.  
 DR SMART; SM00573; HSA; 1.  
 DR SMART; SM00717; SANT; 1.  
 DR PROSITE; PS50090; MYB\_3; 1.  
 KW ATP-binding; Helicase; Hydrolase.  
 SQ SEQUENCE 3124 AA; 340146 MW; E8F57FD6C7BD01E9 CRC64;

Query Match 51.2%; Score 147; DB 4; Length 3124;  
 Best Local Similarity 60.0%; Pred. No. 1.6e-07;  
 Matches 36; Conservative 5; Mismatches 13; Indels 6; Gaps 1;

Qy 1 LVPRGSMATLEKL-----MKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGST 54  
 |||: || :| |: |: ||||| ||||| ||||| ||||| ||||| :|  
 Db 2693 LVPQVSQATGVQLPGKTITPAHFQLLRQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQTTT 2752

# RESULT 9

Q86JW3

ID Q86JW3 PRELIMINARY; PRT; 2048 AA.  
 AC Q86JW3;  
 DT 01-JUN-2003 (TrEMBLrel. 24, Created)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE Hypothetical protein.  
 OS Dictyostelium discoideum (Slime mold).  
 OC Eukaryota; Mycetozoa; Dictyosteliida; Dictyostelium.  
 OX NCBI\_TaxID=44689;  
 RN [1]  
 RP SEQUENCE FROM N.A.

RC STRAIN=AX4;  
 RX MEDLINE=22092622; PubMed=12097910;  
 RA Gloeckner G., Eichinger L., Szafranski K., Pachebat J., Dear P.,  
 RA Lehmann R., Baumgart C., Parra G., April J.F., Guigo R., Kumpf K.,  
 RA Tunggal B., Cox E., Quail M.A., Platzer M., Rosenthal A., Noegel A.A.;  
 RT "Sequence and analysis of chromosome 2 of Dictyostelium discoideum."  
 RL Nature 418:79-85(2002).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=AX4;  
 RA Baumgart C.;  
 RL Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AC116984; AAC051396.1; -.  
 DR InterPro; IPR008938; ARM.  
 DR InterPro; IPR000904; Sec7.  
 DR Pfam; PF01369; Sec7; 1.  
 DR SMART; SM00222; Sec7; 1.  
 DR PROSITE; PS50190; SEC7; 1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 2048 AA; 231362 MW; 7F7F34A35CAB8DB2 CRC64;

Query Match 50.9%; Score 146; DB 5; Length 2048;  
 Best Local Similarity 62.5%; Pred. No. 1.4e-07;  
 Matches 30; Conservative 7; Mismatches 11; Indels 0; Gaps 0;

QY 6 SMATLEKLMKAFESLKSFOQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGS 53  
 |::||:| :: :: || ||||| |  
 Db 988 SISFLERLRVSYLGVEQQQQSNSQQQQQQQQQQQQQQQQQQQQQLQPN 1035

# RESULT 10

Q7Z6S4

ID Q7Z6S4 PRELIMINARY; PRT; 151 AA.  
 AC Q7Z6S4;  
 DT 01-OCT-2003 (TrEMBLrel. 25, Created)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE DJ191N21.2.3 (TATA box binding protein (GTF2D, SCA17, TFIID), variant  
 DE 3) (Fragment).  
 GN TBP.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Griffiths C.;  
 RL Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AL031259; CAD92544.1; -.  
 KW Proteasome.  
 FT NON TER 151 151  
 SQ SEQUENCE 151 AA; 16659 MW; F53926CE2BAC5E6C CRC64;

Query Match 50.5%; Score 145; DB 4; Length 151;  
 Best Local Similarity 59.3%; Pred. No. 1.6e-08;  
 Matches 32; Conservative 7; Mismatches 15; Indels 0; Gaps 0;

QY           6 SMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAAAS 59  
             |:: ||: : : | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db          48 SLSILEEQORQ00AVAAAA 101

07Z6S5

```
ID      Q7Z6S5      PRELIMINARY;      PRT;      208 AA.
AC      Q7Z6S5;
DT      01-OCT-2003 (TrEMBLrel. 25, Created)
DT      01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT      01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE      DJ191N21.2.2 (TATA box binding protein (GTF2D, SCA17, TFIID), variant
DE      2) (Fragment).
GN      TBP.
OS      Homo sapiens (Human).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX      NCBI_TaxID=9606;
RN      [1]
RP      SEQUENCE FROM N.A.
RA      Griffiths C.;
RL      Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
DR      EMBL; AL031259; CAD92543.1; -.
KW      Proteasome.
FT      NON_TER      208      208
SQ      SEQUENCE      208 AA; 22921 MW; 95792234163A9618 CRC64;
```

Query Match 50.5%; Score 145; DB 4; Length 208;  
Best Local Similarity 59.3%; Pred. No. 2.1e-08;  
Matches 32; Conservative 7; Mismatches 15; Indels 0; Gaps 0;

QY           6 SMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAAAS 59  
             |::||: : : : |||||||||||||||||||| | |||:  
Db          48 SLSILEEQQR000000000000000000000000000000000000000AVAAAA 101

09P788

```

ID      Q9P788                PRELIMINARY;          PRT;    653 AA.
AC      Q9P788;
DT      01-OCT-2000 (TrEMBLrel. 15, Created)
DT      01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT      01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE      Putative transcriptional regulatory protein (Fragment).
GN      SPBP35G2.15.
OS      Schizosaccharomyces pombe (Fission yeast).
OC      Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC      Schizosaccharomycetales; Schizosaccharomycetaceae;
OC      Schizosaccharomyces.
OX      NCBI_TaxID=4896;
RN      [1]
RP      SEQUENCE FROM N.A.
RC      STRAIN=972h-;
RA      Seeger K., Harris D., Wood V., Rajandream M.A., Barrell B.G.;
RL      Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
DR      EMBL; AL163702; CAB87377.1; -.

```

```

FT      NON_TER      653      653
SQ      SEQUENCE     653 AA;   73291 MW;   C88A9EEDECF8B80F CRC64;

```

Query Match 50.5%; Score 145; DB 3; Length 653;  
Best Local Similarity 62.5%; Pred. No. 6.2e-08;  
Matches 30; Conservative 6; Mismatches 12; Indels 0; Gaps 0;

```
Qy      3 PRGSMATLEKLMKAFESLSKFQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50
        |   :: :   :: | ||: ||||| ||||| ||||| ||||| |||||
Db     236 PARLISIYONQIQKFRSLQHMQQQQQQQQQQQQQQQQQQQQQQQQQQ 283
```

RESULT 13

O44011

```

ID      O44011          PRELIMINARY;          PRT;   1457 AA.
AC      O44011;
DT      01-JUN-1998 (TrEMBLrel. 06, Created)
DT      01-JUN-1998 (TrEMBLrel. 06, Last sequence update)
DT      01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE      Protein kinase YakA.
GN      YAKA.
OS      Dictyostelium discoideum (Slime mold).
OC      Eukaryota; Mycetozoa; Dictyosteliida; Dictyostelium.
OX      NCBI_TaxID=44689;
RN      [1]
RP      SEQUENCE FROM N.A.
RC      STRAIN=AK800;
RX      MEDLINE=96042901; PubMed=8536963;
RA      Loomis W.F., Welker D., Hughes J., Maghakian D., Kuspa A.;
RT      "Integrated maps of the chromosomes in Dictyostelium discoideum.";
RL      Genetics 141:147-157(1995).
RN      [2]
RP      SEQUENCE FROM N.A.
RC      STRAIN=AK800;
RX      MEDLINE=96224325; PubMed=8643615;
RA      Kuspa A., Loomis W.F.;
RT      "Ordered yeast artificial chromosome clones representing the
RT      Dictyostelium discoideum genome.";
RL      Proc. Natl. Acad. Sci. U.S.A. 93:5562-5566(1996).
RN      [3]
RP      SEQUENCE FROM N.A.
RC      STRAIN=AK800;
RA      Kuspa A., Lu S., Souza G.M.;
RT      "YakA, a protein kinase required for the growth to development
RT      transition in Dictyostelium.";
RL      Submitted (JAN-1998) to the EMBL/GenBank/DBJ databases.
CC      -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
DR      EMBL; AF045453; AAC02554.1; -.
DR      PIR; T14577; T14577.
DR      HSSP; P24941; 1CKP.
DR      GO; GO:0005524; F:ATP binding; IEA.
DR      GO; GO:0004674; F:protein serine/threonine kinase activity; IEA.
DR      GO; GO:0016740; F:transferase activity; IEA.
DR      GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR      InterPro; IPR000719; Prot_kinase.
DR      InterPro; IPR002290; Ser_thr_pkinase.
DR      InterPro; IPR008271; Ser_thr_pkin AS.

```

DR Pfam; PF00069; pkinase; 1.  
DR ProDom; PD000001; Prot\_kinase; 1.  
DR SMART; SM00220; S\_TKc; 1.  
DR PROSITE; PS00107; PROTEIN\_KINASE\_ATP; 1.  
DR PROSITE; PS50011; PROTEIN\_KINASE\_DOM; 1.  
DR PROSITE; PS00108; PROTEIN\_KINASE\_ST; 1.  
KW ATP-binding; Kinase; Serine/threonine-protein kinase; Transferase.  
SQ SEQUENCE 1457 AA; 167111 MW; C1FCDCE99D561856 CRC64;

Qy            2 VPRGSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
              : :: ||     ::    :   :   | | | | | | | | | | | | | | | |  
Db           575 IPOHSLMNGNOILNQHOLFQOLLOOOO OOOO OOOO OOOO OOOO OOOO 623

```

ID      Q8R506                PRELIMINARY;          PRT;    752 AA.
AC      Q8R506;
DT      01-JUN-2002 (TrEMBLrel. 21, Created)
DT      01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT      01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE      Nadrin-102.
OS      Rattus norvegicus (Rat).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX      NCBI_TaxID=10116;
RN      [1]
RP      SEQUENCE FROM N.A.
RA      Harada A., Furuta B., Takeuchi K., Itakura M., Takahashi M., Umeda M.;
RL      Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN      [2]
RP      SEQUENCE FROM N.A.
RX      MEDLINE=20538431; PubMed=10967100;
RA      Harada A., Furuta B., Takeuchi K., Itakura M., Takahashi M., Umeda M.;
RT      "Nadrin, a Novel Neuron-specific GTPase-activating Protein Involved in
RT      Regulated Exocytosis.";
RL      J. Biol. Chem. 275:36885-36891(2000).
DR      EMBL; AB080637; BAB85655.1; -.
DR      InterPro; IPR006632; BAR.
DR      InterPro; IPR000198; RhoGAP.
DR      InterPro; IPR008936; Rho_GAP.
DR      Pfam; PF00620; RhoGAP; 1.
DR      SMART; SM00721; BAR; 1.
DR      SMART; SM00324; RhoGAP; 1.
DR      PROSITE; PS50238; RHOGAP; 1.
SQ      SEQUENCE      752 AA;  82520 MW;  D9002F74E5BD1AE1 CRC64;

```

Qy            24 QQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAAAS    59  
             | ||||| ||||| ||||| ||||| |||||     ||    | ::|



OM protein - protein search, using sw model

Run on: March 12, 2004, 15:22:04 ; Search time 6.94118 Seconds  
 (without alignments)  
 442.596 Million cell updates/sec

Title: US-09-620-955B-10  
 Perfect score: 287  
 Sequence: 1 LVPRGSMATLEKLMKAFESL.....QQQQQQQQQLQPGSTRAAAS 59

Scoring table: BLOSUM62  
 Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0  
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
 Maximum Match 100%  
 Listing first 45 summaries

Database : SwissProt\_42:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Query		DB	ID	Description
	Score	Match Length			
1	196	68.3	3144	1	HD_HUMAN P42858 homo sapien
2	147	51.2	1081	1	GALY_YEAST P19659 saccharomyc
3	145	50.5	339	1	TBP_HUMAN P20226 homo sapien
4	142.5	49.7	607	1	RUN2_MOUSE Q08775 m runt-rela
5	141	49.1	966	1	SSN6_YEAST P14922 saccharomyc
6	140.5	49.0	590	1	HMAA_DROME P29555 drosophila
7	138	48.1	2063	1	NCO6_HUMAN Q14686 h nuclear r
8	137	47.7	376	1	MJD1_HUMAN P54252 homo sapien
9	136.5	47.6	2067	1	NCO6_MOUSE Q9j119 m nuclear r
10	136	47.4	313	1	THAB_HUMAN Q96ek4 homo sapien
11	136	47.4	714	1	FXP2_MOUSE P58463 mus musculu
12	136	47.4	715	1	FXP2_HUMAN O15409 homo sapien
13	136	47.4	716	1	FXP2_PANTR Q8mja0 pan troglod
14	136	47.4	1319	1	MN1_HUMAN Q10571 homo sapien
15	135	47.0	910	1	HCN1_MOUSE O88704 mus musculu
16	135	47.0	1167	1	WC1_NEUCR Q01371 neurospora
17	135	47.0	1177	1	SP97_DICDI Q95zg3 dictyosteli

18	135	47.0	1516	1	NCO2_XENLA	Q9w705	xenopus lae
19	134	46.7	1023	1	CLOC_DROME	O61735	drosophila
20	133.5	46.5	445	1	PO32_MOUSE	P31360	mus musculu
21	133.5	46.5	445	1	PO32_RAT	P56222	rattus norv
22	133	46.3	796	1	CN04_HUMAN	Q9h1b7	homo sapien
23	133	46.3	905	1	SNF5_YEAST	P18480	saccharomyc
24	132.5	46.2	1586	1	SN22_HUMAN	P51531	homo sapien
25	132	46.0	1398	1	NCO3_MOUSE	O09000	m nuclear r
26	131	45.6	705	1	FXP1_MOUSE	P58462	mus musculu
27	131	45.6	2212	1	T230_HUMAN	Q93074	homo sapien
28	130	45.3	623	1	DSH_DROME	P51140	drosophila
29	130	45.3	1424	1	NCO3_HUMAN	Q9y6q9	h nuclear r
30	130	45.3	5262	1	MLL2_HUMAN	O14686	homo sapien
31	129	44.9	521	1	RUN2_HUMAN	Q13950	h runt-rela
32	129	44.9	907	1	ANDR_CANFA	Q9tt90	canis famil
33	129	44.9	1090	1	NIT4_NEUCR	P28349	neurospora
34	129	44.9	1905	1	TAGB_DICDI	P54683	dictyosteli
35	129	44.9	2703	1	NOTC_DROME	P07207	drosophila
36	128	44.6	443	1	PO32_HUMAN	P20265	homo sapien
37	128	44.6	758	1	YM38_YEAST	Q03825	saccharomyc
38	128	44.6	910	1	HCN1_RAT	Q9jkb0	rattus norv
39	128	44.6	1161	1	BM2K_HUMAN	Q9nsyl	homo sapien
40	127	44.3	644	1	BTD_DROME	Q24266	drosophila
41	127	44.3	700	1	BIB_DROME	P23645	drosophila
42	126.5	44.1	919	1	ANDR_HUMAN	P10275	homo sapien
43	125	43.6	902	1	ANDR_RAT	P15207	rattus norv
44	125	43.6	1012	1	PHC1_MOUSE	Q64028	mus musculu
45	125	43.6	3726	1	ABF1_MOUSE	Q61329	mus musculu

# ALIGNMENTS

## RESULT 1

### HD\_HUMAN

ID HD\_HUMAN STANDARD; PRT; 3144 AA.  
AC P42858;  
DT 01-NOV-1995 (Rel. 32, Created)  
DT 01-NOV-1995 (Rel. 32, Last sequence update)  
DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Huntingtin (Huntington's disease protein) (HD protein).  
GN HD OR IT15.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Retina;  
RX MEDLINE=93208892; PubMed=8458085;  
RA Macdonald M., Ambrose C.M., Duyao M.P., Myers R.H., Lin C.S.,  
RA Srinidhi J., Barnes G., Taylor S.A., James M., Groot N., McFarlane H.,  
RA Jenkins B., Anderson M.A., Wexler N.S., Gusella J.F., Bates G.P.,  
RA Baxendale S., Hummerich H., Kirby S., North M., Youngman S., Mott R.,  
RA Zehetner G., Sedlacek Z., Poustka A., Frischauf A.-M., Lehrach H.,  
RA Buckler A.J., Church D., Doucette-Stamm L., O'Donovan M.C.,  
RA Riba-Ramirez L., Shah M., Stanton V.P., Strobel S.A., Draths K.M.,



RA Wales J.L., Dervan P., Housman D.E., Altherr M., Shiang R.,  
 RA Thompson L., Fielder T., Wasmuth J.J., Tagle D., Valdes J., Elmer L.,  
 RA Allard M., Castilla L., Swaroop M., Blanchard K., Collins F.S.,  
 RA Snell R., Holloway T., Gillespie K., Datson N., Shaw S., Harper P.S.;  
 RT "A novel gene containing a trinucleotide repeat that is expanded and  
 RT unstable on Huntington's disease chromosomes. The Huntington's  
 RT Disease Collaborative Research Group.";  
 RL Cell 72:971-983(1993).  
 RN [2]  
 RP SEQUENCE OF 1-90 FROM N.A.  
 RX MEDLINE=95278941; PubMed=7759106;  
 RA Lin B., Nasir J., Kalchman M.A., McDonald H., Zeisler J.,  
 RA Goldberg Y.P., Hayden M.R.;  
 RT "Structural analysis of the 5' region of mouse and human Huntington  
 RT disease genes reveals conservation of putative promoter region and  
 RT di- and trinucleotide polymorphisms.";  
 RL Genomics 25:707-715(1995).  
 RN [3]  
 RP SEQUENCE OF 1-205 FROM N.A.  
 RX MEDLINE=94255787; PubMed=8197474;  
 RA Ambrose C.M., Duyao M.P., Barnes G., Bates G.P., Lin C.S.,  
 RA Srinidhi J., Baxendale S., Hummerich H., Lehrach H., Altherr M.,  
 RA Wasmuth J., Buckler A., Church D., Housman D., Berks M., Micklem G.,  
 RA Durbin R., Dodge A., Read A., Gusella J.F., Macdonald M.E.;  
 RT "Structure and expression of the Huntington's disease gene: evidence  
 RT against simple inactivation due to an expanded CAG repeat.";  
 RL Somat. Cell Mol. Genet. 20:27-38(1994).  
 RN [4]  
 RP SEQUENCE OF 1-117 FROM N.A.  
 RA Matthews P.;  
 RL Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.  
 RN [5]  
 RP SEQUENCE OF 119-934 FROM N.A.  
 RA Lloyd C.;  
 RL Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.  
 RN [6]  
 RP SEQUENCE OF 1212-1290 FROM N.A.  
 RA Mungall A., Odell C.;  
 RL Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.  
 RN [7]  
 RP SEQUENCE OF 1291-1860 FROM N.A.  
 RA Mungall A.;  
 RL Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.  
 RN [8]  
 RP SEQUENCE OF 1862-2820 FROM N.A.  
 RA Buck D.;  
 RL Submitted (MAY-1995) to the EMBL/GenBank/DDBJ databases.  
 RN [9]  
 RP SEQUENCE OF 2563-3144 FROM N.A.  
 RC TISSUE=Brain, Caudate, Frontal cortex, Muscle, and Retina;  
 RX MEDLINE=94093536; PubMed=7903579;  
 RA Lin B., Rommens J.M., Graham R.K., Kalchman M., Macdonald H.,  
 RA Nasir J., Delaney A., Goldberg Y.P., Hayden M.R.;  
 RT "Differential 3' polyadenylation of the Huntington disease gene  
 RT results in two mRNA species with variable tissue expression.";  
 RL Hum. Mol. Genet. 2:1541-1545(1993).  
 RN [10]

RP SUBCELLULAR LOCATION.  
RX MEDLINE=95375771; PubMed=7647777;  
RA Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y., Weber C.,  
RA Agid Y., Hirsch E.C., Mandel J.-L.;  
RT "Cellular localization of the Huntington's disease protein and  
RT discrimination of the normal and mutated form.";  
RL Nat. Genet. 10:104-110(1995).  
RN [11]  
RP CLEAVAGE BY APOPAIN.  
RX MEDLINE=96331285; PubMed=8696339;  
RA Goldberg Y.P., Nicholson D.W., Rasper D.M., Kalchman M.A., Koide H.B.,  
RA Graham R.K., Bromm M., Kazemi-Esfarjani P., Thornberry N.A.,  
RA Vaillancourt J.P., Hayden M.R.;  
RT "Cleavage of huntingtin by apopain, a proapoptotic cysteine protease,  
RT is modulated by the polyglutamine tract.";  
RL Nat. Genet. 13:442-449(1996).  
RN [12]  
RP INTERACTION WITH FBNP3.  
RX MEDLINE=98367036; PubMed=9700202;  
RA Faber P.W., Barnes G.T., Srinidhi J., Chen J., Gusella J.F.,  
RA MacDonald M.E.;  
RT "Huntingtin interacts with a family of WW domain proteins.";  
RL Hum. Mol. Genet. 7:1463-1474(1998).  
CC -!- FUNCTION: May play a role in microtubule-mediated transport or  
CC vesicle function.  
CC -!- SUBUNIT: Binds SH3GLB1 (By similarity). Interacts through its N-  
CC terminus with FBNP3.  
CC -!- SUBCELLULAR LOCATION: Cytoplasmic.  
CC -!- TISSUE SPECIFICITY: Widely expressed with the highest level of  
CC expression in the brain (nerve fibers, varicosities, and nerve  
CC endings). In the brain, the regions where it can be mainly found  
CC are the cerebellar cortex, the neocortex, the striatum, and the  
CC hippocampal formation.  
CC -!- PTM: Cleaved by apopain downstream of the polyglutamine stretch.  
CC The resulting amino-terminal fragment is cytotoxic and provokes  
CC apoptosis.  
CC -!- POLYMORPHISM: The poly-Gln region of HD is highly polymorphic (10  
CC to 35 repeats) in the normal population and is expanded to about  
CC 36-120 repeats in hd patients. The repeat length usually increases  
CC in successive generations, but contracts also on occasion. The  
CC longer expansions result in earlier onset and more severe clinical  
CC manifestations of the disease. The adjacent poly-pro region is  
CC also polymorphic and varies between 7-12 residues. Polyglutamine  
CC expansion leads to elevated susceptibility to apopain cleavage and  
CC likely result in accelerated neuronal apoptosis.  
CC -!- DISEASE: DEFECTS IN HD ARE THE CAUSE OF HUNTINGTON'S DISEASE, AN  
CC AUTOSOMAL DOMINANT NEURODEGENERATIVE DISORDER CHARACTERIZED BY  
CC INVOLUNTARY MOVEMENTS (CHOREA), GENERAL MOTOR IMPAIRMENT,  
CC PSYCHIATRIC DISORDERS AND DEMENTIA. ONSET OF THE DISEASE OCCURS  
CC USUALLY IN THE THIRD OR FOURTH DECADE OF LIFE AND SYMPTOMS  
CC PROGRESSIVELY WORSEN LEADING TO DEATH IN 10 TO 20 YEARS. IT  
CC AFFECTS 1 IN 10,000 INDIVIDUALS OF EUROPEAN ORIGIN. NEUROPATHOLOGY  
CC OF HUNTINGTON'S DISEASE DISPLAYS A DISTINCTIVE PATTERN WITH LOSS  
CC OF NEURONS, SPECIALLY IN THE CAUDATE AND PUTAMEN (STRIATUM).  
CC -!- SIMILARITY: Contains 10 HEAT repeats.  
CC -!- SIMILARITY: Belongs to the hungtintin family.  
CC -!- DATABASE: NAME=HotMolecBase; NOTE=HD entry;

CC

WWW="http://bioinformatics.weizmann.ac.il/hotmolecbase/entries/hunti.htm".

CC

CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
CC or send an email to license@isb-sib.ch).  
CC -----

CC

DR EMBL; L12392; AAB38240.1; -.

DR EMBL; L34020; -; NOT\_ANNOTATED\_CDS.

DR EMBL; L27350; -; NOT\_ANNOTATED\_CDS.

DR EMBL; L27351; -; NOT\_ANNOTATED\_CDS.

DR EMBL; L27352; -; NOT\_ANNOTATED\_CDS.

DR EMBL; L27353; -; NOT\_ANNOTATED\_CDS.

DR EMBL; L27354; -; NOT\_ANNOTATED\_CDS.

DR EMBL; Z68756; -; NOT\_ANNOTATED\_CDS.

DR EMBL; Z49155; CAA89025.1; -.

DR EMBL; Z49208; -; NOT\_ANNOTATED\_CDS.

DR EMBL; Z69649; -; NOT\_ANNOTATED\_CDS.

DR EMBL; Z49154; CAA89024.1; -.

DR EMBL; Z49769; CAA89839.1; -.

DR EMBL; L20431; AAA52702.1; -.

DR PIR; A46068; A46068.

DR Genew; HGNC:4851; HD.

DR MIM; 143100; -.

DR GO; GO:0005737; C:cytoplasm; TAS.

DR GO; GO:0005634; C:nucleus; TAS.

DR GO; GO:0005625; C:soluble fraction; TAS.

DR GO; GO:0008017; F:microtubule binding; TAS.

DR GO; GO:0005515; F:protein binding; IPI.

DR GO; GO:0003714; F:transcription co-repressor activity; TAS.

DR GO; GO:0005215; F:transporter activity; TAS.

DR GO; GO:0007610; P:behavior; TAS.

DR GO; GO:0007397; P:histogenesis and organogenesis; TAS.

DR GO; GO:0006917; P:induction of apoptosis; TAS.

DR GO; GO:0009405; P:pathogenesis; TAS.

DR InterPro; IPR000091; Huntingtin.

DR Pfam; PF03541; Huntingtin; 1.

DR PRINTS; PR00375; HUNTINGTIN.

KW Repeat; Disease mutation; Polymorphism; Triplet repeat expansion;

KW Apoptosis.

FT DOMAIN 205 329 HEAT REPEATS DOMAIN 1.

FT DOMAIN 745 942 HEAT REPEATS DOMAIN 2.

FT DOMAIN 1534 1575 HEAT REPEATS DOMAIN 3.

FT DOMAIN 18 40 POLY-GLN.

FT DOMAIN 41 51 POLY-PRO.

FT DOMAIN 65 80 POLY-PRO.

FT DOMAIN 1439 1442 POLY-THR.

FT DOMAIN 2343 2347 POLY-GLU.

FT DOMAIN 2640 2645 POLY-GLU.

FT SITE 513 514 CLEAVAGE (BY APOPAIN) (POTENTIAL).

FT SITE 530 531 CLEAVAGE (BY APOPAIN) (POTENTIAL).

FT SITE 552 553 CLEAVAGE (BY APOPAIN) (POTENTIAL).

FT SITE 589 590 CLEAVAGE (BY APOPAIN) (POTENTIAL).

```

FT    VARIANT      38      40      Missing.
FT                                     /FTId=VAR_005268.
FT    CONFLICT    2788    2788      V -> I (IN REF. 10).
SO    SEQUENCE    3144 AA;  347855 MW;  9D1BA8528929908F CRC64;

```

## RESULT 2

RT "GAL11 (SPT13), a transcriptional regulator of diverse yeast genes,  
RT affects the phosphorylation state of GAL4, a highly specific  
RT transcriptional activator.";  
RL Mol. Cell. Biol. 11:2311-2314(1991).

CC -!- FUNCTION: Auxiliary transcription activator for genes encoding  
CC galactose-metabolizing enzymes. Essential for normal growth on  
CC nonfermentable carbon sources, for sporulation and mating.  
CC Coactivator that links transcriptional activators such as GAL4  
CC and GRF1/RAP1/TUF1 with the basic transcription machinery,  
CC possibly by protein-protein interactions.  
CC -!- FUNCTION: It has an important role in the negative regulation of  
CC Ty transcription.  
CC -!- MISCELLANEOUS: GAL11 lacks a DNA-domain, it probably complexes  
CC with GAL4 that has the capacity to bind DNA. Association between  
CC GAL11 and GAL4 may serve to expedite phosphorylation of GAL4.  
CC -!- SIMILARITY: TO K.LACTIS GALY, AND SOME, TO YEAST GLUCOSE  
CC REPRESSION MEDIATOR PROTEIN (CYC8).

CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----

DR EMBL; M22481; AAA34622.1; -.  
DR EMBL; Z74793; CAA99056.1; -.  
DR EMBL; X91067; CAA62537.1; -.  
DR PIR; S66736; S66736.  
DR GermOnline; 143473; -.  
DR TRANSEAC; T03313; -.  
DR SGD; S0005411; GAL11.  
DR GO; GO:0000119; C:mediator complex; IDA.  
DR GO; GO:0016455; F:RNA polymerase II transcription mediator ac. . .; IDA.  
DR GO; GO:0006366; P:transcription from Pol II promoter; IDA.  
DR InterPro; IPR008626; GAL11.  
DR Pfam; PF05397; GAL11; 1.

KW Transcription regulation; Activator; Galactose metabolism;  
KW Repeat.

FT DOMAIN 147 158 POLY-GLN.  
FT DOMAIN 422 481 29 X 2 AA TANDEM REPEATS OF Q-A.  
FT DOMAIN 674 696 POLY-GLN.  
FT CONFLICT 171 171 N -> T (IN REF. 1).  
FT CONFLICT 302 302 P -> Q (IN REF. 1).  
FT CONFLICT 499 499 N -> T (IN REF. 1).  
FT CONFLICT 751 751 P -> Q (IN REF. 1).  
SQ SEQUENCE 1081 AA; 120308 MW; 275C78721B5415C7 CRC64;

Query Match 51.2%; Score 147; DB 1; Length 1081;  
Best Local Similarity 51.7%; Pred. No. 1.8e-06;  
Matches 30; Conservative 11; Mismatches 13; Indels 4; Gaps 1;

Qy 6 SMATLEKLMKAFESLKSFQ----QQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRAAAS 59  
::|| : : : : : | | | | | | | | | | | | | | | : | | | | :  
Db 651 NIATQQNMQQSLQQMQHLQQLKMQQQQQQQQQQQQQQQQQQQQQQQQQQHIYPSSTPGVAN 708

# RESULT 3

## TBP\_HUMAN

ID TBP\_HUMAN STANDARD; PRT; 339 AA.  
AC P20226; Q16845; Q9UC02;  
DT 01-FEB-1991 (Rel. 17, Created)  
DT 01-FEB-1996 (Rel. 33, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE TATA-box binding protein (TATA-box factor) (TATA binding factor) (TATA  
DE sequence-binding protein) (Transcription initiation factor TFIID TBP  
DE subunit).  
GN TBP OR TFIID OR TF2D.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A., AND DOMAINS.  
RX MEDLINE=90302006; PubMed=2363050;  
RA Peterson M.G., Tanese N., Pugh B.F., Tjian R.;  
RT "Functional domains and upstream activation properties of cloned  
RT human TATA binding protein.";  
RL Science 248:1625-1630(1990).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Fibroblast;  
RX MEDLINE=90302010; PubMed=2194289;  
RA Kao C.C., Lieberman P.M., Schmidt M.C., Zhou Q., Pei R., Berk A.J.;  
RT "Cloning of a transcriptionally active human TATA binding factor.";  
RL Science 248:1646-1650(1990).  
RN [3]  
RP SEQUENCE FROM N.A., AND VARIANT 92-GLN--GLN-95 DEL.  
RX MEDLINE=90326195; PubMed=2374612;  
RA Hoffmann A., Sinn E., Yamamoto T., Wang J., Roy A., Horikoshi M.,  
RA Roeder R.G.;  
RT "Highly conserved core domain and unique N terminus with presumptive  
RT regulatory motifs in a human TATA factor (TFIID).";  
RL Nature 346:387-390(1990).  
RN [4]  
RP SEQUENCE FROM N.A.  
RA Griffiths C.;  
RL Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.  
RN [5]  
RP INTERACTION WITH NCOA6.  
RX MEDLINE=20036574; PubMed=10567404;  
RA Lee S.-K., Anzick S.L., Choi J.-E., Bubendorf L., Guan X.-Y.,  
RA Jung Y.-K., Kallioniemi O.P., Kononen J., Trent J.M., Azorsa D.,  
RA Jhun B.-H., Cheong J.H., Lee Y.C., Meltzer P.S., Lee J.W.;  
RT "A nuclear factor ASC-2, as a cancer-amplified transcriptional  
RT coactivator essential for ligand-dependent transactivation by nuclear  
RT receptors in vivo.";  
RL J. Biol. Chem. 274:34283-34293(1999).  
RN [6]  
RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 159-337 IN COMPLEX WITH DNA.  
RX MEDLINE=96209823; PubMed=8643494;  
RA Nikolov D.B., Chen H., Halay E.D., Hoffmann A., Roeder R.G.,  
RA Burley S.K.;

RT "Crystal structure of a human TATA box-binding protein/TATA element  
 RT complex.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 93:4862-4867(1996).  
 RN [7]  
 RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 159-339 IN COMPLEX WITH DNA.  
 RX MEDLINE=96346176; PubMed=8757291;  
 RA Juo Z.S., Chiu T.K., Leiberman P.M., Baikarov I., Berk A.J.,  
 RA Dickerson R.E.;  
 RT "How proteins recognize the TATA box.";  
 RL J. Mol. Biol. 261:239-254(1996).  
 RN [8]  
 RP X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 159-337 IN COMPLEX WITH  
 RP GTF2B AND DNA.  
 RX MEDLINE=20086817; PubMed=10619841;  
 RA Tsai F.T.F., Sigler P.B.;  
 RT "Structural basis of preinitiation complex assembly on human pol II  
 RT promoters.";  
 RL EMBO J. 19:25-36(2000).  
 RN [9]  
 RP X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) OF 159-339 IN COMPLEX WITH DR1;  
 RP DRAP1 AND DNA.  
 RX MEDLINE=21354312; PubMed=11461703;  
 RA Kamada K., Shu F., Chen H., Malik S., Stelzer G., Roeder R.G.,  
 RA Meisterernst M., Burley S.K.;  
 RT "Crystal structure of negative cofactor 2 recognizing the TBP-DNA  
 RT transcription complex.";  
 RL Cell 106:71-81(2001).  
 RN [10]  
 RP POLYMORPHISM OF POLY-GLN REGION.  
 RX MEDLINE=99415745; PubMed=10484774;  
 RA Koide R., Kobayashi S., Shimohata T., Ikeuchi T., Maruyama M.,  
 RA Saito M., Yamada M., Takahashi H., Tsuji S.;  
 RT "A neurological disease caused by an expanded CAG trinucleotide repeat  
 RT in the TATA-binding protein gene: a new polyglutamine disease?";  
 RL Hum. Mol. Genet. 8:2047-2053(1999).  
 RN [11]  
 RP POLYMORPHISM OF POLY-GLN REGION.  
 RX MEDLINE=21214723; PubMed=11313753;  
 RA Zuhlke C., Hellenbroich Y., Dalski A., Kononowa N., Hagenah J.,  
 RA Vieregge P., Riess O., Klein C., Schwinger E.;  
 RT "Different types of repeat expansion in the TATA-binding protein gene  
 RT are associated with a new form of inherited ataxia.";  
 RL Eur. J. Hum. Genet. 9:160-164(2001).  
 RN [12]  
 RP POLYMORPHISM OF POLY-GLN REGION.  
 RX MEDLINE=21341926; PubMed=11448935;  
 RA Nakamura K., Jeong S.-Y., Uchiyama T., Anno M., Nagashima K.,  
 RA Nagashima T., Ikeda S.-I., Tsuji S., Kanazawa I.;  
 RT "SCA17, a novel autosomal dominant cerebellar ataxia caused by an  
 RT expanded polyglutamine in TATA-binding protein.";  
 RL Hum. Mol. Genet. 10:1441-1448(2001).  
 RN [13]  
 RP POLYMORPHISM OF POLY-GLN REGION.  
 RX MEDLINE=21937712; PubMed=11939898;  
 RA Silveira I., Miranda C., Guimaraes L., Moreira M.-C., Alonso I.,  
 RA Mendonca P., Ferro A., Pinto-Basto J., Coelho J., Ferreira F.,  
 RA Poirier J., Parreira E., Vale J., Januario C., Barbot C., Tuna A.,

RA Barros J., Koide R., Tsuji S., Holmes S.E., Margolis R.L., Jardim L.,  
 RA Pandolfo M., Coutinho P., Sequeiros J.;  
 RT "Trinucleotide repeats in 202 families with ataxia: a small expanded  
 RT (CAG)<sub>n</sub> allele at the SCA17 locus."  
 RL Arch. Neurol. 59:623-629(2002).  
 CC -!- FUNCTION: General transcription factor that functions at the  
 CC core of the DNA-binding multiprotein factor TFIID. Binding of  
 CC TFIID to the TATA box is the initial transcriptional step of the  
 CC pre-initiation complex (PIC), playing a role in the activation of  
 CC eukaryotic genes transcribed by RNA polymerase II.  
 CC -!- SUBUNIT: Belongs to the TFIID complex together with the TBP-  
 CC associated factors (TAFs). Binds DNA as monomer. Interacts with  
 CC TAFs, TFIIA, TFIIB, NCOA6, DRAP1 and DRI.  
 CC -!- SUBCELLULAR LOCATION: Nuclear.  
 CC -!- POLYMORPHISM: The poly-Gln region of TBP is highly polymorphic (25  
 CC to 42 repeats) in normal individuals and is expanded to about 47-  
 CC 63 repeats in SCA17 patients. Longer expansions may result in  
 CC earlier onset and more severe clinical manifestations of the  
 CC disease.  
 CC -!- DISEASE: Defects in TBP are the cause of spinocerebellar ataxia  
 CC type 17 (SCA17) [MIM:607136]. SCA17 is a rare autosomal dominant  
 CC neurodegenerative disease, characterized by gait ataxia and  
 CC dementia, progressing over several decades to include  
 CC bradykinesia, dysmetria, dysdiadochokinesis, hyperreflexia and  
 CC paucity of movement.  
 CC -!- SIMILARITY: Belongs to the TBP family.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; M55654; AAA36731.1; -.  
 DR EMBL; M34960; AAC03409.1; -.  
 DR EMBL; X54993; CAA38736.1; -.  
 DR EMBL; AL031259; CAA20286.1; -.  
 DR PIR; A34830; TWHU2D.  
 DR PDB; 1CDW; 23-DEC-96.  
 DR PDB; 1C9B; 10-JAN-00.  
 DR PDB; 1JFI; 11-JUL-01.  
 DR PDB; 1TGH; 01-AUG-96.  
 DR TRANSFAC; T00794; -.  
 DR Genew; HGNC:11588; TBP.  
 DR MIM; 600075; -.  
 DR MIM; 607136; -.  
 DR GO; GO:0005669; C:transcription factor TFIID complex; TAS.  
 DR GO; GO:0016251; F:general RNA polymerase II transcription fac. . .; TAS.  
 DR GO; GO:0006367; P:transcription initiation from Pol II promoter; TAS.  
 DR InterPro; IPR000814; TFIID.  
 DR Pfam; PF00352; TBP; 2.  
 DR PRINTS; PR00686; TIFACTORIID.  
 DR PROSITE; PS00351; TFIID; 2.  
 KW Transcription; Nuclear protein; DNA-binding; Repeat; Polymorphism;  
 KW Triplet repeat expansion; Disease mutation; 3D-structure.





OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A. (ISOFORMS 3 AND 4).  
 RX MEDLINE=93342088; PubMed=8341710;  
 RA Ogawa E., Maruyama M., Kagoshima H., Inuzuka M., Lu J., Satake M.,  
 RA Shigesada K., Ito Y.;  
 RT "PEBP2/PEA2 represents a family of transcription factors homologous to  
 RT the products of the Drosophila runt gene and the human AML1 gene.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 90:6859-6863(1993).  
 RN [2]  
 RP SEQUENCE FROM N.A. (ISOFORM 2).  
 RC STRAIN=C57BL/6;  
 RC TISSUE=Osteoblast;  
 RX MEDLINE=97325750; PubMed=9182762;  
 RA Ducey P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G.;  
 RT "Osf2/Cbfa1: a transcriptional activator of osteoblast  
 RT differentiation.";  
 RL Cell 89:747-754(1997).  
 RN [3]  
 RP SEQUENCE FROM N.A. (ISOFORMS 2; 3; 4; 5; 6; 7; 8 AND 9).  
 RC STRAIN=CD2-MYC;  
 RX MEDLINE=97385157; PubMed=9238031;  
 RA Stewart M., Terry A., Hu M., O'Hara M., Blyth K., Baxter E.,  
 RA Cameron E., Onions D.E., Neil J.C.;  
 RT "Proviral insertions induce the expression of bone-specific isoforms  
 RT of PEBP2alphaA (CBFA1): evidence for a new myc collaborating  
 RT oncogene.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 94:8646-8651(1997).  
 RN [4]  
 RP PARTIAL SEQUENCE FROM N.A. (ISOFORMS 2 AND 6), AND ALTERNATIVE  
 RP SPLICING.  
 RX MEDLINE=98322266; PubMed=9651525;  
 RA Xiao Z.S., Thomas R., Hinson T.K., Quarles L.D.;  
 RT "Genomic structure and isoform expression of the mouse, rat and human  
 RT Cbfa1/Osf2 transcription factor.";  
 RL Gene 214:187-197(1998).  
 RN [5]  
 RP SEQUENCE OF 1-98 FROM N.A. (ISOFORMS 1 AND 2).  
 RX MEDLINE=99453726; PubMed=10524201;  
 RA Fujiwara M., Tagashira S., Harada H., Ogawa S., Katsumata T.,  
 RA Nakatsuka M., Komori T., Takada H.;  
 RT "Isolation and characterization of the distal promoter region of mouse  
 RT Cbfa1.";  
 RL Biochim. Biophys. Acta 1446:265-272(1999).  
 RN [6]  
 RP SEQUENCE OF 263-277 AND 305-319.  
 RX MEDLINE=93242761; PubMed=8386878;  
 RA Ogawa E., Inuzuka M., Maruyama M., Satake M., Naito-Fujimoto M.,  
 RA Ito Y., Shigesada K.;  
 RT "Molecular cloning and characterization of PEBP2 beta, the  
 RT heterodimeric partner of a novel Drosophila runt-related DNA binding  
 RT protein PEBP2 alpha.";  
 RL Virology 194:314-331(1993).  
 RN [7]  
 RP SEQUENCE OF 1-35 FROM N.A.

RC STRAIN=129;  
 RA Chi X.-Z., Bae S.-C.;  
 RT "Analysis of the two PEBP2aA/cbfa1 promoter regions.";  
 RL Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.  
 RN [8]  
 RP FUNCTION.  
 RX MEDLINE=97325751; PubMed=9182763;  
 RA Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K.,  
 RA Shimizu Y., Bronson R.T., Gao Y.-H., Inada M., Sato M., Okamoto R.,  
 RA Kitamura Y., Yoshiki S., Kishimoto T.;  
 RT "Targeted disruption of Cbfa1 results in a complete lack of bone  
 RT formation owing to maturational arrest of osteoblasts.";  
 RL Cell 89:755-764(1997).  
 RN [9]  
 RP PHOSPHORYLATION.  
 RX MEDLINE=20127938; PubMed=10660618;  
 RA Xiao G., Jiang D., Thomas P., Benson M.D., Guan K., Karsenty G.,  
 RA Franceschi R.T.;  
 RT "MAPK pathways activate and phosphorylate the osteoblast-specific  
 RT transcription factor, Cbfa1.";  
 RL J. Biol. Chem. 275:4453-4459(2000).  
 CC -!- FUNCTION: Transcription factor involved in osteoblastic  
 CC differentiation and skeletal morphogenesis. Essential for the  
 CC maturation of osteoblasts and both intramembranous and  
 CC endochondral ossification. Cbf binds to the core site, 5'-  
 CC PYGPGYGGT-3', of a number of enhancers and promoters, including  
 CC murine leukemia virus, polyomavirus enhancer, T-cell receptor  
 CC enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I)  
 CC collagen, LCK, IL-3 and GM-CSF promoters.  
 CC -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. The alpha  
 CC subunit binds DNA as a monomer and through the Runt domain. DNA-  
 CC binding is increased by heterodimerization.  
 CC -!- SUBCELLULAR LOCATION: Nuclear.  
 CC -!- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=9;  
 CC Comment=Additional isoforms seem to exist;  
 CC Name=1;  
 CC IsoId=Q08775-1; Sequence=Displayed;  
 CC Name=2;  
 CC IsoId=Q08775-2; Sequence=VSP\_005941;  
 CC Name=3; Synonyms=PEBP2-alpha A1;  
 CC IsoId=Q08775-3; Sequence=VSP\_005940, VSP\_005942;  
 CC Name=4; Synonyms=PEBP2-alpha A2;  
 CC IsoId=Q08775-4; Sequence=VSP\_005940, VSP\_005942, VSP\_005944,  
 CC VSP\_005945;  
 CC Name=5; Synonyms=G1;  
 CC IsoId=Q08775-5; Sequence=VSP\_005939;  
 CC Name=6; Synonyms=G2;  
 CC IsoId=Q08775-6; Sequence=VSP\_005939, VSP\_005943;  
 CC Name=7; Synonyms=U1;  
 CC IsoId=Q08775-7; Sequence=VSP\_005939, VSP\_005946, VSP\_005948;  
 CC Name=8; Synonyms=Y1;  
 CC IsoId=Q08775-8; Sequence=VSP\_005939, VSP\_005947;  
 CC Name=9; Synonyms=Y2;  
 CC IsoId=Q08775-9; Sequence=VSP\_005939, VSP\_005943, VSP\_005947;  
 CC -!- TISSUE SPECIFICITY: Found in thymus and testis, T cell lines but  
 CC not in B-cell lines. Isoform 2 is exclusively found in bone,

CC particularly in osteoblasts; isoforms 3 and 4 are expressed in T-  
 CC cell lines; isoforms 5, 6, 7, 8 and 9 can be found in osteoblasts  
 CC and osteosarcoma cell lines.  
 CC -!- DEVELOPMENTAL STAGE: Expression occurs early during skeletal  
 CC development and is restricted to cells of the mesenchymal  
 CC condensations and of the osteoblast lineage. Expression of isoform  
 CC 2 in the embryo reaches a peak at 12.5 dpc.  
 CC -!- DOMAIN: A proline/serine/threonine rich region at the C-terminus  
 CC is necessary for transcriptional activation of target genes and  
 CC contains the phosphorylation sites.  
 CC -!- PTM: Phosphorylated; probably by MAP kinases (MAPK).  
 CC -!- SIMILARITY: Contains 1 Runt domain.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; D14636; BAA03485.1; -.  
 DR EMBL; D14637; BAA03486.1; -.  
 DR EMBL; AF010284; AAB65409.1; -.  
 DR EMBL; AF005936; AAB82419.1; -.  
 DR EMBL; AF053948; AAC77440.1; -.  
 DR EMBL; AF053951; AAC78623.1; -.  
 DR EMBL; AF053956; AAC78626.1; -.  
 DR EMBL; AF134836; AAF22568.1; -.  
 DR EMBL; AF134836; AAF22569.1; -.  
 DR EMBL; AB013129; BAA85345.1; -.  
 DR EMBL; AB013129; BAA85346.1; -.  
 DR EMBL; AF155360; AAF73290.1; -.  
 DR PIR; A48233; A48233.  
 DR HSSP; O60472; 1CMO.  
 DR TRANSFAC; T01062; -.  
 DR TRANSFAC; T01063; -.  
 DR MGD; MGI:99829; Runx2.  
 DR GO; GO:0005634; C:nucleus; IDA.  
 DR GO; GO:0005515; F:protein binding; IPI.  
 DR GO; GO:0045944; P:positive regulation of transcription from P. . .; IDA.  
 DR InterPro; IPR000040; AML1 Runt.  
 DR InterPro; IPR008967; P53-like.  
 DR Pfam; PF00853; Runt; 1.  
 DR PRINTS; PR00967; ONCOGENEAML1.  
 KW Transcription regulation; DNA-binding; Nuclear protein; ATP-binding;  
 KW Alternative splicing; Phosphorylation.  
 FT DOMAIN 187 314 RUNT.  
 FT DOMAIN 323 607 PRO/SER/THR-RICH.  
 FT DOMAIN 128 156 POLY-GLN.  
 FT DOMAIN 158 175 POLY-ALA.  
 FT NP\_BIND 275 282 ATP (POTENTIAL).  
 FT VARSPLIC 1 79 Missing (in isoform 5, isoform 6, isoform  
 FT 7, isoform 8 and isoform 9).  
 FT /FTId=VSP\_005939.  
 FT VARSPLIC 1 98 MLHSPHKQPQNHKCGANFLQEDCKKALAFKWLISAGHYQPP  
 FT RPTESVSALT TVHAGIFKAASSIYNRGHKFYLEKKGGTMS



RA Mannhaupt G., Stucka R., Ehnle S., Vetter I., Feldmann H.;  
 RT "Molecular analysis of yeast chromosome II between CMD1 and LYS2: the  
 RT excision repair gene RAD16 located in this region belongs to a novel  
 RT group of double-finger proteins.";  
 RL Yeast 8:397-408(1992).  
 RN [4]  
 RP TPR REPEATS.  
 RX MEDLINE=90124639; PubMed=2404612;  
 RA Sikorski R.S., Boguski M.S., Goebel M., Hieter P.A.;  
 RT "A repeating amino acid motif in CDC23 defines a family of proteins  
 RT and a new relationship among genes required for mitosis and RNA  
 RT synthesis.";  
 RL Cell 60:307-317(1990).  
 CC -!- FUNCTION: IT IS INVOLVED IN REPRESSION BY A1-ALPHA2 AND ALPHA2 AND  
 CC IN OTHER SYSTEMS AS A GENERAL REPRESSOR OF TRANSCRIPTION. THIS  
 CC PROTEIN HAS NO OBVIOUS DNA-BINDING DOMAINS. IT MIGHT NOT INTERACT  
 CC DIRECTLY WITH DNA BUT WITH DNA-BOUND PROTEINS.  
 CC -!- SUBCELLULAR LOCATION: Nuclear.  
 CC -!- SIMILARITY: Contains 10 TPR repeats.  
 CC -!- SIMILARITY: TO YEAST GAL1 AND CCR4.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; M23440; AAA34545.1; -.  
 DR EMBL; M17826; AAA35103.1; -.  
 DR EMBL; X66247; CAA46973.1; -.  
 DR EMBL; X78993; CAA55615.1; -.  
 DR EMBL; Z35981; CAA85069.1; -.  
 DR PIR; S25365; S25365.  
 DR GermOnline; 138655; -.  
 DR TRANSFAC; T03687; -.  
 DR SGD; S0000316; CYC8.  
 DR GO; GO:0005634; C:nucleus; IPI.  
 DR GO; GO:0016565; F:general transcriptional repressor activity; IDA.  
 DR GO; GO:0003713; F:transcription co-activator activity; IDA.  
 DR GO; GO:0016481; P:negative regulation of transcription; IDA.  
 DR InterPro; IPR008941; TPR-like.  
 DR InterPro; IPR001440; TPR.  
 DR Pfam; PF00515; TPR; 10.  
 DR SMART; SM00028; TPR; 9.  
 KW Transcription regulation; Repressor; Repeat; TPR repeat;  
 KW Nuclear protein.  
 FT DOMAIN 15 30 POLY-GLN.  
 FT REPEAT 46 79 TPR 1.  
 FT REPEAT 80 113 TPR 2.  
 FT REPEAT 114 147 TPR 3.  
 FT REPEAT 150 183 TPR 4.  
 FT REPEAT 187 220 TPR 5.  
 FT REPEAT 224 257 TPR 6.  
 FT REPEAT 258 291 TPR 7.  
 FT REPEAT 296 329 TPR 8.

FT REPEAT 330 363 TPR 9.  
 FT REPEAT 364 398 TPR 10.  
 FT DOMAIN 493 556 30 X 2 AA TANDEM REPEATS OF Q-A.  
 FT DOMAIN 557 587 POLY-GLN.  
 FT CONFLICT 547 547 K -> Q (IN REF. 3).  
 SQ SEQUENCE 966 AA; 107202 MW; 84B509CF3208C5C0 CRC64;

Query Match 49.1%; Score 141; DB 1; Length 966;  
 Best Local Similarity 100.0%; Pred. No. 5.8e-06;  
 Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 24 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 51  
 |||||  
 Db 563 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP 590

# RESULT 6

## HMAA\_DROME

ID HMAA\_DROME STANDARD; PRT; 590 AA.  
 AC P29555; Q9VER1;  
 DT 01-APR-1993 (Rel. 25, Created)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Homeobox protein abdominal-A.  
 GN ABD-A OR CG10325.  
 OS Drosophila melanogaster (Fruit fly).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
 OC Ephydroidea; Drosophilidae; Drosophila.  
 OX NCBI\_TaxID=7227;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Canton-S;  
 RX MEDLINE=95396803; PubMed=7667301;  
 RA Martin C.H., Mayeda C.A., Davis C.A., Ericsson C.L., Knafels J.D.,  
 RA Mathog D.R., Celniker S.E., Lewis E.B., Palazzolo M.J.;  
 RT "Complete sequence of the bithorax complex of Drosophila."  
 RL Proc. Natl. Acad. Sci. U.S.A. 92:8398-8402(1995).  
 RN [2]  
 RP SEQUENCE FROM N.A. (ISOFORM ABD-A1).  
 RC STRAIN=Berkeley;  
 RX MEDLINE=20196006; PubMed=10731132;  
 RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
 RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,  
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
 RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,  
 RA Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,  
 RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,  
 RA Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,  
 RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
 RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
 RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,  
 RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
 RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
 RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
 RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
 RA Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,

RA Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,  
 RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
 RA Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,  
 RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,  
 RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
 RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
 RA Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,  
 RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
 RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
 RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
 RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,  
 RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
 RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,  
 RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
 RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
 RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
 RA Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,  
 RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,  
 RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
 RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
 RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;

RT "The genome sequence of *Drosophila melanogaster*.";

RL Science 287:2185-2195(2000).

RN [3]

RP SEQUENCE OF 261-590 FROM N.A.

RX MEDLINE=91071585; PubMed=1979297;

RA Karch F., Bender W., Weiffenbach B.;

RT "abdA expression in *Drosophila* embryos.";

RL Genes Dev. 4:1573-1587(1990).

CC -!- FUNCTION: SEQUENCE-SPECIFIC TRANSCRIPTION FACTOR WHICH IS PART OF  
 CC A DEVELOPMENTAL REGULATORY SYSTEM THAT PROVIDES CELLS WITH  
 CC SPECIFIC POSITIONAL IDENTITIES ON THE ANTERIOR-POSTERIOR AXIS.  
 CC REQUIRED FOR SEGMENTAL IDENTITY OF THE SECOND THROUGH EIGHTH  
 CC ABDOMINAL SEGMENTS. ONCE A PATTERN OF ABD-A EXPRESSION IS TURNED  
 CC ON IN A GIVEN PARASEGMENT, IT REMAINS ON THE MORE POSTERIOR  
 CC PARASEGMENT, SO THAT THE COMPLEX PATTERN OF EXPRESSION IS BUILT UP  
 CC IN THE SUCCESSIVE PARASEGMENTS. APPEARS TO REPRESS EXPRESSION OF  
 CC UBX WHENEVER THEY APPEAR IN THE SAME CELL, BUT ABD-A IS REPRESSED  
 CC BY ABDB ONLY IN THE EIGHT AND NINTH ABDOMINAL SEGMENTS.

CC -!- SUBCELLULAR LOCATION: Nuclear (Probable).

CC -!- ALTERNATIVE PRODUCTS:

CC Event=Alternative splicing; Named isoforms=2;

CC Name=Abd-A2;

CC IsoId=P29555-1; Sequence=Displayed;

CC Name=Abd-A1;

CC IsoId=P29555-2; Sequence=VSP\_002394;

CC -!- SIMILARITY: Belongs to the Antp homeobox family.

CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; U31961; AAA84405.1; -.



DR EMBL; U31961; AAA84406.1; -.  
 DR EMBL; X54453; CAA38321.1; -.  
 DR EMBL; AE003715; AAF55359.1; -.  
 DR PIR; A35915; A35915.  
 DR HSSP; P02833; 9ANT.  
 DR TRANSFAC; T01992; -.  
 DR FlyBase; FBgn0000014; abd-A.  
 DR GO; GO:0007438; P:oenocyte development; IMP.  
 DR InterPro; IPR001827; Antennapedia.  
 DR InterPro; IPR001356; Homeobox.  
 DR Pfam; PF00046; homeobox; 1.  
 DR PRINTS; PR00025; ANTENNAPEDIA.  
 DR PRINTS; PR00024; HOMEBOX.  
 DR ProDom; PD000010; Homeobox; 1.  
 DR SMART; SM00389; HOX; 1.  
 DR PROSITE; PS00027; HOMEBOX\_1; 1.  
 DR PROSITE; PS00032; ANTENNAPEDIA; FALSE\_NEG.  
 DR PROSITE; PS50071; HOMEBOX\_2; 1.  
 KW Homeobox; DNA-binding; Developmental protein; Nuclear protein;  
 KW Alternative splicing.  
 FT DOMAIN 35 50 POLY-ALA.  
 FT DOMAIN 51 119 SER-RICH.  
 FT DOMAIN 136 139 POLY-GLN (OPA-REPEAT).  
 FT DOMAIN 144 147 POLY-GLN (OPA-REPEAT).  
 FT DOMAIN 160 165 POLY-GLN (OPA-REPEAT).  
 FT DOMAIN 172 177 POLY-ALA.  
 FT DOMAIN 240 250 POLY-ALA.  
 FT SITE 368 373 ANTP-TYPE HEXAPEPTIDE.  
 FT DNA\_BIND 398 457 HOMEBOX.  
 FT DOMAIN 425 428 POLY-ARG.  
 FT DOMAIN 491 518 POLY-GLN (OPA-REPEAT).  
 FT VARSPLIC 1 260 Missing (in isoform Abd-A1).  
 FT /FTId=VSP\_002394.  
 SQ SEQUENCE 590 AA; 62409 MW; FF080CC2D71ECA82 CRC64;

Query Match 49.0%; Score 140.5; DB 1; Length 590;  
 Best Local Similarity 70.5%; Pred. No. 4.1e-06;  
 Matches 31; Conservative 4; Mismatches 6; Indels 3; Gaps 1;

Qy 11 EKLMKAFESLKSFOQQ---QQQQQQQQQQQQQQQQQQQQQQQLQP 51  
 :: ||| |::|| || ||||| ||||| |||| ||  
 Db 474 QEKMKAQETMKSQQNKQVQQQQQQQQQQQQQQQQQQQQHQQQQQP 517

# RESULT 7

## NCO6\_HUMAN

ID NCO6\_HUMAN STANDARD; PRT; 2063 AA.  
 AC Q14686; Q9NTZ9; Q9UH74; Q9UK86;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Nuclear receptor coactivator 6 (Amplified in breast cancer-3 protein)  
 DE (Cancer-amplified transcriptional coactivator ASC-2) (Activating  
 DE signal cointegrator-2) (ASC-2) (Peroxisome proliferator-activated  
 DE receptor-interacting protein) (PPAR-interacting protein) (PRIP)  
 DE (Nuclear receptor-activating protein, 250 kDa) (Nuclear receptor  
 DE coactivator RAP250) (NRC RAP250) (Thyroid hormone receptor-binding

DE protein).

GN NCOA6 OR AIB3 OR RAP250 OR TRBP OR KIAA0181.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI\_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A., AND INTERACTION WITH CREBBP; NCOA1; GTF2A; TBP;

RP RXRA; ESR1; RARA AND THRA.

RX MEDLINE=20036574; PubMed=10567404;

RA Lee S.-K., Anzick S.L., Choi J.-E., Bubendorf L., Guan X.-Y.,

RA Jung Y.-K., Kallioniemi O.P., Kononen J., Trent J.M., Azorsa D.,

RA Jhun B.-H., Cheong J.H., Lee Y.C., Meltzer P.S., Lee J.W.;

RT "A nuclear factor ASC-2, as a cancer-amplified transcriptional

RT coactivator essential for ligand-dependent transactivation by nuclear

RT receptors in vivo.";

RL J. Biol. Chem. 274:34283-34293(1999).

RN [2]

RP SEQUENCE FROM N.A., HOMODIMERIZATION, AND INTERACTION WITH CREBBP;

RP RXRA; ESR1; NR3C1; RARA; VDR AND THRA.

RX MEDLINE=20325329; PubMed=10866662;

RA Mahajan M.A., Samuels H.H.;

RT "A new family of nuclear receptor coregulators that integrates nuclear

RT receptor signaling through CBP.";

RL Mol. Cell. Biol. 20:5048-5063(2000).

RN [3]

RP SEQUENCE FROM N.A., AND INTERACTION WITH PPARA; PPARG; ESR1; ESR2 AND

RP THR.

RC TISSUE=Testis;

RX MEDLINE=20148724; PubMed=10681503;

RA Caira F., Antonson P., Pelto-Huikko M., Treuter E., Gustafsson J.-A.;

RT "Cloning and characterization of RAP250, a nuclear receptor

RT coactivator.";

RL J. Biol. Chem. 275:5308-5317(2000).

RN [4]

RP SEQUENCE FROM N.A., PHOSPHORYLATION BY PRKDC, AND INTERACTION WITH

RP THR; RAR; EP300 AND CRSP3.

RC TISSUE=Lymphocytes;

RX MEDLINE=20283976; PubMed=10823961;

RA Ko L., Cardona G.R., Chin W.W.;

RT "Thyroid hormone receptor-binding protein, an LXXLL motif-containing

RT protein, functions as a general coactivator.";

RL Proc. Natl. Acad. Sci. U.S.A. 97:6212-6217(2000).

RN [5]

RP SEQUENCE FROM N.A.

RC TISSUE=Bone marrow;

RX MEDLINE=96281124; PubMed=8724849;

RA Nagase T., Seki N., Ishikawa K.-I., Tanaka A., Nomura N.;

RT "Prediction of the coding sequences of unidentified human genes. V.

RT The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by

RT analysis of cDNA clones from human cell line KG-1.";

RL DNA Res. 3:17-24(1996).

RN [6]

RP SEQUENCE FROM N.A.

RX MEDLINE=21638749; PubMed=11780052;

RA Deloukas P., Matthews L.H., Ashurst J., Burton J., Gilbert J.G.R.,

RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,

RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,  
 RA Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,  
 RA Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,  
 RA Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,  
 RA Clegg S., Copley V.E., Collier R.E., Connor R.E., Corby N.R.,  
 RA Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,  
 RA Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,  
 RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,  
 RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,  
 RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,  
 RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,  
 RA Lehvaslaiho M.H., Lerversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,  
 RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,  
 RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,  
 RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,  
 RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,  
 RA Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,  
 RA Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,  
 RA Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,  
 RA Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,  
 RA Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,  
 RA Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,  
 RA Rogers J.;  
 RT "The DNA sequence and comparative analysis of human chromosome 20.";  
 RL Nature 414:865-871(2001).  
 RN [7]  
 RP INTERACTION WITH NCOA6IP.  
 RX MEDLINE=21417756; PubMed=11517327;  
 RA Zhu Y.-J., Qi C., Cao W.-Q., Yeldandi A.V., Rao M.S., Reddy J.K.;  
 RT "Cloning and characterization of PIMT, a protein with a  
 RT methyltransferase domain, which interacts with and enhances nuclear  
 RT receptor coactivator PRIP function.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 98:10380-10385(2001).  
 RN [8]  
 RP INTERACTION WITH RBM14.  
 RX MEDLINE=21423995; PubMed=11443112;  
 RA Iwasaki T., Chin W.W., Ko L.;  
 RT "Identification and characterization of RRM-containing coactivator  
 RT activator (CoAA) as TRBP-interacting protein, and its splice variant  
 RT as a coactivator modulator (CoAM).";  
 RL J. Biol. Chem. 276:33375-33383(2001).  
 RN [9]  
 RP INTERACTION WITH HRMT1L1.  
 RX MEDLINE=22151129; PubMed=12039952;  
 RA Qi C., Chang J., Zhu Y., Yeldandi A.V., Rao S.M., Zhu Y.-J.;  
 RT "Identification of protein arginine methyltransferase 2 as a  
 RT coactivator for estrogen receptor alpha.";  
 RL J. Biol. Chem. 277:28624-28630(2002).  
 RN [10]  
 RP INTERACTION WITH MLL3 AND THE ASCOM COMPLEX.  
 RC TISSUE=Cervical carcinoma;  
 RX MEDLINE=22371496; PubMed=12482968;  
 RA Goo Y.-H., Sohn Y.C., Kim D.-H., Kim S.-W., Kang M.-J., Jung D.-J.,  
 RA Kwak E., Barlev N.A., Berger S.L., Chow V.T., Roeder R.G.,  
 RA Azorsa D.O., Meltzer P.S., Suh P.-G., Song E.J., Lee K.-J., Lee Y.C.,  
 RA Lee J.W.;  
 RT "Activating signal cointegrator 2 belongs to a novel steady-state

RT complex that contains a subset of trithorax group proteins.";  
 RL Mol. Cell. Biol. 23:140-149(2003).  
 RN [11]  
 RP MUTAGENESIS OF 883-THR--GLU-894, AND PHOSPHORYLATION.  
 RX MEDLINE=21635582; PubMed=11773444;  
 RA Ko L., Cardona G.R., Iwasaki T., Bramlett K.S., Burris T.P.,  
 RA Chin W.W.;  
 RT "Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines  
 RT selectivity for ERs and TRs.";  
 RL Mol. Endocrinol. 16:128-140(2002).  
 CC -!- FUNCTION: Nuclear receptor coactivator that directly binds nuclear  
 CC receptors and stimulates the transcriptional activities in a  
 CC hormone-dependent fashion. Coactivates expression in an agonist-  
 CC and AF2-dependent manner. Involved in the coactivation of  
 CC different nuclear receptors, such as for steroids (GR and ERs),  
 CC retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR)  
 CC and prostanoids (PPARs). Probably functions as a general  
 CC coactivator, rather than just a nuclear receptor coactivator. May  
 CC also be involved in the coactivation of the NF-kappa-B pathway.  
 CC May coactivate expression via a remodeling of chromatin and its  
 CC interaction with histone acetyltransferase proteins.  
 CC -!- SUBUNIT: Monomer and homodimer. Interacts with RNPC2 (By  
 CC similarity). Interacts in vitro with the basal transcription  
 CC factors GTF2A and TBP, suggesting an autonomous transactivation  
 CC function. Interacts with NCOA1, CRSP3, RBM14, the histone  
 CC acetyltransferases EP300 and CREBBP, and with the  
 CC methyltransferases NCOA6IP and HRMT1L1/PRMT2. Belongs to the  
 CC ASC-2/NCOA6 complex (ASCOM), which contains ASC-2/NCOA6, the  
 CC retinoblastoma-binding protein RBQ-3/ RBBP5, alpha- and beta-  
 CC tubulins, the trithorax group proteins MLL2 and MLL3, and  
 CC ASH2/ASCL2.  
 CC -!- SUBCELLULAR LOCATION: Nuclear.  
 CC -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in brain,  
 CC prostate, testis and ovary; weakly expressed in lung, thymus and  
 CC small intestine.  
 CC -!- DOMAIN: Contains two Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. Only  
 CC motif 1 is essential for the association with nuclear receptors,  
 CC while adjacent Ser-884 displays selectivity for nuclear receptors.  
 CC -!- PTM: Phosphorylated by PRKDC.  
 CC -!- PTM: Phosphorylation on Ser-884 leads to a strong decrease in  
 CC binding to ESR1 and ESR2.  
 CC -!- MISCELLANEOUS: Frequently amplified or overexpressed in colon,  
 CC breast and lung cancers.  
 CC -!- CAUTION: Ref.1 (AAF16403) sequence differs from that shown due to  
 CC a frameshift in position 88.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; AF177388; AAF13595.1; -.  
 DR EMBL; AF208227; AAF16403.1; ALT\_FRAME.  
 DR EMBL; AF245115; AAF78480.1; -.

DR EMBL; AF128458; AAF37003.1; -.  
 DR EMBL; AF171667; AAF71829.1; -.  
 DR EMBL; D80003; BAA11498.2; ALT\_INIT.  
 DR EMBL; AL109824; CAB92721.1; -.  
 DR Genew; HGNC:15936; NCOA6.  
 DR MIM; 605299; -.  
 DR GO; GO:0005634; C:nucleus; IDA.  
 DR GO; GO:0005667; C:transcription factor complex; TAS.  
 DR GO; GO:0003682; F:chromatin binding; ISS.  
 DR GO; GO:0030331; F:estrogen receptor binding; TAS.  
 DR GO; GO:0046965; F:retinoid X receptor binding; TAS.  
 DR GO; GO:0046966; F:thyroid hormone receptor binding; IDA.  
 DR GO; GO:0003713; F:transcription co-activator activity; IDA.  
 DR GO; GO:0016563; F:transcriptional activator activity; TAS.  
 DR GO; GO:0007420; P:brain development; ISS.  
 DR GO; GO:0001701; P:embryonic development (sensu Mammalia); ISS.  
 DR GO; GO:0007507; P:heart development; ISS.  
 DR GO; GO:0030099; P:myeloid blood cell differentiation; IDA.

Query Match 48.1%; Score 138; DB 1; Length 2063;  
 Best Local Similarity 57.1%; Pred. No. 2.2e-05;  
 Matches 32; Conservative 3; Mismatches 13; Indels 8; Gaps 1;

QY 3 PRGSMATLEKLMKAFE-----SLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 | ||:| |: : |||||  
 Db 232 PSGSLAPPHHPMQPVSVNRQMNPNANFPQLQQQQQQQQQQQQQQQQQQQQQQQQQLQ 287

# RESULT 8

## MJD1\_HUMAN

ID MJD1\_HUMAN STANDARD; PRT; 376 AA.  
 AC P54252; O15284; O15285; O15286; Q8N189; Q96TC3; Q96TC4; Q9H3N0;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Machado-Joseph disease protein 1 (Ataxin-3) (Spinocerebellar ataxia  
 DE type 3 protein).  
 GN MJD OR MJD1 OR SCA3 OR ATX3.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A. (ISOFORM 1), AND VARIANT MJD1A.  
 RC TISSUE=Brain;  
 RX MEDLINE=95179166; PubMed=7874163;  
 RA Kawaguchi Y., Okamoto T., Taniwaki M., Aizawa M., Inoue M.,  
 RA Katayama S., Kawakami H., Nakamura S., Nishimura M., Akiguchi I.,  
 RA Kimura J., Narumiya S., Kakizuka A.;  
 RT "CAG expansions in a novel gene for Machado-Joseph disease at  
 RT chromosome 14q32.1.";  
 RL Nat. Genet. 8:221-228(1994).  
 RN [2]  
 RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2), AND VARIANTS VAL-212;  
 RP AND MJD1A.  
 RX MEDLINE=97418757; PubMed=9274833;  
 RA Goto J., Watanabe M., Ichikawa Y., Yee S.-B., Ihara N., Endo K.,

RA Igarashi S., Takiyama Y., Gaspar C., Maciel P., Tsuji S.,  
 RA Rouleau G.A., Kanazawa I.;  
 RT "Machado-Joseph disease gene products carrying different carboxyl  
 RT termini.";  
 RL Neurosci. Res. 28:373-377(1997).  
 RN [3]  
 RP SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3), AND VARIANT MJD1A.  
 RX MEDLINE=21342815; PubMed=11450850;  
 RA Ichikawa Y., Goto J., Hattori M., Toyoda A., Ishii K., Jeong S.-Y.,  
 RA Hashida H., Masuda N., Ogata K., Kasai F., Hirai M., Maciel P.,  
 RA Rouleau G.A., Sakaki Y., Kanazawa I.;  
 RT "The genomic structure and expression of MJD, the Machado-Joseph  
 RT disease gene.";  
 RL J. Hum. Genet. 46:413-422(2001).  
 RN [4]  
 RP SEQUENCE FROM N.A. (ISOFORM 2), AND VARIANT VAL-212.  
 RC TISSUE=Breast;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length  
 RT human and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RN [5]  
 RP SUBCELLULAR LOCATION.  
 RX MEDLINE=98248424; PubMed=9580663;  
 RA Tait D., Riccio M., Sittler A., Scherzinger E., Santi S., Ognibene A.,  
 RA Maraldi N.M., Lehrach H., Wanker E.E.;  
 RT "Ataxin-3 is transported into the nucleus and associates with the  
 RT nuclear matrix.";  
 RL Hum. Mol. Genet. 7:991-997(1998).  
 RN [6]  
 RP FUNCTION.  
 RX MEDLINE=22323318; PubMed=12297501;  
 RA Li F., Macfarlan T., Pittman R.N., Chakravarti D.;  
 RT "Ataxin-3 is a histone-binding protein with two independent  
 RT transcriptional corepressor activities.";  
 RL J. Biol. Chem. 277:45004-45012(2002).  
 RN [7]  
 RP 3D-STRUCTURE MODELING.  
 RX MEDLINE=22374627; PubMed=12486728;  
 RA Albrecht M., Hoffmann D., Evert B.O., Schmitt I., Wuellner U.,

RA Lengauer T.;  
 RT "Structural modeling of ataxin-3 reveals distant homology to  
 RT adaptins.";  
 RL Proteins 50:355-370(2003).  
 CC -!- FUNCTION: Interacts with key regulators (CBP, p300 and PCAF) of  
 CC transcription and represses transcription. Acts as a histone-  
 CC binding protein that regulates transcription.  
 CC -!- SUBUNIT: Interacts with DNA repair proteins RAD23A and RAD23B.  
 CC -!- SUBCELLULAR LOCATION: Predominantly nuclear, but not exclusively;  
 CC inner nuclear matrix.  
 CC -!- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=3;  
 CC Name=1;  
 CC IsoId=P54252-1; Sequence=Displayed;  
 CC Name=2;  
 CC IsoId=P54252-2; Sequence=VSP\_002784;  
 CC Name=3;  
 CC IsoId=P54252-3; Sequence=VSP\_002783, VSP\_002784;  
 CC -!- TISSUE SPECIFICITY: Ubiquitous.  
 CC -!- POLYMORPHISM: The poly-Gln region of the Machado-Joseph protein is  
 CC highly polymorphic (14 to 41 repeats) in the normal population and  
 CC is expanded to about 55-82 repeats in MJD1 patients. Longer  
 CC expansions result in earlier onset and more severe clinical  
 CC manifestations of the disease.  
 CC -!- POLYMORPHISM: The MJD1a allele carries a single nucleotide  
 CC substitution in codon 349 generating a stop codon instead of a Tyr.  
 CC In the Japanese population, the MJD1a allele seems to be  
 CC significantly associated with Gln expansion.  
 CC -!- DISEASE: Defects in MJD are the cause of Machado-Joseph disease  
 CC (MJD), a neurodegenerative disorder characterized by cerebellar  
 CC ataxia, pyramidal and extrapyramidal signs, peripheral nerve  
 CC palsy, external ophthalmoplegia, facial and lingual fasciculation  
 CC and bulging. This disease is autosomal and dominant, with a late  
 CC onset of symptoms, generally after the fourth decade.  
 CC -!- SIMILARITY: Contains 1 Josephin domain.  
 CC -!- SIMILARITY: Contains 3 ubiquitin-interacting motif (UIM) repeats.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; S75313; AAB33571.1; -.  
 DR EMBL; U64820; AAB63352.1; -.  
 DR EMBL; U64821; AAB63353.1; -.  
 DR EMBL; U64822; AAB63354.1; -.  
 DR EMBL; AB050194; BAB18798.1; -.  
 DR EMBL; AB038653; BAB55645.1; -.  
 DR EMBL; AB038653; BAB55646.1; -.  
 DR EMBL; BC033711; AAH33711.1; -.  
 DR Genew; HGNC:7106; MJD.  
 DR MIM; 607047; -.  
 DR MIM; 109150; -.  
 DR GO; GO:0005737; C:cytoplasm; TAS.

DR GO; GO:0005654; C:nucleoplasm; TAS.  
DR GO; GO:0007399; P:neurogenesis; TAS.  
DR GO; GO:0006289; P:nucleotide-excision repair; TAS.  
DR GO; GO:0007268; P:synaptic transmission; TAS.  
DR InterPro; IPR006155; Josephin.  
DR InterPro; IPR003903; UIM.  
DR Pfam; PF02099; Josephin; 1.  
DR Pfam; PF02809; UIM; 2.  
DR PRINTS; PR01233; JOSEPHIN.  
DR SMART; SM00726; UIM; 2.  
DR PROSITE; PS50330; UIM; 2.  
KW Transcription regulation; Nuclear protein; Repeat;  
KW Alternative splicing; Polymorphism; Triplet repeat expansion.  
FT DOMAIN 1 198 JOSEPHIN.  
FT DOMAIN 224 243 UIM 1.  
FT DOMAIN 244 263 UIM 2.  
FT REPEAT 343 360 UIM 3.  
FT DOMAIN 292 317 POLY-GLN.  
FT VARSPLIC 10 64 Missing (in isoform 3).  
FT /FTId=VSP\_002783.  
FT VARSPLIC 344 376 KACSPFIMFATFTLYLTYELHVIFALHYSSEPL -> DAMS  
FT EEDMLQAAVTMSLETVRNDLKTEGKK (in isoform 2  
FT and isoform 3).  
FT /FTId=VSP\_002784.  
FT VARIANT 212 212 M -> V (in dbSNP:1048755).  
FT /FTId=VAR\_013688.  
FT VARIANT 306 318 QQQQQQQQQQQQR -> G.  
FT /FTId=VAR\_013689.  
FT VARIANT 361 376 Missing (in MJD1A).  
FT /FTId=VAR\_013690.  
FT CONFLICT 252 252 A -> T (IN REF. 2).  
SQ SEQUENCE 376 AA; 43449 MW; C282BED37499480E CRC64;

Query Match 47.7%; Score 137; DB 1; Length 376;  
Best Local Similarity 68.2%; Pred. No. 5.8e-06;  
Matches 30; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

Qy 5 GSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 48  
|: | |: | |: |||:|||||  
Db 273 GTNLTSEELRKRRREAYFEKQQQKQQQQQQQQQQQQQQQQQQQQQQ 316

# RESULT 9

## NCO6\_MOUSE

ID NCO6\_MOUSE STANDARD; PRT; 2067 AA.  
AC Q9JL19; Q9JLT9;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Nuclear receptor coactivator 6 (Amplified in breast cancer-3 protein)  
DE (Cancer-amplified transcriptional coactivator ASC-2) (Activating  
DE signal cointegrator-2) (ASC-2) (Peroxisome proliferator-activated  
DE receptor-interacting protein) (PPAR-interacting protein) (Nuclear  
DE receptor-activating protein, 250 kDa) (Nuclear receptor coactivator  
DE RAP250) (NRC) (Thyroid hormone receptor binding protein).  
GN NCOA6 OR AIB3 OR RAP250 OR PRIP OR TRBP.  
OS Mus musculus (Mouse).



OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2), AND INTERACTION WITH  
 RP PPARA; PPARG; RARA; RXRA; ESR1; ESR2 AND THRB.  
 RC TISSUE=Liver;  
 RX MEDLINE=20250907; PubMed=10788465;  
 RA Zhu Y.-J., Kan L., Qi C., Kanwar Y.S., Yeldandi A.V., Rao M.S.,  
 RA Reddy J.K.;  
 RT "Isolation and characterization of peroxisome proliferator-activated  
 RT receptor (PPAR) interacting protein (PRIP) as a coactivator for  
 RT PPAR.";  
 RL J. Biol. Chem. 275:13510-13516(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A. (ISOFORM 2).  
 RC TISSUE=Breast;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length  
 RT human and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RN [3]  
 RP SEQUENCE OF 786-1142 FROM N.A. (ISOFORM 1), INTERACTION WITH PPARA;  
 RP PPARG; ESR1; ESR2; THRA AND THRB, AND MUTAGENESIS OF LEU-891 AND  
 RP LEU-894.  
 RC TISSUE=Embryo;  
 RX MEDLINE=20148724; PubMed=10681503;  
 RA Caira F., Antonson P., Pelto-Huikko M., Treuter E., Gustafsson J.-A.;  
 RT "Cloning and characterization of RAP250, a nuclear receptor  
 RT coactivator.";  
 RL J. Biol. Chem. 275:5308-5317(2000).  
 RN [4]  
 RP INTERACTION WITH RNPC2.  
 RX MEDLINE=21638469; PubMed=11704680;  
 RA Jung D.-J., Na S.-Y., Na D.S., Lee J.W.;  
 RT "Molecular cloning and characterization of CAPER, a novel coactivator  
 RT of activating protein-1 and estrogen receptors.";  
 RL J. Biol. Chem. 277:1229-1234(2002).  
 CC -!- FUNCTION: Nuclear receptor coactivator that directly binds nuclear  
 CC receptors and stimulates the transcriptional activities in a

hormone-dependent fashion. Coactivates expression in an agonist- and AF2-dependent manner. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ERs), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Probably functions as a general coactivator, rather than just a nuclear receptor coactivator. May also be involved in the coactivation of the NF-kappa-B pathway. May coactivate expression via a remodeling of chromatin and its interaction with histone acetyltransferase proteins. Involved in placental, cardiac, hepatic and embryonic development.

-!- SUBUNIT: Monomer and homodimer. Interacts in vitro with the basal transcription factors GTF2A and TBP, suggesting an autonomous transactivation function. Interacts with NCOA1, CRSP3, RBM14, the histone acetyltransferase proteins EP300 and CREBBP, and with methyltransferase proteins NCOA6IP and HRMT1L1 (By similarity). Interacts with RNPC2. Belongs to the ASC-2/NCOA6 complex (ASCOM), which contains ASC-2/NCOA6, the retinoblastoma-binding protein RBQ-3/ RBBP5, alpha- and beta-tubulins, the trithorax group proteins MLL2 and MLL3, and ASH2/ASCL2 (By similarity).

-!- SUBCELLULAR LOCATION: Nuclear.

-!- ALTERNATIVE PRODUCTS:

Event=Alternative splicing; Named isoforms=2;

Name=1;

IsoId=Q9JL19-1; Sequence=Displayed;

Name=2;

IsoId=Q9JL19-2; Sequence=VSP\_003410;

Note=Acts as a dominant negative repressor;

-!- TISSUE SPECIFICITY: Widely expressed. High expression in testis and weak expression in small intestine.

-!- DEVELOPMENTAL STAGE: Expressed at E9 in placenta and at weaker level in uterus. High expression in neural tube and in CNS throughout development. High expression in sensory ganglia and retina from E11. In the alimentary tract and olfactory epithelium expression was seen from E13. Strong expression present in liver and kidney, from E11 and E13 respectively, and then expression decreased at later stages of development. Moderate expression in lung from E13, while it decreases during postnatal life. Strong expression in thymus from E15 onwards, and in spleen from E17 and during early postnatal life, then, the expression decreases.

-!- DOMAIN: Contains two Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. Only motif 1 is essential for the association with nuclear receptors.

-!- PTM: Phosphorylated (By similarity).

-----

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

-----

DR EMBL; AF216186; AAF35860.1; -.

DR EMBL; BC031113; AAH31113.1; -.

DR EMBL; AF135169; AAF35973.1; -.

DR MGD; MGI:1929915; Ncoa6.

DR GO; GO:0005634; C:nucleus; IDA.

DR GO; GO:0005667; C:transcription factor complex; IDA.

```

ID      THAB_HUMAN          STANDARD;          PRT;    313 AA.
AC      Q96EK4; O94795;
DT      10-OCT-2003 (Rel. 42, Created)
DT      10-OCT-2003 (Rel. 42, Last sequence update)
DT      15-MAR-2004 (Rel. 43, Last annotation update)
DE      THAP domain protein 11 (HRIHFB2206).
GN      THAP11.
OS      Homo sapiens (Human).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Uterus;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length  
 RT human and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RN [2]  
 RP SEQUENCE OF 226-313 FROM N.A., AND SUBCELLULAR LOCATION.  
 RC TISSUE=Brain;  
 RX MEDLINE=99068504; PubMed=9853615;  
 RA Ueki N., Oda T., Kondo M., Yano K., Noguchi T., Muramatsu M.A.;  
 RT "Selection system for genes encoding nuclear-targeted proteins.";  
 RL Nat. Biotechnol. 16:1338-1342(1998).  
 CC -!- SUBCELLULAR LOCATION: Nuclear.  
 CC -!- SIMILARITY: Contains 1 THAP domain.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; BC012182; AAH12182.1; -.  
 DR EMBL; AB015338; BAA34796.1; -.  
 DR Genew; HGNC:23194; THAP11.  
 DR InterPro; IPR006612; DUF\_DM3.  
 DR Pfam; PF05485; THAP; 1.  
 DR SMART; SM00692; DM3; 1.  
 KW Zinc-finger; DNA-binding; Nuclear protein.  
 FT DOMAIN 1 85 THAP.  
 FT ZN\_FING 6 64 THAP-TYPE.  
 FT DOMAIN 95 100 POLY-ALA.  
 FT DOMAIN 104 131 POLY-GLN.  
 FT DOMAIN 201 207 POLY-ALA.  
 SQ SEQUENCE 313 AA; 34327 MW; 47D8B02FF89E5BEB CRC64;

Query Match 47.4%; Score 136; DB 1; Length 313;  
 Best Local Similarity 55.6%; Pred. No. 6e-06;  
 Matches 30; Conservative 5; Mismatches 11; Indels 8; Gaps 1;

Qy 3 PRGSMATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPGSTRA 56  
 | | : | : : | | | | | | | | | | | | | | | | | : : |  
 Db 94 PAGAAAARRRQQQ-----QQQQQQQQQQQQQQQQQQQQQQQQQQSSPSASTA 139

RESULT 11

FXP2\_MOUSE

ID FXP2\_MOUSE STANDARD; PRT; 714 AA.  
 AC P58463;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Forkhead box protein P2.  
 GN FOXP2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6; TISSUE=Lung;  
 RX MEDLINE=21347947; PubMed=11358962;  
 RA Shu W., Yang H., Zhang L., Lu M.M., Morrissey E.E.;  
 RT "Characterization of a new subfamily of winged-helix/forkhead (Fox)  
 RT genes that are expressed in the lung and act as transcriptional  
 RT repressors.";  
 RL J. Biol. Chem. 276:27488-27497(2001).  
 CC -!- FUNCTION: Transcriptional repressor that play an important role in  
 CC the specification and differentiation of lung epithelium. May play  
 CC important roles in developing neural, gastrointestinal and  
 CC cardiovascular tissues.  
 CC -!- SUBCELLULAR LOCATION: Nuclear (Probable).  
 CC -!- TISSUE SPECIFICITY: Highest expression in lung. Lower expression  
 CC in spleen, skeletal muscle, brain, kidney and small intestine.  
 CC -!- DEVELOPMENTAL STAGE: Expressed in developing lung (only distal  
 CC epithelium), neural, intestinal and cardiovascular tissues.  
 CC -!- SIMILARITY: Contains 1 fork-head domain.  
 CC -!- SIMILARITY: Contains 1 C2H2-type zinc finger.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; AF339106; AAK69651.1; -.  
 DR MGD; MGI:2148705; Foxp2.  
 DR GO; GO:0016564; F:transcriptional repressor activity; IDA.  
 DR GO; GO:0016481; P:negative regulation of transcription; IDA.  
 DR InterPro; IPR001766; TF\_Fork\_head.

DR InterPro; IPR007087; Znf\_C2H2.  
 DR Pfam; PF00250; Fork\_head; 1.  
 DR PRINTS; PR00053; FORKHEAD.  
 DR ProDom; PD000425; TF\_Fork\_head; 1.  
 DR SMART; SM00339; FH; 1.  
 DR SMART; SM00355; Znf\_C2H2; 1.  
 DR PROSITE; PS00657; FORK\_HEAD\_1; FALSE\_NEG.  
 DR PROSITE; PS00658; FORK\_HEAD\_2; FALSE\_NEG.  
 DR PROSITE; PS50039; FORK\_HEAD\_3; 1.  
 DR PROSITE; PS00028; ZINC\_FINGER\_C2H2\_1; 1.  
 DR PROSITE; PS50157; ZINC\_FINGER\_C2H2\_2; FALSE\_NEG.  
 KW Transcription regulation; DNA-binding; Zinc-finger; Metal-binding;  
 KW Nuclear protein.  
 FT ZN\_FING 345 370 C2H2-TYPE.  
 FT DNA\_BIND 503 593 FORK-HEAD.  
 FT DOMAIN 53 56 POLY-GLN.  
 FT DOMAIN 123 126 POLY-GLN.  
 FT DOMAIN 131 136 POLY-GLN.  
 FT DOMAIN 152 191 POLY-GLN.  
 FT DOMAIN 200 208 POLY-GLN.  
 FT DOMAIN 222 230 POLY-GLN.  
 SQ SEQUENCE 714 AA; 79820 MW; BCDFB80E28398609 CRC64;

Query Match 47.4%; Score 136; DB 1; Length 714;  
 Best Local Similarity 93.1%; Pred. No. 1.3e-05;  
 Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 24 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPG 52  
 |||||  
 Db 166 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQHPG 194

# RESULT 12

## FXP2\_HUMAN

ID FXP2\_HUMAN STANDARD; PRT; 715 AA.  
 AC O15409; Q8NOW2;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Forkhead box protein P2 (CAG repeat protein 44) (Trinucleotide repeat-  
 DE containing gene 10 protein).  
 GN FOXP2 OR CAGH44 OR TNRC10.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A., ALTERNATIVE SPLICING, AND VARIANT SPCH1 HIS-553.  
 RX MEDLINE=21470412; PubMed=11586359;  
 RA Lai C.S.L., Fisher S.E., Hurst J.A., Vargha-Khadem F., Monaco A.P.;  
 RT "A forkhead-domain gene is mutated in a severe speech and language  
 RT disorder.";  
 RL Nature 413:519-523(2001).  
 RN [2]  
 RP SEQUENCE OF 1-304 FROM N.A.  
 RC TISSUE=Brain cortex;  
 RX MEDLINE=97369492; PubMed=9225980;

RA Margolis R.L., Abraham M.R., Gatchell S.B., Li S.-H., Kidwai A.S.,  
 RA Breschel T.S., Stine O.C., Callahan C., Mcinnis M.G., Ross C.A.;  
 RT "cDNAs with long CAG trinucleotide repeats from human brain."  
 RL Hum. Genet. 100:114-122(1997).  
 RN [3]  
 RP SEQUENCE OF 1-86 FROM N.A.  
 RA Minx P., Hinds K., Sutterer C., Becker M., Ozersky P.;  
 RL Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.  
 RN [4]  
 RP SEQUENCE OF 113-329 FROM N.A.  
 RX MEDLINE=22179809; PubMed=12192408;  
 RA Enard W., Przeworski M., Fisher S.E., Lai C.S.L., Wiebe V., Kitano T.,  
 RA Monaco A.P., Paabo S.;  
 RT "Molecular evolution of FOXP2, a gene involved in speech and  
 RT language."  
 RL Nature 418:869-872(2002).  
 CC -!- FUNCTION: Transcriptional repressor that plays an important role  
 CC in the specification and differentiation of lung epithelium. May  
 CC play important roles in developing neural, gastrointestinal and  
 CC cardiovascular tissues. Involved in neural mechanisms mediating  
 CC the development of speech and language.  
 CC -!- SUBCELLULAR LOCATION: Nuclear (Probable).  
 CC -!- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=3;  
 CC Name=1; Synonyms=I;  
 CC IsoId=O15409-1; Sequence=Displayed;  
 CC Name=2; Synonyms=II;  
 CC IsoId=O15409-3; Sequence=Not described;  
 CC Name=3; Synonyms=III, IV;  
 CC IsoId=O15409-2; Sequence=VSP\_001558;  
 CC -!- TISSUE SPECIFICITY: Expressed at high levels in embryonic and  
 CC adult lung.  
 CC -!- DISEASE: Defects in FOXP2 are the cause of speech-language  
 CC disorder 1 (SPCH1) [MIM:602081]; also known as autosomal dominant  
 CC speech and language disorder with orofacial dyspraxia. Affected  
 CC individuals have a severe impairment in the selection and  
 CC sequencing of fine orofacial movements, which are necessary for  
 CC articulation. They also show deficits in several facets of  
 CC language processing (such as the ability to break up words into  
 CC their constituent phoneme) and grammatical skills.  
 CC -!- DISEASE: Disruption of FOXP2 by a chromosomal translocation  
 CC t(5;7)(q22;q31.2) is the cause of severe speech and language  
 CC impairment.  
 CC -!- SIMILARITY: Contains 1 fork-head domain.  
 CC -!- SIMILARITY: Contains 1 C2H2-type zinc finger.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; AF337817; AAL10762.1; -.  
 DR EMBL; U80741; AAB91439.1; -.  
 DR EMBL; AC003992; -; NOT\_ANNOTATED\_CDS.

DR EMBL; AF515031; AAN03389.1; -.  
 DR EMBL; AF515032; AAN03390.1; -.  
 DR EMBL; AF515033; AAN03391.1; -.  
 DR EMBL; AF515034; AAN03392.1; -.  
 DR EMBL; AF515035; AAN03393.1; -.  
 DR EMBL; AF515036; AAN03394.1; -.  
 DR EMBL; AF515037; AAN03395.1; -.  
 DR EMBL; AF515038; AAN03396.1; -.  
 DR EMBL; AF515039; AAN03397.1; -.  
 DR EMBL; AF515040; AAN03398.1; -.  
 DR EMBL; AF515041; AAN03399.1; -.  
 DR EMBL; AF515042; AAN03400.1; -.  
 DR EMBL; AF515043; AAN03401.1; -.  
 DR EMBL; AF515044; AAN03402.1; -.  
 DR EMBL; AF515045; AAN03403.1; -.  
 DR EMBL; AF515046; AAN03404.1; -.  
 DR EMBL; AF515047; AAN03405.1; -.  
 DR EMBL; AF515048; AAN03406.1; -.  
 DR EMBL; AF515049; AAN03407.1; -.  
 DR EMBL; AF515050; AAN03408.1; -.  
 DR Genew; HGNC:13875; FOXP2.  
 DR MIM; 605317; -.  
 DR MIM; 602081; -.  
 DR InterPro; IPR001766; TF\_Fork\_head.  
 DR InterPro; IPR007087; Znf\_C2H2.  
 DR Pfam; PF00250; Fork\_head; 1.  
 DR PRINTS; PR00053; FORKHEAD.  
 DR ProDom; PD000425; TF\_Fork\_head; 1.  
 DR SMART; SM00339; FH; 1.  
 DR SMART; SM00355; Znf\_C2H2; 1.  
 DR PROSITE; PS00657; FORK\_HEAD\_1; FALSE\_NEG.  
 DR PROSITE; PS00658; FORK\_HEAD\_2; FALSE\_NEG.  
 DR PROSITE; PS50039; FORK\_HEAD\_3; 1.  
 DR PROSITE; PS00028; ZINC\_FINGER\_C2H2\_1; 1.  
 DR PROSITE; PS50157; ZINC\_FINGER\_C2H2\_2; FALSE\_NEG.  
 KW Transcription regulation; DNA-binding; Zinc-finger; Metal-binding;  
 KW Nuclear protein; Chromosomal translocation; Disease mutation;  
 KW Alternative splicing.  
 FT ZN\_FING 346 371 C2H2-TYPE.  
 FT DNA\_BIND 504 594 FORK-HEAD.  
 FT DOMAIN 53 56 POLY-GLN.  
 FT DOMAIN 123 126 POLY-GLN.  
 FT DOMAIN 131 136 POLY-GLN.  
 FT DOMAIN 152 191 POLY-GLN.  
 FT DOMAIN 200 209 POLY-GLN.  
 FT DOMAIN 223 231 POLY-GLN.  
 FT VARSPLIC 1 92 Missing (in isoform 3).  
 FT /FTId=VSP\_001558.  
 FT VARIANT 553 553 R -> H (in SPCH1).  
 FT /FTId=VAR\_012278.  
 FT CONFLICT 134 134 Q -> H (IN REF. 2).  
 FT CONFLICT 290 304 DLTNNSSSTTSSNT -> EEFPVQGPAAVCAGL (IN  
 FT REF. 2).  
 SQ SEQUENCE 715 AA; 79919 MW; 4F9FBDB6D90516E0 CRC64;

Query Match 47.4%; Score 136; DB 1; Length 715;  
 Best Local Similarity 93.1%; Pred. No. 1.3e-05;



Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
QY      24 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPG 52
          |||||||||||||||||||||||||  ||
Db      166 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQHPG 194
```

RESULT 13

FXP2\_PANTR

ID FXP2\_PANTR STANDARD; PRT; 716 AA.  
AC Q8MJA0; Q8MHX3;  
DT 15-MAR-2004 (Rel. 43, Created)  
DT 15-MAR-2004 (Rel. 43, Last sequence update)  
DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Forkhead box protein P2.  
GN FOXP2.  
OS Pan troglodytes (Chimpanzee).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.  
OX NCBI\_TaxID=9598;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22179809; PubMed=12192408;  
RA Enard W., Przeworski M., Fisher S.E., Lai C.S.L., Wiebe V., Kitano T.,  
RA Monaco A.P., Paabo S.;  
RT "Molecular evolution of FOXP2, a gene involved in speech and  
RT language.";  
RL Nature 418:869-872(2002).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22412141; PubMed=12524352;  
RA Zhang J., Webb D.M., Podlaha O.;  
RT "Accelerated protein evolution and origins of human-specific features:  
RT Foxp2 as an example.";  
RL Genetics 162:1825-1835(2002).  
CC -!- FUNCTION: Transcriptional repressor that plays an important role  
CC in the specification and differentiation of lung epithelium. May  
CC play important roles in developing neural, gastrointestinal and  
CC cardiovascular tissues (By similarity).  
CC -!- SUBCELLULAR LOCATION: Nuclear (Probable).  
CC -!- SIMILARITY: Contains 1 fork-head domain.  
CC -!- SIMILARITY: Contains 1 C2H2-type zinc finger.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; AF512947; AAN03385.1; -.  
DR EMBL; AF515051; AAN03409.1; -.  
DR EMBL; AF515052; AAN03410.1; -.  
DR EMBL; AY143178; AAN60056.1; -.  
DR InterPro; IPR001766; TF\_Fork\_head.  
DR InterPro; IPR009058; Wing\_hlx\_DNA\_bnd.

DR InterPro; IPR007087; Znf\_C2H2.  
 DR Pfam; PF00250; Fork head; 1.  
 DR PRINTS; PR00053; FORKHEAD.  
 DR ProDom; PD000425; TF\_Fork\_head; 1.  
 DR SMART; SM00339; FH; 1.  
 DR PROSITE; PS00657; FORK\_HEAD\_1; FALSE\_NEG.  
 DR PROSITE; PS00658; FORK\_HEAD\_2; FALSE\_NEG.  
 DR PROSITE; PS50039; FORK\_HEAD\_3; 1.  
 DR PROSITE; PS00028; ZINC\_FINGER\_C2H2\_1; 1.  
 DR PROSITE; PS50157; ZINC\_FINGER\_C2H2\_2; FALSE\_NEG.  
 KW Transcription regulation; DNA-binding; Zinc-finger; Metal-binding;  
 KW Nuclear protein.  
 FT ZN\_FING 347 372 C2H2-TYPE.  
 FT DNA\_BIND 505 595 FORK-HEAD.  
 FT DOMAIN 53 56 POLY-GLN.  
 FT DOMAIN 123 126 POLY-GLN.  
 FT DOMAIN 131 136 POLY-GLN.  
 FT DOMAIN 152 191 POLY-GLN.  
 FT DOMAIN 201 210 POLY-GLN.  
 FT DOMAIN 224 232 POLY-GLN.  
 SQ SEQUENCE 716 AA; 80061 MW; 3169A2786B42F79F CRC64;

Query Match 47.4%; Score 136; DB 1; Length 716;  
 Best Local Similarity 93.1%; Pred. No. 1.3e-05;  
 Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 24 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQPG 52  
 |||||  
 Db 167 QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQHPG 195

# RESULT 14

## MN1\_HUMAN

ID MN1\_HUMAN STANDARD; PRT; 1319 AA.  
 AC Q10571;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Probable tumor suppressor protein MN1.  
 GN MN1.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE=95249266; PubMed=7731706;  
 RA Deprez R.H.L., Riegman P.H.J., Groen N.A., Warringa U.L.,  
 RA van Biezen N.A., Molijn A.C., Bootsma D., de Jong P.J.,  
 RA Menon A.G., Kley N.A., Seizenger B.R., Zwarthoff E.C.;  
 RT "Cloning and characterization of MN1, a gene from chromosome 22q11,  
 RT which is disrupted by a balanced translocation in a meningioma."  
 RL Oncogene 10:1521-1528(1995).  
 RN [2]  
 RP SEQUENCE OF 1304-1319 FROM N.A.  
 RC TISSUE=Brain;

RX MEDLINE=97145634; PubMed=9026990;  
 RA Dmitrenko V.V., Garifulin O.M., Shostak E.A., Smikodub A.I.,  
 RA Kavsan V.M.;  
 RT "The characteristics of different types of mRNA expressed in the human  
 RT brain.";  
 RL Cyt. Genet. (Russ.) 30:41-47(1996).  
 CC -!- FUNCTION: May play a role in tumor suppression.  
 CC -!- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=2;  
 CC Name=1;  
 CC IsoId=Q10571-1; Sequence=Displayed;  
 CC Name=2;  
 CC IsoId=Q10571-2; Sequence=Not described;  
 CC Note=No experimental confirmation available;  
 CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. Highest levels in  
 CC skeletal muscle.  
 CC -!- DISEASE: Involved in a form of acute myeloid leukemia (AML) by a  
 CC chromosomal translocation t(12;22)(p13;q11) that involves MN1 and  
 CC TEL.  
 CC -!- DISEASE: Defects in MN1 may be a cause of meningiomas, slowly  
 CC growing benign tumors derived from the arachnoidal cap cells of  
 CC the leptomeninges, the soft coverings of the brain and spinal  
 CC cord. Meningiomas are believed to be the most common primary  
 CC tumors of the central nervous system in man.  
 CC -!- CAUTION: It is uncertain whether Met-1 or Met-30 is the initiator.  
 CC -!- DATABASE: NAME=Atlas Genet. Cytogenet. Oncol. Haematol.;  
 CC WWW="http://www.infobiogen.fr/services/chromcancer/Genes/MN1.html".

CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; X82209; CAA57693.1; ALT\_INIT.  
 DR EMBL; Z70218; CAA94179.1; -.  
 DR Genew; HGNC:7180; MN1.  
 DR MIM; 156100; -.  
 DR MIM; 607174; -.  
 KW Anti-oncogene; Chromosomal translocation; Alternative splicing.  
 FT DOMAIN 295 309 POLY-GLN.  
 FT DOMAIN 523 550 POLY-GLN.  
 SQ SEQUENCE 1319 AA; 135943 MW; 21197C9BBA272BE2 CRC64;

Query Match 47.4%; Score 136; DB 1; Length 1319;  
 Best Local Similarity 84.8%; Pred. No. 2.2e-05;  
 Matches 28; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 18 ESLKSFQQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQ 50  
 :||: |||||  
 Db 520 QSLQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQRQ 552

RESULT 15  
 HCN1\_MOUSE

ID HCN1\_MOUSE STANDARD; PRT; 910 AA.  
 AC 088704; 054899; Q9D613;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated  
 DE channel 1 (Brain cyclic nucleotide gated channel 1) (BCNG-1)  
 DE (Hyperpolarization-activated cation channel 2) (HAC-2).  
 GN HCN1 OR BCNG1 OR HAC2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A., AND N-GLYCOSYLATION.  
 RC STRAIN=C57BL/6J; TISSUE=Brain;  
 RX MEDLINE=98070835; PubMed=9405696;  
 RA Santoro B., Grant S.G.N., Bartsch D., Kandel E.R.;  
 RT "Interactive cloning with the SH3 domain of N-src identifies a new  
 RT brain specific ion channel protein, with homology to eag and cyclic  
 RT nucleotide-gated channels.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 94:14815-14820(1997).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=BALB/c; TISSUE=Brain;  
 RX MEDLINE=98295993; PubMed=9634236;  
 RA Ludwig A., Zong X., Jeglitsch M., Hofmann F., Biel M.;  
 RT "A family of hyperpolarization-activated cation channels.";  
 RL Nature 393:587-591(1998).  
 RN [3]  
 RP SEQUENCE OF 377-910 FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Head;  
 RX MEDLINE=21085660; PubMed=11217851;  
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,  
 RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,  
 RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
 RA Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,  
 RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,  
 RA Hayashizaki Y.;  
 RT "Functional annotation of a full-length mouse cDNA collection.";  
 RL Nature 409:685-690(2001).  
 RN [4]  
 RP FUNCTION, AND REGULATION BY CAMP.  
 RX MEDLINE=98292171; PubMed=9630217;  
 RA Santoro B., Liu D.T., Yao H., Bartsch D., Kandel E.R.,

RA Siegelbaum S.A., Tibbs G.R.;  
 RT "Identification of a gene encoding a hyperpolarization-activated  
 RT pacemaker channel of brain."  
 RL Cell 93:717-729(1998).  
 RN [5]  
 RP INTERACTION WITH KCNE2.  
 RX MEDLINE=21313430; PubMed=11420311;  
 RA Yu H., Wu J., Potapova I., Wymore R.T., Holmes B., Zuckerman J.,  
 RA Pan Z., Wang H., Shi W., Robinson R.B., El-Maghrabi M.R., Benjamin W.,  
 RA Dixon J.E., McKinnon D., Cohen I.S., Wymore R.;  
 RT "MinK-related peptide 1: A beta subunit for the HCN ion channel  
 RT subunit family enhances expression and speeds activation."  
 RL Circ. Res. 88:E84-E87(2001).  
 RN [6]  
 RP REGULATION BY CAMP.  
 RX MEDLINE=21351681; PubMed=11459060;  
 RA Wainger B.J., DeGennaro M., Santoro B., Siegelbaum S.A., Tibbs G.R.;  
 RT "Molecular mechanism of cAMP modulation of HCN pacemaker channels."  
 RL Nature 411:805-810(2001).  
 RN [7]  
 RP FUNCTION, AND TISSUE SPECIFICITY.  
 RX MEDLINE=21530492; PubMed=11675786;  
 RA Stevens D.R., Seifert R., Bufer B., Mueller F., Kremmer E., Gauss R.,  
 RA Meyerhof W., Kaupp U.B., Lindemann B.;  
 RT "Hyperpolarization-activated channels HCN1 and HCN4 mediate responses  
 RT to sour stimuli."  
 RL Nature 413:631-635(2001).  
 RN [8]  
 RP INTERACTION WITH HCN2, AND MUTAGENESIS OF GLY-349; TYR-350 AND  
 RP GLY-351.  
 RX MEDLINE=22083667; PubMed=12089064;  
 RA Xue T., Marban E., Li R.A.;  
 RT "Dominant-negative suppression of HCN1- and HCN2-encoded pacemaker  
 RT currents by an engineered HCN1 construct: insights into  
 RT structure-function relationships and multimerization."  
 RL Circ. Res. 90:1267-1273(2002).  
 RN [9]  
 RP OLIGOMERIZATION VIA N-TERMINAL DOMAIN.  
 RX MEDLINE=22162449; PubMed=12034718;  
 RA Proenza C., Tran N., Angoli D., Zahynacz K., Balcar P., Accili E.A.;  
 RT "Different roles for the cyclic nucleotide binding domain and amino  
 RT terminus in assembly and expression of hyperpolarization-activated,  
 RT cyclic nucleotide-gated channels."  
 RL J. Biol. Chem. 277:29634-29642(2002).  
 RN [10]  
 RP MUTAGENESIS OF CYS-303 AND CYS-318.  
 RX MEDLINE=22336443; PubMed=12351622;  
 RA Xue T., Li R.A.;  
 RT "An external determinant in the S5-P linker of the pacemaker (HCN)  
 RT channel identified by sulfhydryl modification."  
 RL J. Biol. Chem. 277:46233-46242(2002).  
 CC -!- FUNCTION: Hyperpolarization-activated ion channel exhibiting weak  
 CC selectivity for potassium over sodium ions. Contributes to the  
 CC native pacemaker currents in heart (If) and in neurons (Ih).  
 CC Activated by cAMP, and at 10-100 times higher concentrations, also  
 CC by cGMP. May mediate responses to sour stimuli.  
 CC -!- SUBUNIT: The potassium channel is probably composed of a homo- or

CC heterotetrameric complex of pore-forming subunits. Heteromultimer  
 CC with HCN2. Interacts with KCNE2. Interacts with the SH3 domain of  
 CC CSK.  
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -!- TISSUE SPECIFICITY: Predominantly expressed in brain. Highly  
 CC expressed in apical dendrites of pyramidal neurons in the cortex,  
 CC in the layer corresponding to the stratum lacunosum-moleculare in  
 CC the hippocampus and in axons of basket cells in the cerebellum.  
 CC Expressed in a subset of elongated cells in taste buds.  
 CC -!- DOMAIN: The segment S4 is probably the voltage-sensor and is  
 CC characterized by a series of positively charged amino acids at  
 CC every third position.  
 CC -!- PTM: N-glycosylated.  
 CC -!- MISCELLANEOUS: Inhibited by extracellular cesium ions.  
 CC -!- SIMILARITY: Belongs to the potassium channel family. HCN  
 CC subfamily.  
 CC -!- SIMILARITY: Contains 1 cyclic nucleotide-binding domain.  
 CC -!- CAUTION: Ref.3 sequence differs from that shown due to a  
 CC frameshift in position 381.

CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; AF028737; AAC53518.1; -.  
 DR EMBL; AJ225123; CAA12407.1; -.  
 DR EMBL; AK014722; BAB29519.1; ALT\_FRAME.  
 DR MGD; MGI:1096392; Hcn1.  
 DR InterPro; IPR000595; cNMP\_binding.  
 DR InterPro; IPR005821; Ion\_trans.  
 DR InterPro; IPR001622; K+channel\_pore.  
 DR InterPro; IPR005820; M+channel\_nlg.  
 DR Pfam; PF00027; cNMP\_binding; 1.  
 DR Pfam; PF00520; ion\_trans; 1.  
 DR SMART; SM00100; cNMP; 1.  
 DR PROSITE; PS00888; CNMP\_BINDING\_1; 1.  
 DR PROSITE; PS00889; CNMP\_BINDING\_2; FALSE\_NEG.  
 DR PROSITE; PS50042; CNMP\_BINDING\_3; 1.  
 KW Transport; Ion transport; Ionic channel; Voltage-gated channel;  
 KW Potassium channel; Potassium; Potassium transport; Sodium transport;  
 KW cAMP; cAMP-binding; Transmembrane; Glycoprotein; Sodium channel.  
 FT DOMAIN 1 135 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 136 156 SEGMENT S1 (POTENTIAL).  
 FT TRANSMEM 163 183 SEGMENT S2 (POTENTIAL).  
 FT DOMAIN 184 208 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 209 229 SEGMENT S3 (POTENTIAL).  
 FT TRANSMEM 238 258 SEGMENT S4 (POTENTIAL).  
 FT DOMAIN 259 289 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 290 310 SEGMENT S5 (POTENTIAL).  
 FT TRANSMEM 334 355 SEGMENT H5 (PORE-FORMING) (POTENTIAL).  
 FT TRANSMEM 361 381 SEGMENT S6 (POTENTIAL).  
 FT DOMAIN 382 910 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 78 129 INVOLVED IN SUBUNIT ASSEMBLY (BY

FT				SIMILARITY).
FT	NP_BIND	464	581	CAMP.
FT	DOMAIN	1	81	GLY-RICH.
FT	DOMAIN	715	777	GLN-RICH.
FT	DOMAIN	878	884	POLY-PRO.
FT	CARBOHYD	327	327	N-LINKED (GLCNAC. . .) (PROBABLE).
FT	MUTAGEN	303	303	C->S: ABOLISHES CONDUCTIVITY.
FT	MUTAGEN	318	318	C->S: ABOLISHES SENSITIVITY TO SULFHYDRIL
FT				MODIFICATION.
FT	MUTAGEN	349	349	G->A: ABOLISHES CONDUCTIVITY; WHEN
FT				ASSOCIATED WITH A-350 AND A-351.
FT	MUTAGEN	350	350	Y->A: ABOLISHES CONDUCTIVITY; WHEN
FT				ASSOCIATED WITH A-349 AND A-351.
FT	MUTAGEN	351	351	G->A: ABOLISHES CONDUCTIVITY; WHEN
FT				ASSOCIATED WITH A-349 AND A-350.
FT	CONFLICT	42	42	G -> R (IN REF. 1).
FT	CONFLICT	394	394	R -> S (IN REF. 3).
SQ	SEQUENCE	910 AA;	102432 MW;	56FD5F328DD972E9 CRC64;

Query Match 47.0%; Score 135; DB 1; Length 910;  
 Best Local Similarity 96.4%; Pred. No. 2e-05;  
 Matches 27; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy	24	QQQQQQQQQQQQQQQQQQQQQQQQQQQQQLQP	51
Db	749	QQQQQQQQQQQQQQQQQQQQQQQQQQQQQP	776

Search completed: March 12, 2004, 15:39:06  
 Job time : 7.94118 secs